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ABSTRACT 
 
MICHAELA A. DINAN: The Effect of Increased PET Imaging on the Staging, Outcomes, 
and Health Care Utilization of Medicare Non-Small Cell Lung Cancer Patients 
(Under the direction of Morris Weinberger, PhD) 
 
Positron Emission Tomography (PET) is an advanced imaging modality that was first 
approved by Medicare in 1998 to differentiate between malignant and benign solitary 
pulmonary nodules. It has since has experienced rapid uptake in clinical practice among both 
Medicare and privately-insured non-small cell lung cancer (NSCLC) patients, despite a lack 
of large randomized trials examining how the use of PET affects NSCLC patient outcomes. 
The three studies in this dissertation used Surveillance Epidemiology and End Results 
(SEER)-Medicare data from 1992 to 2005 to examine how the widespread adoption of PET 
has affected the evaluation, staging, treatment, and health care utilization of Medicare 
beneficiaries with NSCLC.   
By 2005, more than half of all NSCLC patients received one or more PET scans.  
Despite widespread adoption of PET overall, differential rates of PET utilization within 
sociodemographic and regional subgroups persisted through 2005, with lower rates of PET 
use observed among blacks, patients older than age 80, and patients living outside the 
Northeast.  Widespread adoption of PET was accompanied by an increase in the proportion 
of cancers staged as unresectable, reduced rates of lung resection, and decreased inpatient 
health care expenditures by 2005. During the same period, the proportion of patients 
iv 
 
undergoing chemotherapy increased, resulting in an overall increase in expenditures for 
Medicare beneficiaries with NSCLC.   
The widespread use of PET among the Medicare NSCLC occurred non-uniformly, 
induced stage migration, changed patient treatment and costs, but did not improve overall 
survival.  In the era of individualized medicine, the role of PET may shift from an initial 
diagnosis and staging modality to a role in treatment evaluation.  The increased use of PET in 
the Medicare NSCLC patient population and how it affects patient management and health 
care utilization remains an important area of ongoing research and evolving health policy. 
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PREFACE 
 
 
Consistent with the 3-paper option for a dissertation, the first chapter provides the 
introduction and specific aims of the dissertation. Chapter 2 gives a background literature 
review, Chapter 3 presents the conceptual model for the research, along with the research 
questions and hypotheses.  Chapter 4 describes the methodology used for the three studies in 
this dissertation. Chapters 5, 6 and 7 are the three individual manuscripts; because they are to 
be submitted for publication, there are some redundancies across papers. Chapter 8 presents a 
summary of the findings, policy implications, strengths and limitations of the three studies 
and provides directions for future research.  
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CHAPTER 1: INTRODUCTION AND SPECIFIC AIMS 
 
 Positron Emission Tomography (PET) is an advanced imaging modality that was first 
used to differentiate between malignant and benign solitary pulmonary nodules in 19921; it was 
initially approved for this use by Medicare in 19982.  Since then, PET usage has experienced 
rapid uptake in clinical practice among both Medicare and privately-insured non-small cell lung 
cancer patients.3,4  By 2005, more than a third of Medicare lung cancer beneficiaries were 
receiving one or more PET scans.  To date, randomized controlled trials (RCTs) investigating the 
effect of PET on NSCLC have not been adequately powered to detect a survival advantage. 5-8  
Initial epidemiologic analyses of Medicare lung cancer patients9 and one large private California 
insurer 4 have reported that PET usage is associated with significant improvements in patient 
outcomes.    
 The association between PET use and patient outcomes is difficult to interpret because of 
strong patient selection biases, with PET being more likely administered to educated, higher 
income, white, married patients with early stage tumors 4, 9.  In addition, the preferential 
administration of PET in populations with greater access to health care may bias observed 
associations between PET use and positive outcomes.  Moreover, because PET scan is a more 
sensitive detection method, it may result in higher tumor stages being given to biologically 
equivalent cancers, known as stage migration.  A known effect of stage migration is that stage-
specific survival outcomes may appear improved in the absence of any actual patient benefit.  
Studies outside the Medicare population have suggested that increased PET use may result in 
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stage migration;6,10,11 however, this phenomenon has not been studied within the Medicare lung 
cancer population.  Fully understanding the utilization of PET and how it affects staging, 
management, outcomes, and health care spending in lung cancer patients has considerable 
implications for the establishment of future imaging guidelines. 
 Thus, my dissertation, which will study the Medicare lung cancer patient population, has 
three specific aims: 
 
Specific Aim 1:  Characterize the dissemination pattern of PET from 1998-2005 
 A) Assess the association between race, sex, and age and PET use over time 
 B) Model the likelihood that an individual will receive PET over time 
  
Specific Aim 2:  Determine the presence and magnitude of PET-induced stage migration 
and the indirect association of PET use on patient outcomes from 1993-2005 
 A) Determine whether stage migration has occurred over time following the introduction 
of PET in: 
  i) the overall Medicare lung cancer patient population 
             ii) subpopulations within Medicare with differential adoption of PET 
 B) Estimate the magnitude of PET-associated stage migration  
 C) Investigate the indirect effect of PET on lung cancer outcomes over time, controlling 
for PET-induced stage migration 
 
Specific Aim 3:  Investigate the association of increased PET usage with lung cancer patient 
health care utilization within the Medicare population 
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 A) Examine whether individuals undergoing PET vs. those not undergoing PET exhibit 
 differential use of surgical and non-surgical treatment 
 B) Compare changes in surgery rates and health care costs as a function of time following 
the introduction of PET 
  
The three aims in this dissertation examine how the widespread adoption of PET has 
affected the evaluation, staging, treatment, and health care utilization of Medicare beneficiaries 
with NSCLC.  The first study will characterize which NSCLC beneficiaries received PET within 
the Medicare NSCLC patient population between 1998 and 2005 to assess potential selection 
bias and other factors associated with PET use from an epidemiologic perspective.  The second 
study will examine stage migration and survival associated with PET adoption, exploring 
previous claims by others that PET was associated with improved survival.  The third study will 
examine how PET affected the treatment and health care costs of NSCLC beneficiaries. By 
completing these aims, I hope to provide a rigorous characterization and assessment of the use 
and value of PET within the Medicare lung cancer population that can be used to effectively 
inform future health policy. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 Overview 
Cancer is a prevalent condition that accounts for significant morbidity, mortality, and 
healthcare expenditures in the United States.  It is the second leading cause of death in the United 
States, and recently surpassed heart disease as the leading cause of death in Americans younger 
than 85 12.  In 2008 alone, cancer claimed more than half a million lives and cost $228.1 billion, 
including $93.2 billion in direct medical costs 13.  Both the number of Americans affected by 
cancer and the cost of treating cancer have continued to increase in recent years.  Individual 
cancer treatment costs in the United States have increased markedly, with the majority of 
emerging cancer chemotherapeutic agents costing more than $5,000 per month of treatment 14.  
Emerging technologies such as imaging, robotics, and radiation therapy are estimated to be 
responsible for half of the growth in cancer-related healthcare expenditures15-17.  Cancer-related 
expenditures in the United States are expected to grow faster than any other area of healthcare 
expenditures 18.  The majority of cancer patients are insured by Medicare, the policies of which 
not only directly affect health expenditures of Medicare cancer beneficiaries, but also influence 
coverage policies of private insurers and Medicaid programs.19,20 
Lung cancer is the second most common cancer in both men and women, affecting 
approximately 1 of 14 individuals during the course of their lifetime.13  It is also the leading 
cause of cancer-related deaths in the United States.  The American Cancer Society estimated that 
there were 215,000 incident cases and 162,00 deaths from lung cancer in the U.S. in 200813.  
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Death from lung cancer can occur due to compromised lung function, opportunistic infections 
following partial lung obstruction, dehydration, malnutrition, or spread to other vital organs such 
as the brain, adrenal glands, liver, or bone.  Smoking cigarettes is responsible for 80-90% of all 
lung cancers.  Other risk factors include second hand exposure to cigarette smoke, asbestos 
fibers, radon gas, familial predisposition, lung disease, a prior history of lung cancer, and air 
pollution.  Old age is also strongly associated with lung cancer, with 70% of people diagnosed 
after age 65 13.  
There are two types of lung cancer: small cell lung cancer (SCLC) or non-small cell lung 
cancer (NSCLC).  Staging, prognosis, and treatment for these two subtypes differ substantially 
21
.  About 20% of lung cancers are classified as SCLC, which is more aggressive and typically 
limited to smokers.  The remaining 80% of lung cancers are NSCLC 13.  Due to the disparate 
nature of evaluation, staging, treatment, and prognosis of these two lung cancer subtypes, this 
study will only examine NSCLC.    
  
2.2 Staging Systems of Lung Cancer 
Physicians, epidemiologists, and public health proponents have found it useful to 
categorize the spread or aggressiveness of a cancer into discrete stages that reflect treatment and 
prognosis. Staging was first introduced by the World Health Organization in 1929 to categorize 
cervical cancer into four discrete stages 22.  The use of cancer staging has spread and evolved 
subsequently to meet the needs of organizations developing different staging systems for 
different purposes.  Three major staging systems predominate in most tumor registries: 1) 
American Joint Committee on Cancer (AJCC or Tumor, Node, Metastasis (TNM)), 2) 
Surveillance, Epidemiology, and End Results (SEER) summary (SEER SS), and 3) SEER extent 
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of disease (SEER EOD) 23.  Neither the SEER EOD nor SEER SS systems are used clinically, 
but instead are designed to provide historically stable staging definitions to promote robust 
longitudinal epidemiologic studies of cancer.  Instead, the AJCC system, also referred to as the 
Tumor, Node, Metastasis (TNM) system, is used by physicians to guide patient management and 
treatment and to provide information to patients regarding prognosis.  The AJCC published the 
first edition of the Manual for Staging of Cancer in 1977, and has published an updated edition 
roughly every five years since then to keep up with the needs of physicians and evolving clinical 
guidelines (Figure 2.1).  Although the exact details of the AJCC system have evolved with each 
new edition, its basic application over time has remained the same.   
 
Figure 2.1: Timeline of Changes in NSCLC staging system 
   
 The AJCC TNM classification scheme is applied as the first clinical activity in caring for 
a patient with known or presumed lung cancer because this classification determines appropriate 
therapies 24.  This initial clinical staging occurs prior to any surgery or biopsies21 and uses many 
of the procedures used to diagnosis lung cancer including standard chest X-ray, computed 
tomography (CT) scans, spiral CT, magnetic resonance imaging (MRI), positron emission 
tomography (PET), bone scans, and bronchoscopy.  In addition, surgery or biopsies are used to 
gather data on tumor size and pathology, which can more accurately stage the tumor and, 
therefore, determine patient prognosis 1,21.   
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The most recent edition of the AJCC system used by SEER stages a patient’s cancer 
using information about the primary tumor (T), spread to local lymph nodes (N), and the 
presence of metastases (M).  Tumors are scored as follows: Primary tumors are given a “TX” for 
primary tumors that cannot be directly assessed, “T0” indicates no evidence of primary tumor, 
“Tis” indicates carcinoma in situ, “T1” is less than 3 cm and has not invaded the main bronchus, 
“T2” is larger than 3 cm or involves the main bronchus, “T3” directly invades the chest wall, 
diaphragm, or some surrounding tissues, and “T4” if the tumor invades the trachea, heart, large 
vessels, or esophagus. Lymph nodes are similarly given a “NX” if local lymph nodes cannot be 
assessed, “N0” if there are no regional lymph node metastases, “N1” if there is local spread to 
lymph nodes on the same side of the body as the primary tumor, “N2” if this spread reaches the 
area around the heart, and “N3” if lymph nodes on the opposite side of the body or more distant 
lymph nodes are affected.  Metastasis is assigned an “MX” if distant metastasis cannot be 
assessed, “M0” if there are no distant metastases, and “M1 if there are distant metastases.  This 
information is used to assign a categorical stage ranging from Stage I-IV (Table 2.1). 
 
Table 2.1: TNM NSCLC stage 
STAGE TUMOR (T) LYMPH NODE (N) METASTASIS (M) 
Occult Carcinoma TX N0 M0 
Stage 0 Tis N0 M0 
Stage IA T1 N0 M0 
Stage IB T2 N0 M0 
Stage IIA T1 N1 M0 
Stage IIB T2 N1 M0 
 T3 N0 M0 
Stage IIIA T1 N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
Stage IIIB Any T N3 M0 
 T4 Any N M0 
Stage IV Any T Any N M1 
Source: AJCC staging manual, 6th edition 
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Over the time period relevant to this proposal, four AJCC editions have been in effect (Figure 
2.1), however only the 3rd and 6th edition have been used by the SEER registry that was used in this 
research.  Staging from the 3rd edition was provided by SEER prior to the beginning of the proposed study 
period in 1993, and was used until 2003.  In 2003, SEER began using the 6th edition staging system.  
Beginning in 2003, stage I was split into stage IA and IB and stage II was split into stage IIA and 
IIB.  In addition, T3N0 tumors were reclassified from stage IIIA to stage IIB.  As a result, from 
2002 to 2003 there may have been a small increase in the proportion of tumors staged as II and a 
decrease in the proportion of tumors staged as III.   
 
2.3 Treatment of Lung Cancer 
 
 The National Cancer Institute (NCI) and the National Comprehensive Cancer Network 
(NCCN) are two of the leading organizations that provide guidelines for providers and patients 
regarding the appropriate treatment of cancers 25.  Based on stage, lung cancer treatment options 
include surgery, radiation, and/or chemotherapy (includes biologics).  For cancers that have 
spread only locally, surgical removal of the cancer is the principal treatment modality.  For 
patients whose disease has spread to distant locations in the body, referred to as metastatic or 
stage IV disease, surgery is generally not an effective treatment25.  Stage IIIB is treated in the 
same manner as stage IV disease.  Current NCCN guidelines recommend chemotherapy or 
targeted biologic therapy for patients with metastatic or recurrent disease26.  Regardless of 
whether or not surgery is performed, chemotherapy and radiation can be used depending on the 
patient’s health and cancer stage 25.  Higher stages indicate more aggressive cancer and are 
associated with reduced survival time and overall reduced survival.27   
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Stage I tumors (IA & IB) are generally treated by local resection (i.e. surgical removal of 
the tumor).  For individuals who cannot undergo surgery due to poor health or advanced age, 
curative radiation therapy can be used instead.  NCCN guidelines recommend chemotherapy for 
only a subset of stage I tumors, for example those with positive margins (leftover residual tumor) 
following resection 26.  Stage IA tumors are the least aggressive, and have an estimated 5-year 
survival of 75% in the United States, whereas stage IB tumors have a 5-year survival of 55%.  
Stage II tumors (IIA & IIB) have 5-year survival rates of 40-50% and are treated by local 
resection or curative radiation, but may benefit from adjuvant (additional) chemotherapy 
following surgical resection.  Adjuvant radiation therapy is being explored in these patients in 
the setting of clinical trials 25. 
Stage IIIA tumors may be treated by surgery, chemotherapy, and radiation.  Individuals 
with these tumors have an overall poor prognosis with a 5-year survival ranging from 10% to 
35%.  Once the tumor has advanced to stage IIIB, however, patients no longer benefit from 
surgery.  Instead, they may receive chemotherapy and radiation.  Stage IV patients have 
metastatic disease.  Again, surgery and radiation are not effective treatments, because they will 
only act locally.  However, stage IV patients may still be treated using chemotherapy.  Palliative 
radiotherapy can be used to provide relief from symptomatic primary or metastatic tumor sites.  
Patients with stage IIIB and IV have 5-year survival rates of 5% or less with most patients dying 
within a year of diagnosis 25.  
 
2.4  Conventional Evaluation of Lung Cancer 
Approximately 25% of people discover lung cancer during routine chest X-ray or CT 
scans, and may have no symptoms at the time of diagnosis 25.  The remaining cases are 
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diagnosed by symptoms caused by their cancer.  Symptoms can result from the local presence of 
a tumor within the lung, from distant metastases, from hormones produced by the tumor, or 
indirectly via non-specific symptoms common to many cancers.  Local spread within the lungs 
can cause difficulty breathing, wheezing, chest pain, coughing up blood, trouble swallowing, or 
local collapse and infection of the lungs.  Distant metastases in the brain can cause neurologic 
symptoms such as headaches, seizures, stroke, or loss of motor control.  Hormones or substances 
that act like hormones can be produced by lung tumors, which can cause systemic hormone and 
blood calcium imbalances.  Nonspecific symptoms of any cancer including lung can include 
fever, weight loss, weakness, fatigue, and depression 25.  All putative diagnoses of lung cancer 
must be confirmed by the presence of malignant cells by a pathologist.  Physical samples of 
tumor cells can be obtained directly from the tumor itself by bronchoscopy, fine needle 
aspiration (FNA), obtaining a sample of the fluid surrounding the lungs, surgery, or even a 
sample of mucus 25.  After a patient is diagnosed, their cancer is staged. 
 To stage a tumor, physicians use physical examination, patient history, biopsy, surgery, 
and an armament of constantly evolving diagnostic technologies such as imaging or blood tests.  
Imaging tests are frequently used in the evaluation of lung cancer patients, and can include 
standard chest X-rays, CT scans, spiral CT, MRI, PET, bone scans, or bronchoscopy 25.   
 
2.5 PET Evaluation of Lung Cancer 
 The most commonly used form of PET in oncology uses a radioactive mimetic of glucose 
called fluorodeoxyglucose (FDG), which is preferentially absorbed by cancer cells due to their 
high rate of metabolism.  FDG-PET provides an improvement over traditional imaging 
modalities, such as CT scans, which only provide anatomical information such as the size or 
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presence of a lump or lymph node in the lungs.  Studies demonstrating the ability of FDG-PET to 
differentiate benign, or harmless, nodules in the lung from metabolic active lung cancer were 
first published in 1992 1.  In subsequent studies and comparisons with traditional imaging 
modalities, PET has been shown to provide a more sensitive and specific assessment of 
pulmonary nodules (small lumps in the lung) and metastasis of NSCLC lung cancer 6, 25, 28.  PET 
can be used to assess neurologic 29 and cardiovascular 30 disease.  However, in recent years its 
greatest use by far has been related to cancer.25 
 
 The first use of PET scans to differentiate malignant and benign solitary pulmonary 
nodules (SPN) occurred in 1992.  On January 1, 1998, PET was approved by Medicare for the 
characterization of SPNs and the initial diagnosis and staging of NSCLC (Figure 2.2).  This 
initial coverage was expanded to include restaging of NSCLC on July 1, 2001.  As of January 28, 
2005, the use of PET was approved for all cancers, including NSCLC, provided that its use was 
part of a Medicare-approved research study 2.  Following the initial approval of PET in 1998, a 
number of studies have documented a rapid increase in PET among the general Medicare as well 
as other populations 3, 4, 31. It is important to note that although PET scans can be used for non-
cancer indications 2 in neurology29, 32  or cardiology,30 these claims are categorized separately 
within Medicare and can be differentiated from their use for cancer (see Chapter 4:Methods). 
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Figure 2.2: Timeline of Medicare coverage determinations for use in NSCLC2. 
 
 
 
2.6 Stage Migration 
 In 1985, Feinstein and colleagues published a seminal paper that examined the staging of 
lung cancer patients before and after the introduction of several new diagnostic imaging 
technologies, including radionuclide scanning, CT, and ultrasonography 33.  In this study, the 
authors compared survival of two cohorts of patients, one treated between 1953 and 1964 and the 
other in 1977 and followed through 1982.  After analyzing all available data, the later cohort 
appeared to have improved stage-specific survival compared to the earlier cohort.  However, the 
authors noticed that the later cohort also exhibited differences in the stage distribution as 
compared to the earlier cohort.  They hypothesized that observed differences in survival might be 
artifacts of the improved diagnostic techniques that had been introduced after 1964.  They found 
that when they ignored the results of these tests and staged both cohorts using clinical 
manifestations such as anorexia, weight loss or fatigue (instead of technology-based 
assessments), both stage distribution and survival no longer differed between the two cohorts.  
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These results demonstrated that the use of novel, more sensitive diagnostic techniques had led to 
more aggressive staging of patients, but an artificial increase in patient survival (Figure 2.3).   
 
Figure 2.3: Stage migration in NSCLC patients as a result of improved diagnostic 
technology (Printed with permission)  
 
 
 They named this phenomenon of stage migration in cancer the “Will Rogers 
Phenomenon” after American comedian and philosopher Will Rogers, who was reported to have 
made a remark regarding the American geographic migration during the great depression of the 
1930s: “When the Okies left Oklahoma and moved to California, they raised the average 
intelligence level in both states.” 
 More than two decades later, Chee et al.10 studied patients diagnosed with NSCLC 
between 1994 and 2004 within a California-based statewide cancer surveillance system. These 
patients were followed until study completion in 2006 or death.  They found that in the years 
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following the introduction of PET (1999-2004) the number of stage IV cancers increased and the 
number of stage III cancers decreased (Figure 2.4) with an improvement in outcomes.  However, 
stage migration must be carefully considered when evaluating the value of new, more sensitive 
diagnostic tests.  
 
Figure 2.4: Stage migration in a large California private insurer lung cancer population 
(From Chee et al. 10  Printed with permission) 
  
  
 
 
 
 
 
 
 
 
 
 
 
In addition to stage migration, earlier detection of cancer can result in artificial 
improvement in survival.  Survival is measured from the time of diagnosis.  Making an earlier 
diagnosis of the same cancer makes it appear that a patient has lived longer by shifting when the 
survival clock is started.  This phenomenon, known as zero time-shift 33, also has the potential to 
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affect associations between patient survival and new diagnostic tests.  In theory, a zero time-shift 
would be detected as an overall increase in the prevalence of disease; however, this has not been 
previously studied in NSCLC and PET, and is considered outside the scope of this proposal. 
 
2.7 Changes in PET use 
 New or emerging technologies have not always disseminated uniformly among the 
American public, and PET has been no exception.  Regional availability of PET varied 
significantly during its initial adoption.  A study of regional imaging rates documented that in 
1998, the rate of PET use was 15 times higher in New York than Dallas34.  The same study 
suggested that heterogeneity in regional PET use has continued to persist as late as 2007, albeit 
at a reduced level.   
Over the past two decades the use of non-invasive diagnostic imaging tests such as PET 
have shifted from radiologists to non-radiologists35, 36.  In recent years, these tests have continued 
to shift from hospital outpatient facilities to private practices.  This shift has been accompanied 
by the direct purchase or leasing of PET scanners by private practice physicians.  The number of 
PET scanners owned or leased by non-radiologist, private practice physicians  has increased 
seven-fold between 2002 and 2007 37.  The vast majority of physicians (95%) now in possession 
of PET scanners are in internal medicine, medical oncology, cardiology, radiation oncology, or 
primary care.  The changing use of PET over time has been observed in other countries in recent 
years 38. 
 In order to address the changing landscape of PET use in the oncology community, in 
2005 the Centers for Medicare & Medicaid Services (CMS) began providing coverage for any 
PET scan involved in oncology provided that it was part of “Coverage with Evidence 
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Development” (CED) 2.  In order to fully capitalize on potential evidence from CED, CMS 
allowed the creation of the National Oncologic PET Registry (NOPR) 39.  The NOPR is an 
internet-based, prospective registry sponsored by the Academy of Molecular Imaging (AMI) and 
managed by the American College of Radiology (ACR) through the American College of 
Radiology Imaging Network (ACRIN).  The NPOR obtains information regarding physician 
treatment plans before and after performing PET.  Initial findings from the NPOR have 
suggested that roughly one of three physicians will change their decision to treat or not treat 
following a PET scan40.  The NPOR only receives information for PET scans provided as part of 
CED, and therefore does not include the use of PET for previously approved indications, 
including NSCLC.  Findings from the NPOR study may not be generalizable to PET use in 
NSCLC or other approved PET indications.  In response to findings from the NPOR, CMS 
announced a decision to expand coverage to include a single PET scan for any solid tumor or 
myeloma in April 200941.  Following this expansion of coverage, NPOR has continued to collect 
information on PET usage that remains covered under CED. 
 
2.8 Disparities in Medical Technology Use 
 Disparities in race, gender, and age have been observed with regards to cancer health care 
access, treatment, and survival22,42-59.  In general young, white, educated, high income, and urban 
individuals are more likely to receive emerging health care services.  A study of elderly 
Medicare patients observed that whites were more likely to receive 23 different procedures and 
tests than blacks.  In particular, they found that whites especially had an advantage with regards 
to receiving new or higher-technology services 42.  Studies of other cancer diagnostic or 
screening technologies have demonstrated differential use by demographic characteristics, with 
17 
 
older, black, rural, poorly-educated, females being least likely to receive the newest technology 
for colorectal cancer screening.  PET scanners are expensive resources that may not be available 
at disadvantaged hospitals. African Americans and whites are often treated at different hospitals 
47
, with hospitals that treat large proportions of African American patients being less likely to 
perform emerging medical procedures on any of their patients 22.   
 A study of SEER-Medicare patient outcomes between 1991 and 2002 found a significant 
difference in survival between blacks and whites with NSCLC in overall mortality.  Blacks with 
stage III-IV disease fared worse than whites with stage III-IV disease during the most recent 
study period, which ranged from 2000-2002 period, but not earlier periods 56.  Emerging medical 
technology such as PET could be culprits in reintroducing disparities in NSCLC management 
and outcomes.   
 
2.9 Significance and contribution 
 Concerns have emerged that the rapid adoption of emerging medical devices and imaging 
technologies may be unduly influenced by less stringent FDA approval requirements than those 
required for new drugs 60, high profit margins 61, and inadvertent payment incentives 20.  Not 
surprisingly, high-end imaging services such as CT, MRI, and PET are among the most frequent 
sources of competition acknowledged among hospitals and physicians 62.  There are additional 
concerns that the use of high-end imaging appears to be additive in nature and does not replace 
the need for conventional imaging methods and results in increased healthcare utilization and 
costs 63.  Previous analyses have suggested that the high cost of PET, reimbursed by Medicare in 
2004 at $1,774 per scan 64, may be in part justified by a purported association with improved 
NSCLC patient survival  9,11.  However, high cost and ethical considerations have precluded the 
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ability to conduct large, adequately-powered randomized, controlled trials to definitively assess 
the overall indirect effect of PET on patient outcomes.  Epidemiologic assessments of PET have 
not fully eliminated potential bias due to either selection bias or stage migration 9, or have not 
been conducted in the Medicare cancer population 10.   
Fully understanding the utilization of PET and how it affects evaluation, staging, 
treatment, and health care utilization in NSCLC patients has considerable implications for the 
establishment of future imaging guidelines.  The proposed study will examine the possibility of 
PET as a culprit for promoting disparities in NSCLC management and outcomes.  By carefully 
characterizing and controlling for selection bias and stage migration, the proposed study will 
arrive at population level estimates of the association of PET with both favorable patient 
outcomes and unfavorable health care costs in order to best inform the balance of future health 
care policy. 
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CHAPTER 3: RESEARCH QUESTIONS AND HYPOTHESES  
 
 
 The goals of the proposed study are to: 1) characterize the spread of PET throughout the  
 
Medicare lung cancer population, 2) assess the presence and magnitude of PET-induced stage  
 
migration in the Medicare lung cancer patient population and its effect on patient outcomes, and  
 
3) estimate the effect of PET on healthcare costs and utilization in the context of stage migration. 
 
 Aim1 will examine the dissemination of PET into the Medicare lung cancer patient 
population from 1998 to 2005.  The conceptual model (Figure 3.1) examines the influence of 
age, gender, and race on the likelihood of a patient receiving PET.  I hypothesize that this effect 
is mediated, in part, through general accessibility to health care.  A previous study by Farjah et 
al. 65 found that younger, female, whites had higher rates of advanced diagnostic tests in the 
Medicare lung cancer population. 
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Figure 3.1: Conceptual model of the relationship between demographic factors, access to 
healthcare, PET use, staging, treatment, costs, and outcomes.   
 
 
3.1 Specific Aim 1 
Research Question 1: How has PET diffused in the Medicare NSCLC patient population with 
regards to age, race, and gender over time? 
H1a: During the initial adoption of PET, patients who tend to have the most access to 
health care were most likely to receive PET.  Specifically, younger, white, females will 
be most likely to receive PET.   
H1b: Receipt of PET will be initially biased heavily towards younger, white, females.  
As PET adoption becomes more widespread, the association between PET use and age, 
gender, and race will decrease. 
 
 Specific Aims 2 and 3 will examine the magnitude of PET induced stage migration and 
its effects on outcomes, healthcare utilization, and costs.  The conceptual model (Figure 3.1) is 
based on the hypothesis that PET use will affect patient staging, which will in turn affect patient 
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treatment and management, which will result in changes in patient outcomes, health utilization, 
and costs.  The use of PET will affect health care costs through the direct cost of the imaging 
scan. 
 
3.2 Specific Aim 2 
Research Question 2a: Was the adoption of PET associated with stage migration in the overall 
Medicare NSCLC patient population over time? 
H2a1: The proportion of beneficiaries diagnosed with stage IV NSCLC cancer in the 
overall Medicare population will be positively correlated with the proportion of 
beneficiaries receiving PET for those diagnosed with NSCLC between 1993 and 2005. 
H2a2: Individuals diagnosed in the post-PET subgroup (2004-2005) will demonstrate a 
significant increase in the relative proportion of stage IV cancers compared to pre-PET 
and initial-PET subgroups (1993-1994 and 1998-1999). 
Research Question 2b: Did the adoption of PET result in differential stage migration over time 
in subsets of the Medicare lung cancer patient population that experienced differing rates of PET 
use? 
 H2b1:  Younger, white, females in the post-PET subgroup (2004-2005) will demonstrate 
a significant increase in the relative proportion of stage IV lung cancers as compared to the pre-
PET subgroups (1993-1994 and 1998-1999), whereas old, minority, males will not. 
H2b2: The older, minority, male population will have experienced slower rates of PET 
 adoption and will see less stage migration between 1993 and 2005 than the younger, white, 
female population. 
Research Question 2c: What is the magnitude of PET-associated stage migration? 
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 H2c: A beneficiary receiving one or more PET scans will be more likely to be 
 diagnosed with stage IV cancer than a beneficiary who has not received a PET scan. 
Research Question 2d: Previous studies by Farjah et al. 9 and Chee et al.10 have suggested 
strong associations between PET use and survival in which the use of PET is associated with 30-
50% increased survival rates in NSCLC patients.  It is possible that previously observed 
associations between PET use and survival are a result of selection bias or stage migration.  Is 
there a positive association between PET use and improved patient outcomes after controlling for 
both selection biases and stage migration? 
H2d: Beneficiaries receiving one or more PET scans will have increased 2-year survival 
compared to beneficiaries who did not receive PET. However, the observed association 
between PET use and increased survival will be smaller in magnitude or disappear 
altogether after correctly adjusting for PET selection biases estimated in Aim 1 and PET 
associated stage migration estimated in Aim 2. 
 
3.3 Specific Aim 3 
Research Question 3a: Is differential treatment of lung cancer associated with PET use in the 
overall Medicare lung cancer population? 
H3a1: Beneficiaries receiving one or more PET scans will be more likely to have a 
diagnosis of stage IV cancer, which will reduce the number of overall patients receiving 
futile surgical treatment with a curative intent in the 2004-2005 cohort.   
H3a2: Beneficiaries receiving one or more PET scans will on average receive more 
aggressive non-surgical treatment (radiation and chemotherapy) than those who did not 
receive PET in the 2004-2005 cohort.   
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Research Question 3b: Is the cost of treating lung cancer associated with the use of PET? 
 H3b1: PET use will be associated with higher total costs and lower surgical costs in the  
 overall NSCLC Medicare population.  Higher costs will be associated with PET use as a 
 result of an association between PET and health care access.  Total surgical costs will be 
 reduced due to a reduction in the number of futile thoracotomies (unnecessary surgery). 
H3b2: Populations with higher PET propensity will experience overall cost savings 
relative to lower PET propensity populations in the post-PET subgroup (2004-2005) 
compared to pre-PET subgroups (1993-1994 and 1998-1999) due to sparing of 
unnecessary surgical treatment costs of correctly diagnosed stage IV patients.   
  
24 
 
 
 
 
CHAPTER 4: METHODS 
 
 
4.1 Overview 
 
 The overall objectives of the project are to characterize the following phenomena within 
the Medicare lung cancer population: 1) adoption of PET, 2) PET-induced stage migration and 
its effect on patient outcomes, and 3) changes in health care utilization as result of PET use. To 
address these objectives I conducted a secondary analysis of the SEER-Medicare linked dataset 
composed of SEER data for the years 1993 through 2005 and linked Medicare data for the years 
1992 through 2007.  Proposed research questions, hypotheses, and analyses are summarized by 
aim in Table 4.1.   
 
4.2 Data 
 4.2.1 Medicare Claims data 
 Medicare is the nation’s single largest medical insurer, providing coverage for 97% of the 
U.S. population ages 65 and older66.  Medicare standard analytic files include denominator files 
and corresponding inpatient, outpatient, carrier, and durable medical equipment claims from the 
CMS.  The inpatient files contain institutional claims for facility costs covered under Medicare 
Part A, and the outpatient files contain claims by institutional outpatient providers (eg, hospital 
outpatient departments, ambulatory surgery centers). The carrier files contain provider claims for 
services covered under Medicare Part B. The denominator files contain beneficiary identifiers, 
sex, race/ethnicity, birth dates, dates of death, ZIP codes, and information about program 
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eligibility and enrollment 67.  Enrollment information from the denominator files are included in 
the provided SEER Patient Entitlement and Diagnosis Summary File (PEDSF) file.  The SEER  
linked Medicare data provides both cancer and non-cancer controls matched by geographic 
region 66.  Medicare claims describe Medicare payments, and have been used routinely in the 
literature to determine the cost of services to Medicare and estimate overall health care 
expenditures.68  
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Table 4.1: Proposed Research Questions, Hypotheses, and Analyses Summarized by Aim 
Hypotheses Analysis Cohort 
AIM 1 – Q1: How has PET disseminated within Medicare? 
H1a White, young, females will be more likely to have 
received PET 
Pr(PET) = f(β0 + β1 Race + β2 Sex + β3 Age 
+ β4 Year) Dataset 1 
(1998-2005) H1b 
As availability of PET increases with year of 
diagnosis, the association between PET and race, 
sex, and age will decrease 
Pr(PET) = f(β0 + β1 Race + β2 Sex + β3 
Age + β4 Year + interaction w/ race, sex, 
and age) 
AIM 2 – Q2A: Was PET adoption associated with stage migration in the overall Medicare 
population? 
H2a1 
Prevalence of stage IV cancer will be correlated with 
PET use in the overall Medicare population between 
1993-2005  
Descriptive plot Dataset 2 
(1993-2005) 
H2a2 
Prevalence of stage IV cancer will be highest in the 
post-PET era 
Chi-Squared test Dataset 3 
(Post vs Pre-
PET) 
AIM 2 – Q2B: Did subsets of the Medicare population with differential PET adoption exhibit 
differential stage migration? 
H2b1 
As a group, young white females will experience 
exaggerated stage migration compared to old black 
males between 1993-2005  
Descriptive plot Dataset 2 
(1993-2005) 
H2b2 
As a group, young white females will have more 
stage IV cancer in the post-PET era, while old black 
males will not 
Chi-Squared test Dataset 3 
(Post vs Pre-
PET) 
AIM 2 – Q2C: What is the magnitude of PET-associated stage migration? 
H2c Receipt of PET will be associated with increased 
stage IV cancer 
Pr(Stage IV) = f(β0 + β1 PET)  Dataset 3 
(Post-PET only) 
AIM 2 – Q2D: Is PET use associated with increased two-year survival? 
H2d 
Beneficiaries receiving PET will have unchanged 
two-year survival after adjusting for selection bias 
and stage migration 
Pr(2yr-Surviva)l = f(β0 + β1 PET + β2 Stage 
+ βPET*Stage)  
Dataset 3 
(Post-PET only) 
AIM 3 – Q3A: Is PET use associated with altered patient management? 
H3a1 
Surgical treatment will decrease over time w/ the 
introduction of PET.  PET use will be associated 
with less frequent surgical treatment   
Pr(Chem, Radiotherapy, or Surgery) 
       = f(β0 + β1 PET + β2 Stage + β Year)  Dataset 2 
(1996-2005) 
H3a2 PET use will be associated with more frequent non-
surgical therapy 
AIM 3 – Q3B: Is PET use associated with increased total health care utilization? 
H3b1 
PET use will be associated with higher non-inpatient 
costs in the overall Medicare population due to 
increased health care access 
Non-Inpatient Costs = β0 + β1 PET + β2 
Stage + βYear +/- βTreat Dataset 2 
(1996-2005) 
 H3b2 
Inpatient/Surgical costs will decrease over time as a 
result of reducing futile thoracotomy costs following 
the adoption of PET 
Total and Inpatient Costs = β0 + β1 PET + 
β2 Stage + βYear +/- βTreat 
See sections 4.3.1 and 4.4.1 for detailed description of datasets 1-3.  
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 4.2.2 SEER (Surveillance, Epidemiology, and End Results) data 
 The SEER cancer registry is a large population-based cancer registry that tracks the 
incidence of all cancers in selected geographic regions within the United States.  The registry 
first began tracking cancers in 1973, and in 1991 first began linking with Medicare claims 66.  
SEER-Medicare data have since provided a unique opportunity to allow population-based 
analysis of cancer care 69.  Patients within the SEER registry are considered to provide a 
reasonable representation of the overall U.S. population, however it should be noted that 
compared to the overall U.S. population, patients within the SEER registry are overall more 
likely to be non-white, live in non-poverty areas, and live in urban areas66.  Information collected 
through SEER is provided within the SEER Patient Entitlement and Diagnosis Summary File 
(PEDSF) and includes patient demographics, date of diagnosis, cancer stage, histology, grade, 
treatment provided within 4 months diagnosis, and cause of death.  The registry does not include 
information about cancer screening, how a cancer was diagnosed, treatment beyond 4 months 
after diagnosis, or long-term disease status 66.   
 The combined SEER-Medicare data have been used previously to study a number of 
aspects or features that affect cancer care quality and include sociodemographics 67, physician70 
and hospital71 characteristics, surgery72, chemotherapy73, radiation74, comorbidities75, 
complications76, screening77, relapse78, and costs68.  For the purposes of this study, the key 
information gained from the SEER portion of the SEER-Medicare linked data will be the 
diagnosis of NSCLC, AJCC cancer stage, and patient and local demographics.  The key 
information gained from the Medicare linked claims data will be PET use, cancer treatment, and 
health care costs.  A list of all variables and corresponding data sources is shown in Table 4.2.  
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Several registries were added to SEER in 2000.  Comparisons within the SEER-Medicare data 
that include years before and after 2000 will be limited to SEER registries present in all years. 
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Table 4.2: Summary of All Variables and Data Sources 
Variable Variable 
Type 
Source Derivation/Notes 
Age Continuous SEER - PEDSF Age at diagnosis 
Cumulative    
     incidence    
     (observation 
     time) 
Continuous SEER - PEDSF Time from diagnosis to death, hospice, HMO, or two years, 
whichever is shortest  
Diagnosis date Continuous SEER - PEDSF Monthly 
Education Categorical SEER – PEDSF Zip code level quartiles 
Gender Dichotomous SEER – PEDSF  
Income Categorical SEER – PEDSF Zip code level quartiles 
Marital Status Categorical SEER – PEDSF  
Race Categorical SEER – PEDSF  
Region Categorical SEER – PEDSF  
Residence 
     Type 
Categorical  SEER – PEDSF  
Stage Categorical SEER – PEDSF -AJCC 3rd edition through 2003, AJCC 6th edition afterwards 
-Modified AJCC 3rd edition through 2003 
-SEER summary staging 
-SEER historic staging 
2-yr Survival Dichotomous SEER – PEDSF Alive or deceased at 2 years 
Chemo/ 
Radiation 
Dichotomous  SEER – PEDSF 
Medicare 
Indicates if the patient had any record of chemotherapy or 
radiotherapy in either SEER or Medicare claims.  Medicare 
HCPS codes are used per Farjah et al. (2009). 
Surgery Dichotomous SEER – PEDSF 
Medicare 
Indicates if the patient had any record of chemotherapy or 
radiotherapy in either SEER or Medicare claims.  Medicare 
HCPS codes are used per Farjah et al. (2009).  
NCI 
Comorbidity 
Index 
Continuous Medicare Determined using Medicare claims in the year prior to cancer 
diagnosis 
Total Health 
Care Costs 
Continuous Medicare Line item summed Medicare payments using all patient claims 
from all inpatient, outpatient, carrier file, medical device file, 
and home health file.  Technically these are payments, not costs.  
They do not include patient co-pays or deductibles, but instead 
indicate the amount that Medicare paid for a given service. 
Inpatient 
Health Care 
Costs 
Continuous Medicare Total Health Care Costs, limited to inpatient file. 
Non-Inpatient 
Health Care 
Costs 
Continuous Medicare Total Health Care Costs, excluding inpatient file. 
PET receipt Dichotomous Medicare:  
Carrier Files 
Outpatient Files 
 
Determined by the presence of any one of the following HCPCS 
during the specified window: 
78810-78816, G0125, G0126, G0163, G0164, G0165, G0210-
G0228, G0231-G0234, G0213-G0215, G0226-G0228,  
G0235, G0252, G0253, G0254, G0296, G0330, G0331 
Distance to 
PET 
Continuous Derived Zip code based distance calculation between patient and nearest 
zip code with a PET facility 
PET facility / 
provider 
Dichotomous Derived Derived by identifying the first date at which any PET 
providing or referring physician files a claim at that facility.  
From that date forward, the facility is considered a PET facility. 
PET propensity 
score 
Continuous Derived Logistic Regression 
NCI: National Cancer Institute 
HCPCS: Healthcare Common Procedure Coding System 
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4.3 Specific Aim 1  
 Characterize the dissemination pattern of PET from 1998 to 2005 in the SEER-
Medicare NSCLC patient population.  Previous analyses have demonstrated a significant 
selection bias in the application of PET, finding that PET use in the Medicare lung cancer patient 
population is significantly higher in educated, high income, white, married individuals with early 
stage tumors9,10.  It is not clear how the severity and magnitude of these selection biases have 
changed over time.  Non-uniform dissemination of PET and/or patient selection biases may have 
confounded previous studies of the value of PET technology.  This aim examines dissemination 
patterns of PET in a nationally representative sample of lung cancer patients.  Specifically, I 
hypothesize that the increased use of PET in Medicare beneficiaries with NSCLC will be 
observed among patients who are young, white, and female.  I hypothesize that non-uniform 
dissemination and selection biases were most severe following the introduction of PET and that 
these biases have lessened with wider adoption of PET.   
 
4.3.1 Cohort Structure and Inclusion/Exclusion Criteria  
 The study cohort for Aim 1 is composed of the SEER-Medicare sample for the years 
1998 through 2007 (Figure 4.1).  Because Aim 1 relies on the comparison of beneficiaries who 
do and do not receive, PET, the study population is restricted to years in which some 
beneficiaries received PET.  Fewer than 5% of Medicare beneficiaries diagnosed with NSCLC 
before 1998 received any PET scans. 79  The proportion of beneficiaries receiving PET continued 
to be low for patients diagnosed in 1998 in preliminary analyses (not shown), with only 1.3% of 
all lung cancer beneficiaries having undergone one or more PET scans within two years of their 
diagnosis.  The proposed SEER-Medicare cohort will be restricted to 1998 and later to ensure 
31 
 
that each cohort year contains an adequate proportion of PET receiving beneficiaries.  The 
exclusion of the 1996 and 1997 cohorts may help to avoid potential bias caused by differences in 
the timing of PET administration between the 1996 and 1997 cohorts and later cohorts.  Since 
PET was not approved until 1998, individuals receiving PET within the 1996 and 1997 cohorts 
would have likely have done so after one to two years of their cancer diagnosis.  As a result, PET 
use within the 1996 and 1997 cohorts would be mostly used for restaging or treatment evaluation 
and might systematically differ from PET used in later cohorts for diagnosis or staging. 
Figure 4.1: Aim 1 Cohort Structure.  Dataset/Population 1. 
 
The basic cohort structure identifies individuals with a SEER-based diagnosis of NSCLC 
lung cancer similar to a previous study by Farjah et al. (2009)9.  Patients were excluded if they 
were diagnosed at autopsy/death, were younger than 66 years old, did not have NSCLC 
pathology, had another malignancy in the year prior (using Medicare claims), and did not have 
both part A and B coverage, or were enrolled in a health maintenance organization (HMO).   
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Patients were additionally required to have at least one Medicare based ICD-9-CM diagnosis of 
lung cancer (162.2, 162.3, 162.4, 162.5, 162.8, 162.9, or 231.2) on a carrier, inpatient, or 
outpatient claim within the two months prior to or following the SEER NSCLC cancer diagnosis.  
Each patient was followed for two years from the date of diagnosis (Figure 4.1).  This distinct 
time frame provides a well-delineated period over which cancer-related imaging procedures can 
be assessed 3.  Additionally, confining the analysis to a two-year period allows for equivalent 
follow-up for all patient cohorts through the 2005 cohort.   
 To be considered a new-onset or incident case, beneficiaries were required to have been 
eligible for fee-for-service Medicare for a minimum of one year (i.e., must be ages 66 or older) 
to provide a year of prior claims from which comorbidities can be determined.  A summary of 
datasets and cohorts used in each aim are provided in Table 4.3. 
 
Table 4.3: Summary of Datasets and Cohorts 
Dataset SEER data  
(Years of Diagnosis) 
Medicare 
Claims 
Aims Motivation 
1 1998-2005 1997-2007 1 Capture continuous trends during 
period of PET adoption 
2 1993-2005 1992-2007 2, 3 Capture continuous trends during 
period before and during PET 
adoption 
3 Pre-PET (1993-1994) 
Initial-PET (1998-1999) 
Post-PET(2004-2005) 
1992-1996 
1997-2001 
2003-2007 
2, 3 Characterize discrete cohorts that 
occured well before, just before, and 
at peak PET usage 
 
 
4.3.2 Study Variables and Controls 
 The key dependent variable studied in Aim 1 was a dichotomous variable (receiving PET 
scans within two months prior to or following SEER lung cancer diagnosis).  This variable will 
be operationalized using HCPCS codes within the Medicare-linked carrier files.  HCPCS codes 
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are used for various procedures or services for which Medicare claims must be billed.  For the 
vast majority of medical services, HCPCS codes use current procedural terminology (CPT) 
codes developed and maintained by the American Medical Association (level I HCPCS codes).  
However, in cases where CPT codes do not exist or do not adequately describe a medical service 
for the purpose of Medicare, unique HCPCS codes are created (level II HCPCS codes). 
CPT/HCPCS codes corresponding to PET administration for Medicare beneficiaries differentiate 
between PET scans used to assess oncologic, cardiovascular, or neurologic conditions.  I have 
used CPT/HCPCS previously to quantify PET scan use in the Medicare cancer patient 
population3 (Table 4.4).  PET can also be used for non-cancer related purposes.  Medicare first 
covered the use of FDG-PET for non-cancer related purposes on July 1, 2001, for the assessment 
of heart tissue viability and seizures that are resistant to initial therapy.  The goal of the current 
study is to assess the spread of PET use in the context of lung cancer care.  As a result, only lung 
cancer related uses of PET or combined PET/CT (Table 4.4) will be counted as PET scans.  
Patients who have had one or more PET scan administered in the two months prior to the SEER 
month of diagnosis through 4 months later were considered to have received PET. 
Table 4.4: PET CPT/HCPCS codes relevant to lung cancer 
PET Type CPT (Level I) codes HCPCS (Level II) codes 
PET- Tumor  78810-78813  
PET/CT -Tumor  78814-78816  
PET – NSCLC  G0125, G0126, G0210-G0212, G0234 
PET – NOS*  G0235  
*Site not otherwise specified 
 The key independent variables studied in Specific Aim 1 are year, PET availability (for 
propensity scoring) and patient demographics, specifically race, gender, and age.  Race, gender, 
and age are all available from the SEER-PEDSF file.  Race was defined as used in a previous 
study of PET and lung cancer by Farjah et al. 9 to allow comparability between studies and age 
will be modeled as a continuous variable (Table 4.2).   
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 Table 4.5: Primary dependent and independent demographic variables. 
Dependent Variable Possible Values Variable Type 
Receipt of PET One or more PET scans, No PET scans Dichotomous 
   
Primary Independent 
     Variables 
  
Race Black, Non-black Categorical 
Gender male, female Dichotomous 
Elderly >80 years old Dichotomous 
Year Calendar Year Continuous 
 
 Several factors may affect the decision to administer PET directly or represent general 
indicators of health care access (see conceptual model – Figure 3.1) and must be controlled 
(Table 4.6).   
Table 4.6: Proposed Aim 1 control variables. 
Control Variables Possible Values Variable Type 
Distance to PET <40 Miles, ≥ 40 miles Dichotomous 
Income (Census) lowest quartile, upper three quartiles, missing Categorical 
Education (Census) lowest quartile, upper three quartiles, missing Categorical 
Marital Status married, not married, missing Categorical 
NCI Comorbidity 
Index 
0, 1, 2+ comorbidities Categorical 
Region SEER region Categorical 
Residence Type metropolitan, urban, rural Categorical  
NCI: National Cancer Institute. 
In a previous study by Farjah et al. 9, variables that were significantly associated with 
differential use of staging modalities in single variable analyses included region, income, 
education, marital status, and residence type (Table 4.6), all of which were included as controls.  
The comorbidity index developed by Klabunde et al. (2000) 80 was used to assess the severity of 
patient comborbidities using Medicare claims for the year prior to diagnosis.  This comorbidity 
index was included as a control to adjust for the presence of other illnesses, which may affect 
patient treatment decisions.   
I also controlled for distance of individuals to facilities offering PET.  Distance of 
individuals to the closest PET facility was derived using Medicare carrier claims data.  Each 
Medicare claim contains a unique identifier for both the performing and referring physician, as 
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well as a zip code for where a service was performed.  Using carrier files, I determined the first 
date that a physician performed or referred a NSCLC patient for an oncologic PET.  From this 
date forward, this physician and the location of service (zip code) were considered to be PET 
providers and PET providing locations, respectively.  In the case that multiple claims are filed 
for the same PET scan (i.e. technical and professional components), the location closer to the 
patient was considered the location of service.  Distance from patient to nearest PET location 
(using zip codes) was calculated.  This distance to closest PET facility was determined at the end 
of the window used to assess PET use (4 months after diagnosis).   
 All control variables are summarized by aim in Table 4.7.  All main dependent and 
independent variables are summarized by aim in Table 4.8. 
 
Table 4.7: Summary of Control Variables by Aim 
Control Variable Possible Values Variable Type Aims 
Elderly Age > 80, Age ≤ 80 Dichotomous All 
Cumulative 
incidence 
(observation time) 
Months Continuous 3 
Distance to PET < 40 miles, ≥ 40 miles Categorical 1 
Education lowest quartile, upper three quartiles, 
missing 
Categorical All 
Gender male, female Dichotomous All 
Income lowest quartile, upper three quartiles, 
missing 
Categorical All 
Marital Status married, not married, missing Categorical All 
NCI Comorbidity 
Index 
number of comorbidities Continuous All 
Race white, black, other, missing Categorical All 
Region SEER region Categorical All 
Residence Type metropolitan, urban, rural Categorical  All 
Stage I, II, IIIA, IIIB, IV, Unknown Categorical 2d 
Advanced Disease Early (I-IIIA), Advanced (IIIB-IV), 
Unknown 
Categorical 2d, 3 
Year of Diagnosis 1993-2005 Continuous 1a 
NCI: National Cancer Institute 
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Table 4.8: Summary of Main Dependent and Independent Variables by Aim 
Aim Dependent Variables Independent Variables 
1 Receipt of PET (dichotomous) Race 
Gender 
Age (categorical) 
Year (continuous) 
2 Stage IV (dichotomous) 
Two-year Survival (percentile) 
PET propensity (dichotomous) 
Receipt of PET 
 
3 Surgery, Radiation, Chemo (dichotomous) Receipt of PET (dichotomous) 
Year (categorical) 
 
Inpatient, Non-Inpatient, and Total Health Care 
Costs (continuous) 
 
 
 4.3.3 Statistical Analyses 
 Aim1 tested hypotheses H1a and H1b, which suggest that younger, white, females will be 
most likely to receive PET during the initial adoption of PET and that this bias will decrease as 
PET becomes more widespread.  I tested the initial hypothesis H1a using the following logistic 
regression model: 
 
 Pr(PET) = f(β0 + β1 Race + β2 Sex + β3 Age + β4 Year +  β Controls)  
            Eq 1A  
 A logit model was used in order to yield odds ratios indicating the relative likelihood that 
an individual received PET.  In order to test the hypothesis H1b that demographic biases 
decrease with the adoption of PET, I added calendar year as an index of PET availability and 
interacted it with race, sex, and age.  This second model was implemented as a linear probability 
model (LPM) in order to yield readily interpretable interaction coefficients. 
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 Pr(PET) = f(β0 + β1 Race + β2 Sex + β3 Age + β4 Year + β5 Race * Year  + β6 Sex* Year  + 
β7 Age* Year + β Controls )  
           Eq 1B   
  
 4.3.4 Expected Outcomes, Strengths, Limitations, and Alternative Methods 
 Aim 1 assessed demographic biases in the administration of PET in the SEER-Medicare 
NSCLC patient population.  Additionally, the aim assessed whether or not these biases are 
improving over time by observing whether discrepancies in PET use decrease from 1998 and 
2005 as year increases.   
The key variable assessed by Aim 1 is receipt of any PET.  I performed sensitivity 
analyses to confirm that dissemination of PET is not sensitive to the six month window ( 2 
months prior, 4 months following diagnosis) used to assess receipt of PET: I repeated the 
analysis using PET received within one year of diagnosis.  I hypothesized that analysis results 
between the original and sensitivity analyses would yield qualitatively similar results over a 
range of PET receipt window lengths.  Additional sensitivity analyses included controlling for 
SEER registry. 
The key limitation of this aim is that only PET scans paid for by Medicare are recorded.  
Patients who pay for PET scans out of pocket or have additional, private insurance might be 
receiving PET scans prior to approval by Medicare.  Given its cost, this phenomenon should 
occur infrequently.  It may be possible to assess how often patients receive non-Medicare 
covered PET scans by comparing Medicare-based PET counts with SEER records for PET scans 
used in the two month period before and four months after diagnosis.  An additional limitation 
was that because PET availability and time are highly correlated, it is not possible to disentangle 
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whether time or PET availability is responsible for changes in PET administration biases and so 
year alone will be examined for sake of conceptual clarity.   
 
4.4 Specific Aim 2 
 Determine the presence and magnitude of PET-induced stage migration and the 
indirect association of PET use on patient outcomes.  The introduction of novel screening or 
diagnostic methodologies can result in stage migration.  An association between PET use and 
lung cancer stage migration has been suggested by a study of one large private insurer10 and a 
small randomized trial6.  However, the presence and magnitude of stage migration associated 
with PET has not been examined previously in the Medicare lung cancer patient population.  
PET is a diagnostic tool and cannot directly affect patient outcomes, but it can indirectly affect 
patient outcomes by changing patient treatment decisions.  The existence of PET induced stage-
migration in the Medicare lung cancer population may bias analyses of PET and must be 
controlled for to accurately assess the indirect effect of PET on patient outcomes.   This aim 
determined the magnitude of PET associated stage migration within the Medicare lung cancer 
population and used it to derive updated estimates of the survival benefit associated with PET.   
 
 4.4.1 Study Population and Inclusion/Exclusion Criteria 
 Two distinct study cohorts were used in Aim 2.  The first consisted of all individuals in 
the SEER-Medicare data diagnosed with NSCLC between 1993-2005 (Figure 4.1) and the latter 
referred to three specific subgroups within the SEER-Medicare data for patients diagnosed with 
NSCLC in 1993-1994 (pre-PET), 1998-1999 (initial-PET), and 2004-2005 (post-PET; Figure 
4.2). 
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Figure 4.2: Aim 2 (part 1) cohort structure.  Dataset/Population 2 
 
 The study cohort for the first part of Aim 2 is composed of SEER data for the years 1993 
through 2005 and linked Medicare data for the years 1992 through 2007.  It was used to examine 
changes in stage distribution over time as a function of PET.  The cohort includes a long time 
span in order to provide clear pre-PET and post-PET samples for investigating changes in stage 
distribution.  The study population was selected to begin in 1993 in order to allow for a full year 
of Medicare claims in the year prior to establish NCI comorbidity index.  Data from 1991 were 
excluded, as preliminary analyses of the Medicare 5% dataset suggest that the 1991 data may 
contain a different number of lung cancer cases and may systematically differ from other years. 
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The study cohort for the second part of Aim 2 (Dataset/Population III)  was composed of 
SEER data subgroups diagnosed in years 1993-1994 (pre-PET), 1998-1999 (initial-PET), and 
2004-2005 (post-PET), with linked Medicare data for the years 1992-1996, 1997-2001, and 
2003-2007 (Figure 4.3).  It was used to examine 2-year survival as a function of PET.  Discrete 
subgroups were used to allow discrete statistical modeling of two periods before the widespread 
use of PET (pre-PET and initial-PET) and one period after (post-PET).  Each subgroup combines 
two neighboring years of diagnosed patients in order to effectively double the sample size of the 
study.  The earliest subgroup was composed of all patients diagnosed in 1993 or 1994 and 
followed for two years (pre-PET subgroup).  The first use of PET in the diagnosis or staging of 
lung cancer was not published until 199281, suggesting that this pre-PET subgroup had zero or 
near zero PET exposure.  The initial-PET subgroup was composed of all patients diagnosed in 
1998 or 1999 and followed for two years.  This subgroup was selected to begin in 1998, because 
consistent staging definitions for NSCLC were used between 1998 and 2003.  The post-PET 
subgroup is composed of all patients diagnosed in 2004 or 2005 and followed for two years.  The 
post-PET subgroup was chosen as the latest possible two-year subgroup with data.  The use of 
PET has increased rapidly within Medicare lung cancer patients in recent years3, and choosing 
the latest possible subgroup years ensured the largest portion of patients with PET. 
Patient inclusion/exclusion criteria are those used in Aim 1.  Two years of follow-up 
provides adequate follow-up to examine changes in NSCLC outcomes, especially for advanced 
stage disease (III and IV).  The median survival of advanced stage IIIB or IV NSCLC has been 
generally placed at one year or less 82.  Two-year survival rates by cancer stage (see background) 
range from approximately 5% for stage IV cancer to 10-25% for Stage III, 40-50% for Stage II, 
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and 50-80% for Stage I 27, 82.  The two-year window for follow-up is therefore expected to 
capture most failures for advanced stage III and IV patients, which are the focus of this study. 
 
 
Figure 4.3: Aim 2 (part two) and Aim 3 cohort structure.  Dataset/Population 3. 
 
   
 4.4.2 Study Variables 
 The key dependent variables in Aim 2 are: 1) lung cancer stage distribution and 2) 2-year 
survival (Table 4.9).  Lung cancer stage distribution was measured as the proportion of patients 
having stage IV lung cancer, as PET-induced stage migration has been previously shown to 
primarily result in a shift from stage III to stage IV cancer 10.  AJCC cancer stage is provided in 
the SEER registry data.  It should be noted that SEER staging uses all available clinical, surgical, 
and pathological data in order to determine cancer stage, some of which may not have been 
available to physicians prior to making treatment decisions.  Alternative stage definitions within 
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SEER include SEER modified AJCC 3rd edition, SEER summary stage, and SEER historic stage.  
Overall survival in lung cancer patients is typically defined using median survival or five-year 
survival.  However, the cohorts defined within this study span two years.  To allow all cohorts to 
have equal follow-up time, survival was assessed at two years.  Two-year survival was obtained 
using the SEER-reported death date, which is confirmed by multiple sources including those 
used by Medicare 67.  Two-year survival was chosen over median survival, as the original work 
on stage migration by Feinstein et al. (1985) 33 found that percent survival was more amenable to 
analyses of stage migration.  Unlike median survival, the percent survival of a group changes 
predictably as members are added or removed, facilitating analyses of stage migration and 
shifting between groups. 
 The key independent variable was having undergone any PET scans between two months 
prior to and 4 months following diagnosis.  PET was only examined within these six months of 
diagnosis to help limit observed PET scans to those used for diagnostic or staging roles and to 
coincide with SEER-provided stage, which is based on information obtained within four months 
following diagnosis.   
Table 4.9: Aim 2 dependent and independent variables 
Dependent Variables Possible Values Variable Type 
Lung Cancer Stage IV Stage IV, Non-stage IV (I,II,III) Dichotomous 
Overall Two-Year 
Survival 
Survived, Died Dichotomous 
Independent Variables   
PET propensity score* 0-100% Continuous 
PET within two years of 
diagnosis 
Any PET, No PET Dichotomous 
*PET propensity score was used for propensity score matching sensitivity analysis.  PET propensity score was not 
used as an independent variable in a regression model, but was instead generated as part of the matched analysis. 
 
 
 Control variables that might have affected patient stage or outcomes were used including 
both the demographic and control variables (Table 4.7) used in Aim 1 (age, race, sex, income, 
region, and education).  Patient comorbidities were included as controls using the NCI 
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combordity index80, which has been shown previously to affect overall survival in cancer 
patients75,80,83.   
Previous studies of PET administration have demonstrated that white, educated, high-
income, married females are most likely to receive PET9,10.  It is likely that receipt of PET is 
associated with better access to health care.  Analyses that use receipt of PET as an independent 
variable will capture the effect of access to health care, and will detect an artificial association 
between PET receipt and patient survival that is actually due to health care access.  To mitigate 
this potential source of omitted variable bias (health care access), patients were additionally 
matched by their likelihood, or propensity, of receiving PET, explored tangentially in Aim 1.  
The probability that each patient received PET was calculated using a probit model and the 
variables described in equation 1A along with year interaction terms.  The purpose of this PET 
propensity score was to model PET selection bias.  The PET propensity score was be calculated 
using data from 1996-2005.  The PET propensity score is a continuous variable that can, in 
theory, range from 0 to 100.  The identification of equally likely PET candidates was used to 
provide matched controls in sensitivity analyses. 
  
4.4.3 Statistical Analyses 
 Using Medicare-SEER data, the stage distribution of Medicare NSCLC patients was 
examined from 1993-2005 (dataset/population II).  The overall distribution of stage I, II, III, and 
IV lung cancer was plotted over time alongside the frequency of PET use.  Stage distribution in 
the overall Medicare NSCLC is expected to lie somewhere between populations with high and 
low PET propensity to illustrate stage migration associated with the introduction of PET in the 
overall Medicare population.  This was repeated in the likely and unlikely PET candidate 
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populations, with the hypothesis that stage migration would be larger in sub-populations that 
were more likely to receive PET. 
 The second set of statistical analyses used study population 3 to perform more specific 
subgroup comparisons.  The overall stage-specific incidence of lung cancer patients was 
compared in aggregate between subgroups diagnosed in 1993-1994, 1998-1999, and 2004-2005 
corresponding to two pre-PET and one post-PET utilization time points (study population 3).  
The frequency of stage III and stage IV lung cancer was compared using chi-square tests, with 
the hypothesis that stage IV lung cancer rates increased at the expense of stage III cancers 
following the introduction of PET.   
 
Within the 1996-2005 subgroup, logistic regression was used to assess the magnitude of 
PET-induced stage migration from stage III to stage IV disease.  The following logit model was 
used to examine to what extent the administration of PET resulted in stage III cancers being 
reclassified as stage IV cancers: 
 
  Pr(Stage IV) = f(β0 + β1 PET + β Controls + ε)  
          Eq 2A 
 I tested the hypothesis that receipt of one or more PET scans was associated with 
improved 2-year survival, correcting for both PET-induced stage migration and selection bias 
(hypothesis H2d).  To correct for PET selection bias, an additional sensitivity analysis was 
performed among equally likely PET candidates (propensity score matched).  As an additional 
precaution, patients who did not survive for at least two months were excluded from the analysis, 
since such patients might have poor performance status and appear sick enough at diagnosis to 
discourage unnecessary PET.  The inclusion of extremely sick patients might have otherwise 
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resulted in a spurious association between PET and improved survival.  PET is suspected to 
cause migration from stage III to stage IV classification.  Two-year patient survival was 
compared using the following model within stage I, stage II, and late stage (stage III or IV) 
disease. 
 
 Two-Year Survival = f(β0 + β1 PET + β Controls)  
          Eq 2B  
 Lastly, two-year survival was plotted in unlikely vs. likely PET candidate populations 
over the 1993-2005 period both in aggregate and broken down by stage.  The hypothesis was that 
two-year survival increased in populations receiving PET relative to those that did not.  All 
regression analyses in Aim 2 was carried out using clustered errors (at the level of SEER 
registry) 81. 
 
 4.4.4 Expected Outcomes, Strengths, Limitations, and Alternative Methods 
 Successful completion of this aim attempted to identify the presence and magnitude of 
stage-migration associated with increased PET scan use among the Medicare population.  In 
addition, it would provide more accurate estimates of PET benefit in lung cancer patient 
outcomes.    
 The previous study of PET-induced stage migration by Chee et al. 2008, 10 did not find an  
association between PET and stage I and II cancer incidence.  PET should not be able to provide 
a real survival advantage in these groups since PET would not result in a change of clinical 
management.  However, increased survival of stage I or II patients could be observed for two 
reasons.  First, patients receiving PET may receive more thorough health care and treatment.  For 
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example, they may have better access to care and PET scans if they live in an urban vs. rural 
environment, are uneducated, or are poor, etc.  I will try to adjust for this by limiting the analysis 
to likely PET candidates.  Second, PET could result in a zero time shift, whereby lung cancers 
are diagnosed sooner than they normally would have.  A zero time shift would artificially result 
in improved survival.  An independent means of confirming the presence of a zero time shift 
would be to examine the overall prevalence of lung cancer in the general Medicare population as 
a function of Year.  If lung cancer prevalence increases overall with PET, it would suggest the 
presence of a zero time shift.   
 
4.5 Specific Aim 3 
 Assess the effect of increased PET usage on lung cancer patient health care 
utilization and costs within the Medicare population.  PET scan usage and costs are among 
the fastest growing areas of health care utilization in the Medicare cancer patient population3.  
PET scan use in lung cancer patients outside the Medicare cancer patient population has resulted 
in changes in lung cancer staging and management5, 7.  Stage migration within Medicare 
(evaluated in Aim 2) and resultant altered patient management could affect utilization of 
additional health care resources, and could potentially decrease health care costs in the Medicare 
lung cancer patient population if unnecessary treatment, particularly futile thoracotomy, is 
avoided as a result of increased PET imaging discovering occult metastatic disease.  
 
 4.5.1 Study Population and Inclusion/Exclusion Criteria 
 Aim 3 used the same inclusion/exclusion criteria and subgroup cohort structure described 
in Aim 2 (part two, Figure 4.2) to perform discrete analyses between 1) pre/initial-PET and post-
PET periods and 2) within the post-PET period as well as continuous analysis of patients 
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diagnosed between 1996-2005 (subset of Aim 2 dataset, part one).  For each patient health care 
expenditures and treatments were calculated based on Medicare claims made during the 1-year 
period following diagnosis.   
  
 4.5.2 Study Variables and Controls 
 The key dependent variables in Aim 3 were treatment and total health care payments.  
Treatment options for lung cancer include surgery, radiation, chemotherapy, or some 
combination thereof.  Stage I-IIIA disease is primarily managed with surgery, whereas stage IIIB 
and IV disease is not.  Because PET is hypothesized to discover occult metastatic disease, PET 
will most likely affect decisions whether or not to use surgery.  As a result, this study will focus 
on treatment decisions with regards to surgery, chemotherapy, or radiation therapy, and no 
treatment (Table 4.10).  CPT/HCPCS codes was used to identify resection, chemotherapy, and 
radiation therapy per Farjah et al. 9   Additionally, Medicare Durable Medical Equipment (DME) 
claims were examined for National Drug Codes (NDCs) that correspond to chemotherapy.  Total 
health care costs was calculated by summing all line item Medicare claims from the inpatient, 
outpatient, and carrier files and adjusting for inflation to 2008 dollars using consumer pricing 
index.79 
 
Table 4.10: Aim 3 dependent variables 
Dependent Variables Possible Values Variable Type 
Treatment Resection, Other (Radio/Chemotherapy), None Categorical 
Total Health Care Claims Dollars adjusted to 2008 Continous 
 
 The key independent variable was receipt of PET in the two months prior to or four 
months following diagnosis (Aim 2).  Preliminary analyses confirmed that over 90% of PET 
scans were received within the first month or two of diagnosis and prior to or concomitant with 
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treatment within the Medicare-SEER data.  Control variables were the same as those discussed in 
Aim 2. 
 
 4.5.3 Statistical Analyses 
 Using Medicare-SEER data, Aim 3 analyzed changes in stage-specific health care 
utilization and costs of lung cancer patients undergoing PET imaging between 1993-1994, 1998-
1999 and 2004-2005 (Figure 4.2: dataset/population 3).   
  
 In hypothesis H3a1, I tested whether or not receipt of PET was associated with fewer 
surgeries.  To do this I compared individuals receiving any PET vs. no PET within the subgroup 
of patients diagnosed in 1996-2005.  Logistic regression was used to model whether or not PET 
affects the likelihood of an individual to receive surgery.  The regression was modeled with and 
without controlling for cancer stage and its interaction with receipt of PET.  Controlling for stage 
allowed me to examine whether individuals getting PET receive the same aggressiveness of 
treatment for the same stage cancer.  Not controlling for stage examined overall rates of 
treatment.  Overall thoracotomy rates were expected to decrease as a result of stage migration.  I 
hypothesized that a shift in total thoracotomy rates would only be apparent when stage was not 
controlled for.   
To test the hypothesis that PET was associated with an increased use of chemotherapy 
and radiation, a similar logistic regression tested whether or not a patient received other 
treatment, regardless of whether or not the patient underwent surgery: 
 
 Pr(Treatment) = f(β0 + β1 PET + β Controls)  
         Eq 3A 
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The frequency of patients undergoing surgery (resection), other treatment, and no 
treatment was compared between subgroups using chi-squared tests.   
I tested the hypothesis that total 1-year Medicare payments (costs) were decreased in 
patient populations receiving PET due to avoidance of futile thoracotomies (hypothesis H3b1).  
Total 1-year Medicare payments were compared between individuals receiving PET and not 
receiving PET within the 2004-2005 (Post-PET) cohort, controlling for stage.   
 
 Total Health Care Costs = β0 + β1 Year + β1 PET + β1 Stage + β Controls  
         Eq 3B 
  
One-year cost was compared in aggregate before and after the introduction of PET within 
groups adopting PET (high PET propensity) vs. those groups not adopting PET (low PET 
propensity).  Each pre-PET subgroup (1993-1994, pre-PET; 1998-1999, initial-PET) was 
separately compared to the post-PET subgroup (2004-2005).  PET is expected to reduce costs 
through the reduction of futile thoracotomies and related expenses.     
Each cost analysis was performed both with and without controlling for the cumulative 
observation time (time to death, hospice, or managed care).  Analyses using cumulative 
observation time will provide payments and treatment utilization per unit time.  Additional 
sensitivity analyses controlled for SEER registry, limited analysis years to 1998-2003 to provide 
consistent stage definitions, and used an alternative 4 month minimum survival exclusion 
criteria.  All regression analyses in Aim 3 was carried out using clustered errors (at the level of 
SEER registry) 81. 
 
4.5.4 Expected Outcomes, Strengths, Limitations, and Alternative Methods 
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 Successful completion of this aim sought to provide overall and stage-specific estimates 
of health care utilization and costs associated with the use of PET technology.  Controlling for 
PET-induced stage migration and selection bias should provide a more accurate assessment of 
the actual costs and benefits of PET technology in the management of lung cancer in the 
Medicare patient population.  Medicare-specific estimates of changes in survival, treatment, and 
costs associated with PET use in lung cancer will help inform future Medicare health policy 
decisions.  I hypothesized that PET use would be associated with more aggressive stage-specific 
patient management and higher overall health care utilization and costs.  However, overall health 
care utilization and costs may be decreased in populations using PET due to the ability to avoid 
unnecessary treatment.   
Earlier detection of NSCLC using PET may increase the period of time during which a 
patient receives expensive therapy.  Costs may be affected by the total time during which a 
patient submits claims through Medicare, which can be shortened to less than two years if a 
patient joins an HMO, dies, or enters hospice.  The total time during which a patient is likely to 
file claims, or cumulative incidence function, was used to repeat cost analyses normalizing for 
the length of patient observation.  Similar results were expected from both analyses. Each cost 
analysis was repeated controlling for observation length (cumulative incidence) to investigate 
this possibility. 
 I performed sensitivity analyses to confirm that cost analyses are not sensitive to the 2 
year window used to assess costs: I repeated the analysis using costs accrued within varied 
window lengths (for example total costs  within one year of diagnosis).  I expected analysis 
results between the original and sensitivity analyses to yield qualitatively similar results over a 
range of cost receipt window lengths.   
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 Aim 3 examines total patient claims, which included health care services performed for 
any reason among patients with a recent diagnosis of NSCLC and reflects costs in these patients 
incurred for both cancer and non-cancer related purposes.  Patient prescription drugs or 
chemotherapy not administered by a physician are not captured in the Medicare data, which 
excludes oral prescription medications such as oral chemotherapy or supportive medications (e.g. 
medications for nausea or pain).  Costs not covered by Medicare (aka deductibles or privately 
insured expenses) are not available in the Medicare data.   
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CHAPTER 5:  DEMOGRAPHIC AND REGIONAL VARIATION IN THE USE 
OF POSITRON EMISSION TOMOGRAPHY FROM 1998 TO 2005 IN THE 
MEDICARE NON-SMALL CELL LUNG CANCER POPULATION 
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ABSTRACT 
 
Context:  
The use of positron emission tomography (PET) increased rapidly among Medicare 
beneficiaries with non-small cell lung cancer (NSCLC) following its approval in 1998. 
Which demographic and regional subgroups were the recipients of this new technology 
and how its utilization changed over time is poorly understood.  Understanding which 
patients had PET as part of their initial diagnostic evaluation is critical in order to 
determine the effect of PET on the clinical evaluation and management of NSCLC. 
 
Objective:  
To characterize changes in the receipt of PET within the Medicare NSCLC patient 
population between 1998 and 2005.   
 
Design, Setting, and Patients:  
Retrospective analysis of demographic, clinical, and claims data from Surveillance 
Epidemiology and End Results (SEER)-Medicare patients diagnosed with NSCLC 
between 1998 and 2005. 
 
Main Outcome Measures:  
Use of one or more PET scans as a function of patient factors among newly diagnosed 
cases of NSCLC between 1998 and 2005. 
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Results:  
A total of 36,759 cases of NSCLC diagnosed between 1998 and 2005 met study criteria.  
By 2005, more than half of all NSCLC patients received one or more PET scans 
regardless of demographic subgroup.  Ninety percent of patients received their initial 
PET scan concurrent with or prior to any treatment.  Multivariable logistic regression of 
PET use between 1998 and 2005 suggested that patients who received PET were more 
likely to be married, be non-black, younger than age 81, and live in the Northeast (all 
P<0.001).  Imaging rates increased more rapidly in patients who were non-black 
(P≤0.01), younger than age 81, and lived in the Northeast and South compared with the 
Midwest and West (P<0.001). 
 
Conclusion:  
The use of PET imaging in the NSCLC Medicare patient population was initially 
concentrated among non-black patients younger than 81.  Despite widespread adoption of 
PET among all subgroups, differences in overall PET utilization within 
sociodemographic and regional subgroups remained through 2005.  How patterns of 
unequal PET dissemination have affected patient management, healthcare utilization, and 
outcomes remains an important area of future research. 
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5.1 Introduction 
 
Positron Emission Tomography (PET) is an advanced imaging modality that 
began to be used to differentiate malignant and benign solitary pulmonary nodules in 
19921 and was initially approved for this use by Medicare in 19982.  Since then, PET 
utilization has increased in clinical practice among both Medicare and privately-insured 
NSCLC patients3,4.  By 2006, Medicare beneficiaries with lung cancer received an 
average of one PET scan per patient3.   
Previous studies suggest that the rapid expansion of PET may have occurred non-
uniformly throughout the NSCLC patient population.  Multimodality staging of NSCLC, 
which often includes PET, was more likely between 1998 and 2002 to be used in 
educated, higher income, white, married patients with early stage tumors4.  Large 
regional variation in PET use has been documented: In 1998, the rate of PET use was 15 
times higher in New York than Dallas, a difference that has persisted as late as 2007, 
albeit at a reduced level5.  The observed regional differences may reflect general trends 
among Medicare beneficiaries undergoing diagnostic and imaging utilization6.   
Large, randomized clinical trials that evaluate the impact of PET on outcomes in 
NSCLC would be difficult to justify and financially prohibitive.  Previous observational 
studies have reported an association between PET and superior NSCLC patient outcomes 
in Medicare beneficiaries4 and one large privately insured California population7.  
However, such findings may be biased if PET is selectively administered to populations 
with greater access to health care.  Understanding how this emerging technology is being 
used in the Medicare population and how its use has changed over time is critical to 
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understanding how PET utilization affects patient management, outcomes, and costs.  
Thus, we test the hypotheses that: (1) the initial adoption of PET among the Medicare 
NSCLC patient population was greater among younger, white, well-educated individuals 
living in wealthy communities and (2) this difference decreased as the use of PET 
became more widespread.   
 
5.2 Methods 
 
Data Source 
 
Data are from the Surveillance Epidemiology and End Results (SEER)-Medicare 
linked data.  SEER-Medicare is a collaborative effort between the National Cancer 
Institute (NCI) and Centers for Medicare and Medicaid Services (CMS) that links 
routinely-collected population-based data from cancer registries across the country to 
Medicare administrative data and health care claims. The SEER data provide 
demographic and incident cancer characteristics including grade, and stage for 
approximately 25% of the U.S. cancer population. Medicare provides health insurance for 
97% of Americans aged 65 and older, and these data reflect health care services used and 
co-morbid health conditions present.  SEER-Medicare data have been used previously to 
examine factors that affect cancer care quality including sociodemographics, physician 
and hospital characteristics, surgery, chemotherapy, radiation, comorbidities, 
complications, screening, relapse, and costs8-18.   
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Study Population 
 
All analyses were conducted using SEER-Medicare data from the 12 SEER 
registries that were continuously active from 1998 (the first year PET was approved for 
use for Medicare beneficiaries) onward. Within these registries, we included all patients 
who had a diagnoses of cancer of the lung and bronchus with microscopically confirmed 
NSCLC histology between 1998 and 2005, were age > 66 years at diagnosis, and had 
Medicare Part A & B coverage without participating in a Health Maintenance 
Organization (HMO) or Medicare Part C for the year prior to and following their 
diagnosis or until death.  We excluded patients who were diagnosed at autopsy or death, 
or had another diagnosis of malignancy in the year prior to their NSCLC diagnosis.  We 
excluded patients who did not survive at least 2 months from diagnosis to exclude 
clinically morbid patients for whom we expected factors associated with PET use would 
be significantly different compared to the general population. To help ensure full 
acquisition of claims for cancer-related claims, patients were required to have a primary 
diagnosis of lung cancer on an inpatient, outpatient, or carrier-based Medicare claim 
(International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-
CM] diagnosis of lung cancer [162.2-162.9, 231.2]). 
 
Study Variables 
 
 The primary dependent variable was receipt of one or more PET scans within two 
months prior to, or four months after, NSCLC diagnosis.  Receipt of PET scans was 
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detected using the following Healthcare Common Procedure Coding System codes within 
the Medicare outpatient and carrier files: G0125, G0126, G0163, G0164, G0165, G0235, 
G0252, G0253, G0254, G0296, G0330, G0331, 78810-78816, G0210-G0228, G0231-
G0234, G0213-G0215, G0226-G02283.  Receipt of PET was considered to be concurrent 
with, or prior to, treatment if it occurred prior to or during the first month for which a 
surgical, radiation therapy, or chemotherapy claim was reported 9.  Distance to PET was 
modeled as a dichotomous variable (>40 miles vs. <= 40 miles) to define groups with 
maximally different PET use based on preliminary analyses and was based on previous 
literature demonstrating differential treatment of patients located >40 miles from 
treatment facilities19.  We used inpatient, outpatient, and carrier Medicare claims records 
to calculate the National Cancer Institute (NCI) comorbidity index20.  Patients were 
categorized as having zero, one, or more than one comorbidity. 
 All remaining variables were obtained from the SEER Patient Entitlement and 
Diagnosis Summary File (PEDSF). Demographic variables included age, sex, race, 
ethnicity, marital status, and local census tract characteristics (metropolitan urban or rural 
status; percent not-finishing high school; percentage below the poverty line; and percent 
black).  Histology of NSCLC was classified as either adenocarcinoma, large cell 
carcinoma, squamous cell, or NSCLC otherwise undifferentiated using the ICD-O-3 
(International Classification of Disease in Oncology 3rd Edition) code on SEER 
diagnosis.  Therapies undergone by patients within 4 months of diagnosis included 
surgery, chemotherapy, and radiotherapy.  The 12 SEER registries included in the study 
were grouped according to their census regions: Northeast (Connecticut), Midwest 
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(Detroit, Iowa), South (Atlanta, Rural Georgia), and West (San Francisco, Hawaii, New 
Mexico, Seattle, Utah, San Jose, Los Angeles).   
 
Statistical Analysis 
 
 PET use was stratified using categorical specifications of all analyzed variables.  
Patients were classified into early (1998-1999), middle (2001-2002), or late (2004-2005) 
cohorts to provide analysis of distinct phases of PET adoption.  This classification was 
used to compare baseline characteristics of all NSCLC cases over time using chi-square 
tests.  The proportion of patients receiving one or more PET scans as a function of 
subgroup and year of diagnosis were plotted to observe changes in PET use over time.  
 To address endogeneity, all models excluded variables that could potentially be 
affected by receipt of PET (e.g., disease stage, treatment decisions, overall survival).  In 
all models, we present odds ratios (OR) and 95% confidence intervals (CI).  The 
association between receipt of PET and patient characteristics was examined with a 
multivariable logit and linear probability model (LPM).  In a second linear probability 
model, patient characteristics were interacted with year of diagnosis, to explore how the 
association between receipt of PET and patient characteristics changed over time as PET 
availability increased.  An LPM was used instead of a logit model to examine the 
interaction between patient characteristics and year, since interaction terms within logit 
models differ by observation and are not amenable to generalized interpretation.21  Errors 
were clustered by SEER registry for all regressions22.  Two separate sensitivity analyses 
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of PET receipt were performed by 1) expanding the window for PET to one year 
following diagnosis and 2) controlling for SEER registry. 
  
5.3 Results 
 
Study Population 
 
 We identified 128,006 Medicare beneficiaries diagnosed with one or more cases 
of cancer of the lung and bronchus in the SEER registries between 1998 and 2005; 
among these patients, a total of 129,241 separate diagnoses of incident lung cancer were 
identified (some patients had two separate cases of primary lung cancer separated by over 
a year during the study period).  We sequentially excluded patients (Figure 5.1) who 
were diagnosed at death or autopsy, were younger than 66 years of age, did not have 
microscopically-confirmed NSCLC histology, had another malignancy in the year before 
or after their diagnosis, participated in an HMO or did not have part A and part B 
coverage for the year before and after their diagnosis, did not survive a minimum of 2 
months from their diagnosis, did not have an undocumented prior malignancy, and had to 
have a Medicare claims-based ICD-9 diagnosis of lung cancer within two months prior to 
and four months following SEER diagnosis.  The final cohort consisted of 36,759 
NSCLC cases. 
 
Baseline Patient Characteristics by Early, Middle, and Late PET Adoption Cohorts 
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Baseline characteristics differed among NSCLC patients by early (1998-1999), 
middle (2001-2002), and late (2004-2005) PET adoption cohorts (Table 5.1).  The 
diffusion of this innovative imaging technology into practice was evident in the 
consistently increasing proportion of beneficiaries who received at least one scan PET 
scan during the period from two months before, until four months after, diagnosis: 7.5% 
in 1998-1999; 30.8% in 2001-2002; and 51.5% in 2004-2005 (P<0.0001).   The initial 
PET scan occurred either concurrently with, or prior to, treatment in over 90% of patients 
across all years.  Compared with patients diagnosed during the later cohorts, patients 
diagnosed during earlier cohorts had to travel farther to reach the nearest PET facility, 
were younger, more frequently male, were more likely to be married, had fewer 
comorbidities, and came from census tracts with less education (All P < 0.001).  
 
Comparison of PET-Receiving Patients in Late vs. Early Cohorts 
 
 To compare differences between the early and late adoption of PET, we compared 
characteristics of patients who received PET during the earliest vs. latest cohorts of 
NSCLC patients.  Univariate comparisons (Table 5.2) revealed that, compared to the late 
cohort, the patient population who received PET in the early cohort had half as many 
individuals older than age 80 (11% vs. 20%), more patients without any comorbidities 
(60% vs. 50%), and almost half as many individuals from census tracts within the top 
quartile of percent black composition (13% vs. 22%).  Between 1998 and 2005 there was 
a regional shift in PET use, with a doubling of the proportion of patients in our sample 
coming from the Northeast (18% vs. less than 9%), a several-fold increase in patients 
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from the South, and an 8% absolute decrease in patients from the Midwest (38% vs. 30%; 
all P<0.001).    
 
Characteristics Associated With Receipt of PET in Late vs. Early Cohorts 
 
Despite shifts in the relative composition of patients receiving PET, all subgroups 
experienced large increases in PET use over the study period, with at least half of all 
patients receiving PET by 2005 regardless of race, region, age, or local sociodemographic 
factors (Figures 5.2A and 5.2B).  Despite widespread adoption of PET overall, patients 
older than age 80, blacks, and individuals from less educated or more impoverished 
census tracts had lower utilization of PET that persisted through 2005.  PET use 
increased preferentially in the Northeast beginning in 2001, following the Medicare 
coverage expansion of PET for the diagnosis, staging, and re-staging of NSCLC.  Patients 
living more than 40 miles from the closest PET providing facility had lower PET 
utilization during the first half of the study period, but exhibited equal use of PET by 
2005.    
 Multivariable logistic regression using both a logit and LPM model (Table 5.3, 
Model 1) of PET use between 1998 and 2005 using suggested that patients who received 
PET were more likely to be married, female, non-black, under the age of 80, come from 
non-impoverished census tracts, and live in the Northeast (all P≤0.01).  To examine how 
patient characteristics associated with PET changed over time, we modeled the 
interaction between patient characteristics and year of diagnosis within the LPM model 
(Table 5.3, Model 2).  Imaging rates increased more rapidly among patients who were 
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married, non-black, under age 81, and lived in the Northeast and South compared with 
the Midwest and West (P≤0.01).  With each increasing year, PET utilization in patients 
over age 80 lagged an additional 1.2 percentage points behind younger patients.  Black 
patients lagged an additional 0.8 percentage points behind non-blacks with each 
increasing calendar year of diagnosis.  Patients with a single comorbidity were more 
likely to receive a PET scan during later years of the study. 
 Sensitivity analyses were conducted using PET scans performed within 12 months 
prior to and following NSCLC diagnosis, in addition to the initial definition.  Overall 
rates of PET use increased by roughly 10% using this method, but did not qualitatively 
change these analysis results.  Regressions run including SEER registry as a control did 
not qualitatively affect the analysis results. 
 
5.4 Discussion 
 
PET utilization among NSCLC patients increased following its approval by 
Medicare in 1998, reaching a utilization rate of 50% or more by 2005 regardless of race, 
age, region, or local census characteristics.  Despite widespread adoption of PET overall, 
patients who were older, black, or from less educated or more impoverished census tracts 
had lower utilization of PET that persisted through 2005, with an absolute deficit in PET 
utilization of approximately ten percentage points within each group.  Expansion of PET 
occurred preferentially within the Northeast following Medicare expansion of PET 
indications for the diagnosis, staging, and restaging of NSCLC in 2001.  Although we 
initially hypothesized that the unequal utilization of PET would decrease with increasing 
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PET availability, we found that differences in absolute utilization rates increased among 
subgroups based on race, age, marital status, and region through 2005. 
Heterogeneous spread of PET use may increase as new guidelines and approved 
uses emerge.  On July 1 2001, PET was approved for the diagnosis, initial staging, and 
restaging of NSCLC.  This national coverage determination should in theory have equally 
affected the adoption of PET use in NSCLC nationwide.  However, between 2001 and 
2002, the Northeast (Connecticut) registry increased its use of PET significantly faster 
than all other registries.  It has been previously shown that the introduction of new 
technology often occurs heterogeneously during the early phases of growth 23 5 24.  Our 
results suggest that issuing national coverage determination may also introduce a 
potential source of increased heterogeneous use of existing technology.   
Possible explanations for disparate use of PET include differences in the 
availability of technology, cost, physician preference, and patient preference.  PET 
scanners are expensive resources that may not be available at disadvantaged hospitals.  
PET was initially approved for use in early stage, or as yet undiagnosed lung cancer.  
Patients that typically present with NSCLC at later stages of disease, such as those in 
disadvantaged socioeconomic areas, might be less likely to receive PET as a result.  The 
direct relationship between receipt of PET and stage is complicated, as both PET and 
stage can causally affect each other.  Disparities in race, gender, and age have been 
observed with regards to cancer health care access, treatment, and survival 25-43, 
particularly with regards to receiving new or higher-technology services 26.  African 
Americans and whites are often treated at different hospitals 31, with hospitals that treat 
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large proportions of African American patients being less likely to perform emerging 
medical procedures on any of their patients 25.    
 Whether or not PET improves outcomes or reduces costs is unclear. Potential 
benefits include earlier diagnosis, more accurate staging, and avoidance of unnecessary, 
aggressive treatments such as thoracotomy in the setting of metastatic disease.  Small 
randomized controlled trials have suggested that PET can alter management decisions in 
as many as one-third of newly-diagnosed NSCLC patients 44.  Larger randomized 
controlled trials are lacking, and epidemiologic studies have shown mixed results.  A 
study by Farjah et al. suggested that PET use was associated with decreased mortality 4.  
However, such findings must be interpreted cautiously given the clear heterogeneity of 
adoption of PET in the Medicare population, selection bias, and the potential for stage 
migration and the accompanying Will Roger’s phenomena 45, in which upstaging disease 
appears to improve stage-specific survival.  Among NSCLC SEER-Medicare patients 
with advanced stage disease, blacks fared worse than whites from 2000-2002 period, but 
not earlier periods40.  The differential adoption of emerging medical technology has 
previously been implicated in introducing such disparities in cancer management and 
outcomes46.  Regardless of the true benefit of PET, this study demonstrates that PET use 
did not spread equitably within the Medicare NSCLC patient population and that this 
unintended discrepancy in care persisted despite high overall uptake. 
 This study has several limitations as a retrospective, claims-based analysis. First, 
only PET scans paid for by Medicare could be detected in our analysis.  However, it is 
likely that relatively few PET scans for our sample of Medicare beneficiaries would be 
paid by third party insurers or out of pocket.  Second, it is unknown how reliable 
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Medicare claims data are for determining receipt of PET. However, studies examining the 
accuracy of Medicare claims for assessing alternative imaging modalities such as 
mammography have had observed concordance rates of 94% 47.  How reliable Medicare 
claims data are for determining the receipt of PET or other advanced imaging modalities 
may be a potential area of future investigation.  Third, patients within the SEER registry 
are overall more likely to be non-white, live in non-poverty areas, and live in urban 
areas22, which may limit the ability to generalize our findings. Fourth, we did not 
incorporate patient stage, treatment decisions, survival, or other factors that could 
themselves altered by receipt of PET.  Finally, SEER-Medicare data are released with a 
several year lag, limiting the ability of the analysis to extend beyond 2005 at the time of 
the study.  
Advanced imaging studies such as PET, computed tomography, and magnetic 
resonance imaging represent some of the fastest growing areas of resource utilization 
within the Medicare cancer population.  We found that differences in utilization within 
sociodemographic and regional subgroups remained through 2005.  In this study, we 
examined only the first PET scan administered to patients.  Future areas of research may 
include the use of multiple PET scans in the same individuals, the timing and purpose of 
follow-up scans, and longer term monitoring.  The role of access to PET providing 
facilities and providers may also grant insight into how PET has spread from a health 
systems perspective.  Although we found differential utilization rates among specified 
subgroups, it is unclear as to whether this represents relative under-utilization vs. over-
utilization.  The input of unequal adoption of PET on patient care, outcomes, and costs 
remain an important area of current and future health policy research.   
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Table 5.1: Baseline demographic characteristics of all NSCLC cases by year of diagnosis 
(early – 1998-1999/ middle - 2001-2002/ late - 2004-2005) 
 
Characteristic 
 
Year of Diagnosis 
 
P Valuea 
 Early Cohort 
1998-1999 
(n = 8,939) 
Middle Cohort 
2001-2002 
(n = 9,367 ) 
Late Cohort 
2004-2005 
(n = 10,436) 
Overall 
1998-2005 
(n = 36,759) 
 
Any PET scans, No. (%) 380 (4.7) 3062 (32.7) 6303 (60.4) 12811 (34.9) <.0001 
Distance to PET <= 40 miles, 
No. (%) 4845 (60.4) 8257 (88.2) 9739 (93.3) 30544 (83.1) 
<.0001 
Age > 80, No. (%) 1460 (18.2) 1965 (21) 2342 (22.4) 7576 (20.6) <.0001 
Male, No. (%) 4416 (55.1) 4947 (52.8) 5312 (50.9) 19459 (52.9) <.0001 
Race, No. (%)     0.004 
Caucasian/Other 8269 (92.5) 8618 (92.0) 9574 (91.7) 33794 (91.9)  
Black 670 (8.4) 749 (8) 862 (8.3) 2965 (8.1)  
Comorbid conditions, No. (%)     <.0001 
0 4514 (56.3) 4939 (52.7) 5186 (49.7) 19304 (52.5)  
    1 2185 (27.3) 2676 (28.6) 3071 (29.4) 10512 (28.6)  
    2+ 1318 (16.4) 1752 (18.7) 2179 (20.9) 6943 (18.9)  
Census tract characteristics:  
(Highest Quartile) 
     
     Did not complete high school 1714 (26.3) 2005 (24.8) 2163 (23.3) 7782 (24.7) 0.0001 
     Percent below poverty line 1721 (26.4) 1986 (24.6) 2177 (23.5) 7725 (24.5) 0.0002 
     Percent black 1633 (25) 1992 (24.7) 2252 (24.3) 7734 (24.5) 0.57 
Married (%) 4533 (56.5) 5036 (53.8) 5496 (52.7) 19883 (54.1) <.0001 
Metropolitan (%) 6819 (85.1) 8041 (85.8) 8977 (86) 31452 (85.6) 0.02 
Any Therapy (%) 6791 (84.7) 7916 (84.5) 8755 (83.9) 30964 (84.2) 0.03 
Histology     <.0001 
     Adenocarcinoma 3890 (48.5) 3791 (40.5) 4371 (41.9) 16051 (43.7)  
     Large Cell 876 (10.9) 683 (7.3) 575 (5.5) 306 (7.7)  
     Other* 395(4.9) 2218 (23.7) 2820 (27.0) 341 (18.9)  
     Squamous Cell 2856 (35.6) 2675 (28.6) 2670 (25.6) 564 (29.7)  
Region     0.0004 
     West 3464 (43.2) 4173 (44.6) 4749 (45.5) 16281 (44.3)  
     Midwest 2847 (35.5) 3116 (33.3) 3376 (32.4) 12418 (33.8)  
     Northeast  1156 (14.4) 1455 (15.5) 1626 (15.6) 5642 (15.3)  
     South 550 (6.9) 623 (6.7) 685 (6.6) 2418 (6.6)  
a
 Chi-Squared test for association with cohort. 
* Composed of adenosquamous, carcinoid, carcinoid with mesenchymal features, salivary, and unclassified 
histologies. 
NSCLC: non-small cell lung cancer; PET: positron emission tomography. 
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Table 5.2: Univariate comparison of NSCLC patients receiving PET during the early 
(1998-1999) vs. late (2004-2005) phases of PET adoption 
 
Characteristic 
 
Patients Receiving One or More PET Scans 
 Early (1998-1999) 
(N = 380) 
Late (2004-2005) 
(N = 6,303) 
P Value a 
Miles to PET ≤ 40, No. (%)  319 (84) 5915 (93.8) <.0001 
Age > 80, No. (%) 40 (10.5) 1241 (19.7) <.0001 
Male, No. (%) 210 (55.3) 3185 (50.5) 0.07 
Race, No. (%)   0.25 
Caucasian/Other 364 (95.8) 5893 (93.5)  
Black 16 (4.2) 410 (6.5)  
Comorbid conditions, No. (%)   0.001 
0 226 (59.5) 3142 (49.9)  
    1 97 (25.5) 1880 (29.8)  
    2+ 57 (15) 1281 (20.3)  
Census tract characteristics:  
(Highest Quartile) 
   
     Did not complete high school 49 (16.1) 1133 (20.3) 0.08 
     Percent below poverty  line 59 (19.4) 1138 (20.4) 0.68 
     Percent black 38 (12.5) 1247 (22.3) <.0001 
Married (%) 243 (64) 3470 (55.1) 0.0007 
Metropolitan (%) 340 (89.5) 5446 (86.4) 0.09 
Any Therapy (%) 348 (91.6) 5600 (88.9) 0.10 
Histology   <.0001 
     Adenocarcinoma 215 (56.6) 2682 (42.6)  
     Large Cell 24 (6.3) 297 (4.7)  
     Other* 21 (5.5) 1646 (26.1)  
     Squamous Cell 120 (31.6) 1678 (26.6)  
Region   <.0001 
     West 202 (53.2) 2873 (45.6)  
     Midwest 144 (37.9) 1873 (29.7)  
     Northeast  †34 (<8.9) 1133 (18)  
     South †34 (<8.9) 424 (6.7)  
a
 Chi-Squared test for association with cohort. 
* Composed of adenosquamous, carcinoid, carcinoid with mesenchymal features, salivary, and unclassified 
histologies 
†Northeast and South Categories have been combined for the 1998-1999 cohort to suppress cell sizes <11. 
NSCLC: non-small cell lung cancer; PET: positron emission tomography. 
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Table 5.3: Multivariable logistic regression comparing NSCLC patients receiving one or 
more PET scans vs. patients receiving no PET scans 
 
 
Characteristic 
 
Logit Model 
 
Linear Probability Model 
 
Model 1  
Overall PET Use 
 
Model 1 
Overall PET Use 
Model 2 
 Changes over time 
 Coefficent 
 
OR 
(95% CI) 
Coefficient Base 
Coefficent 
Intxn w/ Year 
Coef. † 
Miles to PET > 40 -0.56** 0.57 (0.45-0.73) -4.4   -1.4 -1.3 
Age > 80 -0.43** 0.65 (0.61-0.69)     -7.6**   -2.7*     -1.2** 
Black -0.35** 0.71 (0.67-0.74)     -5.6**   -2.7*    -0.8* 
Comorbidity      
    One 0.06 1.06 (0.99-1.14) 1.1 -0.8     0.5** 
     Multiple 0.03 1.03 (0.97-1.09) 0.4 -0.9 0.3 
Census tract:  
% Education  
< 12 years   
 
  
     2nd QRTL -0.19 0.83 (0.71-0.97) -3.5 -4.5 0.3 
     3rd QRTL   -0.31* 0.73 (0.58-0.93) -5.7 -6.1 0.1 
     4th QRTL   -0.48* 0.62 (0.45-0.86)   -8.3* -6.4 -0.5 
Census tract:  
% below poverty line   
 
  
     2nd QRTL  0.06 1.06 (0.92-1.22) 1.1 1.2 0 
     3rd QRTL  0.10 1.11 (0.96-1.28) 1.6 3.3 -0.4 
     4th QRTL  -0.02 0.98 (0.83-1.16) -0.7 2.6 -0.8 
Census tract: 
% Black   
 
  
     2nd QRTL  0.03    1.03 (0.90-1.18) 0.7 -0.5 0.3 
     3rd QRTL  0.11 1.11 (0.93-1.33) 2.2 0.7 0.3 
     4th QRTL  0.01    1.01 (0.86-1.20) 0.6 -0.3 0.2 
Male   -0.09* 0.92 (0.87-0.97)     -1.6** -0.7 -0.2 
Married (%)      0.15** 1.16 (1.11-1.22)     2.7** 0.7   0.5* 
Metropolitan (%) -0.13 0.87 (0.76-1.01) -0.2 2.7 -0.9 
Region      
      
     West  0.27  1.31 (1.01-1.71) 4.5 1 1 
     Northeast       0.47**  1.60 (1.36-1.90)     8.7** -3.1     3** 
     South -0.02  0.98 (0.82-1.19) -0.2     -8.2**     2** 
Year     0.50** 1.65 (1.55-1.77)     9.2**     10.6**  
*P≤.01, **P ≤.001.  OR: Odds Ratio; CI: Confidence Interval; NSCLC: non-small cell lung cancer; PET: positron 
emission tomography; QRTL: Quartile; Intxn: Interaction; Coef: Coefficient 
†Model 2 included an interaction term between each patient characteristic in model 1 and the year of diagnosis, with 
1998 used as the reference category.  Interaction coefficients represent the additional association of a patient 
characteristic w/ PET use for each year after 1998.  
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Figure 5.1: CONSORT Diagram of Study Inclusion/Exclusion Criteria 
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Figure 5.2A: Proportion of NSCLC Patients Receiving One or More PET Scans by Subgroup and Year of Diagnosis from 
1998-2005. 
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Figure 5.2B: Proportion of NSCLC Patients Receiving One or More PET Scans by Subgroup and Year of Diagnosis from 
1998-2005. 
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CHAPTER 6: PET-INDUCED STAGE MIGRATION AND SELECTION BIAS FROM 
1998 TO 2005 IN THE MEDICARE NON-SMALL CELL LUNG CANCER 
POPULATION 
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Context: 
The use of Positron Emission Tomography (PET) spread rapidly among the Medicare lung 
cancer patient population following its approval in 1998.  Previous studies have suggested that 
increasing PET use may be associated with improved outcomes in non-small cell lung cancer 
(NSCLC).  However, this association may be complicated by PET-induced stage migration and 
selection bias.  How PET affects the staging, management, and outcomes of NSCLC patients 
remains an important question in the Medicare NSCLC patient population. 
  
Objective: 
To examine the association between PET use and overall survival in the Medicare beneficiaries 
with NSCLC, controlling for PET-induced stage migration and selection bias. 
 
Design, Setting, and Patients: 
Retrospective analysis of SEER-Medicare data to characterize changes in overall survival, stage-
specific survival, and stage distribution within the Medicare NSCLC patient population between 
1998 and 2005. 
 
Main Outcome Measures: 
Two-year overall survival, stage-specific survival, and stage distribution. 
 
Results: 
A total of 207,291 cases of NSCLC diagnosed between 1993 and 2005 met study criteria.  By 
2005, 62% of patients diagnosed with NSCLC received one or more PET scans, compared with 
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only 4% in 1998.  Overall two-year survival among the Medicare NSCLC population increased 
less than two percentage points between 1998 and 2005, despite the widespread adoption of PET.  
The total proportion of patients staged with advanced, or stage IIIB/IV, disease increased from 
40% to 50% between 1998 and 2005.  Upstaging of disease was accompanied by stage-specific 
improved survival, with two-year survival of advanced disease increasing from 10% to 16% 
between 1998 and 2005.  PET was more likely to be administered to patients with less advanced 
disease and greater overall two-year survival. 
 
Conclusion: 
Overall survival of Medicare NSCLC patients increased by less than two percentage points 
between 1998 and 2005, despite the widespread adoption of PET.  The introduction of PET 
coincided with substantial stage migration among Medicare NSCLC patients, with a concomitant 
increase in advanced stage disease and decrease in unstaged disease.  The frequent use of PET 
among NSCLC patients with less advanced disease appears to account for previously observed 
associations between receipt of PET and a two-fold increased rate of survival.  The increased use 
of PET in the Medicare NSCLC patient population and how it affects patient management and 
health care utilization remains an important area of ongoing research and evolving health policy. 
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6.1 Introduction 
 
Positron Emission Tomography (PET) is an advanced imaging modality used in the 
clinical diagnosis, staging, and restaging of non-small cell lung cancer (NSCLC) patients.  The 
use of PET in NSCLC was initially approved by Medicare in 19981 and has since increased 
rapidly in both Medicare and privately-insured lung cancer patients2,3.   
The use of PET, particularly in conjunction with dedicated dual PET/CT scanners, provides more 
sensitive detection of occult metastatic NSCLC compared with CT alone.4-6  However, it is 
unclear whether or not the use of PET affects patient outcomes, particularly survival.  To date, 
there have been only four RCTs examining the use of PET in NSCLC.  These trials have 
consistently demonstrated PET-induced upstaging of disease due to PET’s ability to detect occult 
metastatic spread, but have not been powered to detect a change in patient survival. 7-10   
Previous observational studies have reported an association between PET and improved 
NSCLC patient outcomes.3,11  However, such findings may be biased if PET is selectively 
administered to populations with greater access to health care.  PET is a more sensitive method 
of detecting extent of disease than conventional staging technologies.  It is typically used in 
conjunction with older technology such as computed tomography (CT).  PET scans are 
recommended for patients with early stage disease, specifically to rule out the presence of occult 
metastatic disease prior to surgery.4  Because PET is used in addition to conventional CT or 
other staging modalities, the application of PET to a population can result in higher tumor stages 
being assigned to biologically equivalent cancers, a phenomenon known as stage migration 
(Figure 6.1).  A known effect of stage migration is that stage-specific survival outcomes may 
appear improved in the absence of any actual patient benefit.  This phenomena is particularly 
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germane because an epidemiologic study of one large private California insurer12 and three out 
of four small randomized controlled trials (RCTs)7-10 have suggested that PET may result in 
upstaging of occult metastatic NSCLC from early to late stage disease 12.  
A previous study of Medicare beneficiaries with NSCLC found a two-fold increased 
association between PET and overall survival3.  Limitations of the study included possible 
selective administration of PET to patients with less advanced disease and stage migration. In 
this study, we seek to understand how PET is associated with the outcomes of Medicare 
beneficiaries with NSCLC.  Specifically, we test the hypothesis that adoption of PET among 
Medicare beneficiaries with NSCLC was associated with upstaging and detection of occult 
metastatic disease, improvement in stage-specific survival, and no change in overall survival.  
 
6.2 Methods 
 
Data Source 
 
Data are from the Surveillance Epidemiology and End Results (SEER)-Medicare linked 
data.  SEER-Medicare is a collaborative effort between the National Cancer Institute (NCI) and 
Centers for Medicare and Medicaid Services (CMS) that links routinely-collected population-
based data from cancer registries across the country to Medicare administrative data and health 
care claims. The SEER data include demographic and incident cancer characteristics including 
grade, and stage for approximately 25% of the U.S. cancer population. Medicare provides health 
insurance for 97% of Americans aged 65 and older, and these data reflect health care services 
used and co-morbid health conditions.  SEER-Medicare data have been used previously to 
examine factors that affect cancer care quality including sociodemographics, physician and 
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hospital characteristics, surgery, chemotherapy, radiation, comorbidities, complications, 
screening, relapse, and costs13-23.  This study was approved by the Office of Human Research 
Ethics at the University of North Carolina, Chapel Hill.   
 
 
Study Population 
 
All analyses were conducted using SEER-Medicare data from the 12 SEER registries that 
were continuously active from 1998 (the first year PET was approved for use for Medicare 
beneficiaries) onward. Within these registries, we included all patients who had a diagnoses of 
cancer of the lung and bronchus with microscopically confirmed NSCLC histology between 
1998 and 2005, were > 66 years at diagnosis, and had Medicare Part A & B coverage without 
participating in a Health Maintenance Organization (HMO) or Medicare Part C for the year prior 
to and following their diagnosis or until death.  We excluded patients who were diagnosed at 
autopsy or death, or had another diagnosis of malignancy in the year prior to their NSCLC 
diagnosis.  We excluded patients who did not survive at least 2 months from diagnosis to exclude 
patients with poor performance status for whom PET administration was thought to be unlikely.  
To identify patients likely to have complete Medicare claims related to their NSCLC 
management, patients were required to have a primary diagnosis of lung cancer on an inpatient, 
outpatient, or carrier-based Medicare claim (International Classification of Diseases, Ninth 
Revision, Clinical Modification [ICD-9-CM] diagnosis of lung cancer [162.2-162.9, 231.2]). 
   
Study Variables 
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 The primary outcomes were stage at diagnosis and survival at two years.  Cancer stage 
was ascertained from SEER data and extrapolated to the staging system used by the American 
Joint Committee on Cancer (AJCC) 3rd edition to provide a common staging system throughout 
the study period. 24  Within the SEER data, patients diagnosed prior to 2003 are staged using the 
AJCC 3rd edition, while patients diagnosed in 2004 and later are staged using the AJCC 6th 
edition.  To provide consistent 3rd edition staging, we converted the 6th edition staged cancers to 
the 3rd edition by reverting the staging of T3N0 tumors from IIB to IIIA, collapsing stage IA and 
IB into stage I, and collapsing stage IIA and IIB into stage II.  Alternative staging systems 
available within SEER were investigated for trends in stage migration including SEER-modified 
AJCC 3rd edition (available 1993-2003), SEER summary staging, and the SEER historic staging. 
25
  Survival at two years was obtained from SEER date of death.  We chose to evaluate survival 
at two years to provide a clinically meaningful endpoint that would also allow us to be able to 
detect changes in survival across all disease stages, which ranges between 5% to 75% as a 
function of stage.26   
Receipt of PET was detected using outpatient and carrier claims in the period two months prior 
to, and four months following SEER diagnosis to coincide with the 4-month period used by SEER to 
provide cancer stage from 1998 onward27.  To control for patient access to PET, we extracted all PET 
claims from 1993 to 2005 to identify all outpatient facility providers and universal physician 
identification numbers (UPINs) associated with a PET claim during the study period.  A patient was 
defined as having accessed a PET provider or outpatient facility if he or she had any claims from 
a facility, provider, or referring provider that had previously offered a PET scan within the study 
population.  Histograms of the total number of PET-scanned patients per facility and provider 
were generated to assess PET access patterns.  SEER-based patient zip codes and Medicare carrier 
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claim zip codes were used to determine the straight-line distance between patients and the closest location 
of PET administration at the time of diagnosis. 28,29   
All remaining variables were obtained from the SEER Patient Entitlement and Diagnosis 
Summary File (PEDSF).  Demographic variables included age, sex, race, ethnicity, marital status, and 
local census tract characteristics (metropolitan urban or rural status; percent not-finishing high school; 
percent below the poverty line; and percent black).  Histology of NSCLC was classified as 
adenocarcinoma, large cell carcinoma, squamous cell, or NSCLC otherwise undifferentiated using the 
ICD-O-3 (International Classification of Disease in Oncology 3rd Edition) code on SEER diagnosis.  
Antineoplastic interventions delivered within 4 months of diagnosis were categorized as surgery, 
chemotherapy, or radiotherapy.  The 12 SEER registries included in the study were grouped according to 
their census regions: Northeast (Connecticut), Midwest (Detroit, Iowa), South (Atlanta, Rural Georgia), 
and West (San Francisco, Hawaii, New Mexico, Seattle, Utah, San Jose, Los Angeles). 
 
Statistical Analysis 
 
 As with the initial report of technology-induced stage migration in lung cancer30, we used 
categorical specifications of study variables because they change more predictably than group 
averages or medians as members of one group migrate to another.  To study change in staging 
and survival over time, patients were grouped by year of NSCLC diagnosis into cohorts 
representing the pre-PET (1993-1994), initial-PET (1998-1999), and post-PET (2004-2005) 
phases of PET adoption observed in previous work.31  Baseline patient characteristics of all 
NSCLC cases between the pre-, initial, and post-PET cohorts were compared using chi-squared 
tests to assess general differences in the Medicare NSCLC population over the study period.  
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Two-year periods representing distinct phases of PET adoption were chosen to provide discrete 
assessments of the effect of PET at specific phases in the use of PET. 
Overall trends in stage distribution and survival were plotted by year of diagnosis from 
1993 through 2005 among the overall Medicare NSCLC population and by age group, race, 
number of comorbidities, and region.  Advanced disease was defined as stage IIIB or IV, which 
corresponds clinically to incurable disease.   
We employed multivariable logistic regression and univariate comparisons to analyze the 
association of PET with stage migration and survival.  Multivariable logistic regression was 
performed using three separate regression models.  All models included patients diagnosed 
between 1996 and 2005 for whom 2000 census demographic variables were available.  Model 1 
analyzed the likelihood of stage IV disease as a function of receipt of PET, controlling for patient 
demographics including year of diagnosis, age, race, sex, marital status, residence in a 
metropolitan area, and region as well as census tract-based levels of local education, income, and 
demographic composition.  To control for access to PET, we included whether or not patients 
received any of their care at a PET providing physician or facility.  Survival was modeled at two 
years as a function of PET and the same control variables.  This survival analysis was performed 
both excluding (model 2) and including (model 3) cancer stage as well as its interaction with 
PET to assist in interpreting the regression results in the setting of suspected PET-induced stage 
migration.   
As an additional sensitivity analysis for our regression models, we attempted to mitigate 
selection bias by matching the propensity of patients to receive a PET scan based on available 
demographics.32 33  First, for all patients diagnosed between 1996 and 2005 we estimated the 
probability that each patient would receive a PET scan, as a function of all patient characteristics 
94 
 
used in Models 1-3 (except for stage or survival for analyses of stage and survival, respectively), 
cancer registry, and interaction of each variable with year.  We then used this estimated 
probability as a propensity score to indicate the likelihood that a patient would receive a PET 
scan based on available patient characteristics.  Nearest available matching by propensity score 
was used to match patients receiving vs. not receiving PET.32 33  Propensity matched patients 
who actually did and did not receive a PET scan were then analyzed using multivariable 
regression analysis.  The quality of the propensity score match was evaluated by univariate 
analysis of patient characteristics and plotting propensity score distributions before and after 
matching. 
Additional sensitivity analyses were also conducted.  Regression analyses were repeated 
controlling for SEER registry to ensure findings were not registry specific. Sensitivity to changes 
in the collection and/or reporting of SEER NSCLC stage in 1998 and again in 2004 was 
evaluated by repeating the analysis limited to patients diagnosed between 1998 and 2003.  All 
survival analyses were repeated using a minimum survival of 4 months to assess sensitivity to 
the 2-month survival inclusion criteria.  Errors were clustered by SEER registry for all 
regressions34.  Significance was assessed using a cutoff of P < 0.001 to control false positives 
from multiple hypothesis testing.  All analyses were conducted using SAS version 9.2 (SAS 
Institute, Cary NC).   
 
6.3 Results 
 
 
Study Population 
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 We identified 204,664 Medicare beneficiaries diagnosed with cancer of the lung and 
bronchus in the included SEER registries between 1993 and 2005.  From these beneficiaries we 
identified 207,291 cases of incident lung cancer.  We sequentially excluded patients (Figure 6.2) 
who were diagnosed at death or autopsy, were younger than 66 years of age, did not have 
microscopically-confirmed NSCLC histology, had another malignancy in the year before or after 
their diagnosis, participated in an HMO or did not have part A and B coverage for the year 
before and after their diagnosis, did not survive a minimum of 2 months from their diagnosis, did 
not have an undocumented prior malignancy.  Patients were additionally required to have a 
Medicare claims-based ICD-9 diagnosis of lung cancer within two months prior to and four 
months following SEER diagnosis.  The final cohort consisted of 58,575 NSCLC cases. 
To analyze the effect of PET over time, we designated three periods for longitudinal 
comparison of PET vs. non-PET NSCLC diagnoses: pre- (1993-1994), initial (1998-1999), and 
post- (2004-2005) PET periods.  Patients diagnosed during different cohorts exhibited 
significantly different patient demographics (Table 6.1).  In later years, NSCLC Medicare 
patients were composed of a larger percentage of patients older than 80 years old, female 
patients, blacks, patients with comorbidities, and non-married patients (P<0.0001).  Patients who 
received PET were demographically distinct from patients who did not receive a PET scan and 
were more likely to be black, not receive treatment, and to come from sociodemographically 
disadvantaged census tracks (Table 6.2).   
 
Increased Use of PET and Stage Migration 
As reported previously31, the use of PET spread rapidly from 1998 to 2005, with an 
increase from 5% to 60% of NSCLC patients receiving one or more PET scans in the initial vs. 
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post-PET patient cohorts (P<0.0001; Table 6.3).  Increased rates of PET use between 1998 and 
2005 were accompanied by an increase in the proportion of patients with advanced disease (stage 
IIIB and IV; Figure 6.3), whereas the incidence of unstaged disease decreased in later cohorts 
(P<0.0001).  Stage IV disease experienced the largest absolute increase, increasing from 23% 
33% between 1993 and 2005.  Prior to 1998, the proportion of patients with advanced disease 
remained stable at 40%.  The increase in the proportion of patients with advanced stage disease 
following the introduction of PET persisted after stratifying by demographic subgroups based on 
race, region, age, and number of comorbidities (Figure 6.4).  The incidence of unstaged disease 
declined from 26% in 1993 to 10% by 2005.  Patients with unstaged disease were less likely to 
undergo treatment of any kind or to receive a PET scan and were more likely to be older, have 
more comorbidities, and were the only patients with carcinoid tumors (P<0.0001).   
In addition to clinical AJCC staging, we observed an increase in the frequency of 
advanced stage disease among the overall Medicare NSCLC population across all staging 
systems available through the SEER registry including the modified AJCC, SEER summary, and 
SEER historical staging systems (Figure 6.3).  Patients that were unstaged using strict AJCC 3rd 
edition criteria were predominantly (60%) reclassified as early disease by the SEER-modified 
AJCC stage. 
Because the information used to obtain SEER AJCC stage changed in 1998 and again in 
2004 we alternatively examined changes in stage distribution between patients diagnosed in 
1998-1999 vs. 2002-2003.  We observed similar changes over this time period.  Stage IV disease 
increased by 5.7% from 43.6% to 49.2% (P<0.0001), unstaged disease decreased by 5.5% from 
20.7% to 15.2%, and PET utilization increased from 4.7% to 44.7% from 1998-1999 to 2002-
2003. 
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Selective Administration of PET to Patients with Early Stage Disease 
PET was selectively administered to patients with early stage disease by both univariate 
and multivariable regression analyses.  In univariate analyses, patients who received PET had 
lower rates of advanced stage disease.  Patients receiving PET had an increased incidence of 
stage I disease (31% vs. 20%) and decreased incidence of stage IV disease (24% vs. 31%; Table 
6.4).  Among patients within the 2004-2005 cohort, 70% of those with early or unknown stage 
disease received a PET scan compared with 50% of patients with advanced stage disease.  We 
found similar results using multivariable analyses that controlled for patient demographics, 
which revealed that the administration of PET predicted a 50% decreased likelihood of being 
diagnosed with stage IV disease (Table 6.5).  Regression models restricted to patients propensity 
score matched by survival and demographic characteristics (N=14,444) yielded similar findings. 
 
Survival Analyses 
Following the introduction of PET in 1998, stage-specific survival improved or remained 
the same across all stages (Figure 6.4).  During this same period, overall survival remained 
relatively constant. Specifically, a non-significant trend towards an increase in overall survival of 
less than 2% occurred between the initial and post-PET adoption periods (1998-1999 vs. 2004-
2005; Table 3; P = 0.01).  Sensitivity analysis examining changes between 1998-1999 and 2002-
2003 revealed no change in overall 2-year survival (33.7% vs. 33.6%; P = 0.85).  Larger 
improvements in two-year survival rates occurred in the overall population in the period 
extending prior to PET between 1993 and 2005 (3.7%; Table 6.3) and were concentrated among 
older patients and patients with multiple comorbidities (Figure 6.5).  Following the introduction 
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of PET, stage-specific survival remained unchanged or improved, with a large increase in 
survival among patients with advanced stage disease.  Two-year survival for advanced stage 
disease was stable at 10% in the years prior to 1998 and had increased to 16% by 2005.  In 
univariate analysis, survival was significantly higher among patients who received PET vs. 
patients who did not receive PET (46% vs. 29%, P<0.001; Table 6.4). 
Multivariable regression analysis was used to assess the association of PET with patient 
overall survival at two years, controlling for patient demographics and year of diagnosis (Table 
6.5).  Models were analyzed both excluding (model 2) and including (model 3) NSCLC stage to 
examine the effect of stage migration on the association between PET and survival.  In both 
models the receipt of PET was significantly (P<0.0001) associated with improved patient 
survival.  Controlling for stage resulted in a much smaller survival advantage being associated 
with PET, reducing the survival odds ratio of PET from 2.6 to 1.4, suggesting a significant 
contribution of stage migration to the observed benefit of PET.  Both models found decreased 
survival associated with being older, having comorbidities, living in areas with lower education, 
being male, and being not married.  Increasing stage was associated with progressively worse 
two-year survival (model 3, P<0.0001).  Regression models restricted to patients propensity 
score matched by stage and demographics (N=2,924) yielded similar findings. 
 
Propensity Matched Sensitivity Analysis 
 
Patients were separately matched in order to allow comparison of either stage or survival.  
Analysis of stage was performed on patients matched for survival, while analysis of survival was 
matched for stage.  A total of 38,359 cases diagnosed between 1996 and 2005 had all covariates 
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available for matching.  A total of 14,444 patients who did and did not receive a PET scan were 
matched for their propensity to receive a PET scan for stage analysis.  A total of 2,924 patients 
were similarly matched for survival analysis.  Distribution of patient PET propensity scores were 
similar among matched, but not unmatched, patients who had vs. had not received a PET scan 
(Figure 6.5). Unmatched patients who received PET were demographically distinct from 
patients who did not receive a PET scan and were more likely to be black, not receive treatment, 
and to come from sociodemographically disadvantaged census tracks (Table 6.2).  Patients with 
matched propensity to receive PET were demographically similar between patients who did and 
not receive a PET scan (Table 6.6). 
 
Sensitivity Analyses 
 Matching by propensity score, limiting analysis to patients diagnosed between 1998 and 
2003, controlling for SEER registry, limiting analysis to patients surviving  4 months or more, 
and limiting survival analysis to early stage disease did not qualitatively change any reported 
trends or results unless specifically stated above. 
 
6.4 Discussion 
In this study, we provide evidence that the widespread adoption of PET within the 
Medicare NSCLC population between 1998 and 2005 was not accompanied by improved patient 
survival.  Instead, we found that the adoption of PET was characterized by stage migration, 
improvement in stage-specific survival, and selective administration of PET to patients with 
early stage disease.  Our findings here suggest that previous epidemiologic associations between 
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PET and improved patient outcomes may be a manifestation of PET-induced stage migration and 
selective administration of PET to patients with early stage disease. 
Following the introduction of PET in 1998 we observed significant stage migration 
within the Medicare NSCLC population, which was characterized by an increase in advanced 
stage disease.  Between 1997 and 2003, the proportion of all Medicare NSCLC patients with 
advanced or stage IIIB/ IV disease increased by 10%, coinciding with an increase in PET 
utilization from 0% to 50%.  We observed an increase in advanced or distant disease using both 
clinically (clinical and modified AJCC 3rd edition) and longitudinally relevant (SEER summary 
and SEER historic) staging systems. This increase in advanced stage disease was observed both 
overall analyses and after stratification by demographic subgroups, suggesting that the observed 
stage migration was not due to demographic shifts over time in patient age, race, number of 
comorbidities, or region.  Superimposed on the increase in stage IV disease was a steady decline 
in unstaged disease from 1993 through 2005.  It is possible that the use of PET may have 
reduced the number of patients with unstaged disease, however it is important to note that a 
decrease in patients with unstaged disease was also observed prior to the introduction of PET. 
We found that PET was selectively administered to patients with early stage disease by 
both univariate and multivariable regression analyses.  Patients who received PET had a roughly 
50% higher proportion of early disease and 50% lower proportion of stage IV disease compared 
to patients who did not receive a PET scan, with PET being used in 70% of early stage disease 
vs. 50% of advanced stage disease patients by 2004-2005.  We found similar results using 
multivariable analyses that controlled for patient demographics, which revealed that the 
administration of PET was half as likely in patients with stage IV disease.  PET is a more 
sensitive modality for detecting extent of disease, which is generally used after conventional 
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diagnostic and imaging workup has been completed.  Because PET is used in addition to existing 
staging modalities, the use of PET should only be able to increase the stage of newly diagnosed 
disease.  As a result, we predicted that the use of PET would be positively associated with 
increased disease stage.  Instead, we found that PET was negatively associated with advanced 
stage disease.  Because PET cannot be used to downstage disease, the only plausible explanation 
for this is that PET was preferentially administered to patients with early stage disease.  This is 
likely due to the appropriate use of PET in evaluating primarily localized disease for evidence of 
occult metastases and avoidance of PET use in frank metastatic disease in line with 2003 
recommendations by the American Society of Clinical Oncologists (ASCO). 4  PET may be less 
likely to be used in patients with poor performance status or in patients with improved health 
care access, which we were unable to measure in our study.  Limiting the analysis to patients 
who survived 4 months from observation did not affect analysis results, suggesting that poor 
performance status was not the dominant factor driving selective administration of PET to 
patients with non-metastatic disease. 
We found that the combination of PET-induced stage migration and selective 
administration of PET to patients with early stage disease resulted in an association of PET with 
improved survival.  Following the introduction of PET in 1998, stage-specific survival improved 
or remained the same across all stages.  The largest increase was observed among advanced stage 
disease, which experienced an increase in 2 year survival from 10% to 15%.  During this period, 
overall survival remained relatively constant.  Specifically, no significant change in overall 
survival occurred between the initial and post-PET adoption periods (1998-1999 vs. 2004-2005).  
Stable or increased stage-specific survival across all stages in the absence of overall increases in 
survival can only be mathematically explained by migration of patients between stage groups, 
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indicating that stage-specific increases in survival were predominantly an artifact of stage 
migration.  Interpretation of multivariable regression analyses was complicated by the presence 
of selection bias and stage migration.  Regression models that controlled for stage attributed a 
much smaller survival advantage to PET, reducing the odds ratio associated with PET from 2.6 
to 1.4, suggesting a significant contribution of stage migration to the observed benefit of PET.  
PET and stage are both causally related to one another, endogenous, and therefore subject 
to bias when modeled with conventional survival analysis techniques.  Combined with the 
presence of significant stage migration, this endogeneity may explain previous associations 
between the use of PET and improved patient survival.  A previous analysis in a privately 
insured population by Chee et al. 12 similarly found a direct association between the use of PET 
and roughly two-fold improved survival in the absence of any change in overall patient survival.  
Previous work by Farjah et al. 3 suggested that PET was similarly associated with a two fold 
increase in survival, but did not control for selection bias or stage migration. Had a two-fold gain 
in survival been truly afforded by the use of PET, overall improvement in NSCLC survival 
should have increased by over 25% following uptake of PET by more than half of the Medicare 
NSCLC population.  This finding was not observed in our study and has not been previously 
reported in the literature, therefore it is unlikely that PET use itself was responsible for 
improvements in stage-specific survival but rather the Will-Rogers effect of reallocation of 
patients to different stage categories based upon the application of PET.12  Stage-specific 
increases in survival of advanced stage NSCLC 28 are also consistent with this observation.  
Taken together, our findings urge caution for future work seeking to establish a causal 
relationship between imaging and outcomes.      
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To date, there have been only four RCTs examining the use of PET in NSCLC, which 
have consistently demonstrated PET-induced upstaging of disease but have not detected a change 
in patient survival in the setting of limited statistical power. 7-10  In addition to their being a lack 
of empirical evidence supporting a survival advantage of PET, it is not clear how PET would 
increase survival of advanced stage disease for which there is no cure.  In the case of stage IV 
disease, we observed an increased in survival from 10% to 15%, or a relative 50% increase in 
survival.  Others have previously observed improved survival in advanced NSCLC disease and 
have concluded that these improvements have been a result of improved treatment. 35  Stage 
migration would explain both this large improvement in incurable disease and the simultaneous 
lack of change in survival in the overall NSCLC population, a phenomena previously dubbed the 
Will Rogers phenomena12,30. 
Over the extended 1993-2005 period, we observed an increase in overall survival of 3.7 
percentage points, which occurred largely prior to the introduction of PET in 1998.  This could 
reflect improved management of cancer, including antineoplastic therapies and supportive care 
(i.e. growth factors), management of patient comorbidities, or perhaps earlier detection 
coinciding with increased use of CT, MRI, or other imaging modalities.  Since 1997, ASCO 
guidelines have recommended a combination of radiation and chemotherapy for patients with 
good performance status and unresectable (typically stage III or IV) disease. 4  In 2003, the 
ASCO recommendation was further expanded to recommend the use of dual vs. single 
chemotherapy agents.  Recently, a randomized trial of early palliative care found a survival 
benefit comparable to chemotherapy, 36 highlighting the potential for other factors besides 
chemotherapy to have affected patient survival.  The effect of increasing chemotherapy use on 
overall survival may have affected the trends in survival that we observed in our study.   A 
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modest increase in the survival of patients older than 80 and patients with multiple comorbidities 
lends support to idea of modestly improved supportive care of older or moribund patients during 
the study period. 
PET has the potential to provide value to patients, physicians, and potentially health care 
insurers regardless of whether or not PET is capable of improving patient outcomes.  The use of 
PET, particularly in conjunction with dedicated dual PET/CT scanners, provides more sensitive 
and specific staging of NSCLC compared with CT alone4-6  and may facilitate physician-patient 
communication regarding patient prognosis and treatment options.  The ability of PET to impact 
survival may change in the future with the use of PET in evaluating emerging molecularly-
targeted therapies, which were infrequently used during the time frame analyzed by this study.   
Another potential benefit of PET is the avoidance of futile thoracotomy, which occurs when a 
patient with occult metastatic disease undergoes local, definitive treatment for an incurable 
disease.  Of the four randomized trials investigating the use of PET in NSCLC to date, three have 
suggested that the use of PET may result in appropriate upstaging and reduction of futile 
thoracotomy7-9 and one has suggested potential cost savings,37 although it is unknown whether or 
not these benefits can be extrapolated from small, single center RCTs to the general Medicare 
NSCLC population. Continuing evaluation of the effect of PET on cancer patient evaluation, 
management, and outcomes will likely be aided in the future by the continued implementation of 
national, prospective databases of PET use such the National Oncologic PET Registry 
(NOPR).38-40   
There are a number of topics regarding the use of PET in cancer patients that may 
warrant further research. The ability of PET to impact survival may change with the emergence 
of molecularly-targeted therapies, which were infrequently used during the time frame analyzed 
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by this study.  The increased use of PET and its role in clinical decision making and use, timing, 
and value in conjunction with other diagnostic and evaluative tests are also areas of future 
research.  How patient performance status affects the likelihood of receiving PET might help 
provide a more accurate model of how performance status affects imaging use and how these 
factors might impact attempts to legislate changes in health care reform.  Our findings urge 
caution for future studies that seek to establish a causal relationship between imaging and 
outcomes.  Future research to improve or create new methodologies capable of accurately 
addressing such questions in the setting of endogeneity would be extremely valuable. Of note, a 
decrease in patients with unstaged disease was also observed prior to the introduction of PET.  
How and why this change occurred might help further inform studies involved NSCLC staging 
in ongoing research. 
 
Limitations 
 This study was a retrospective, claims-based analysis. Only PET scans paid for by 
Medicare could be detected in our analysis.  However, it is likely that relatively few PET scans 
for Medicare beneficiaries would be paid by third party insurers or out of pocket.  To minimize 
the proportion of missed claims, all analyses were limited to Medicare beneficiaries with both 
part A and B coverage and no HMO participation or part C coverage for the 12 months prior to 
and following their diagnosis.  Patients within the SEER registry are overall more likely to be 
non-white, live in non-poverty areas, and live in urban areas,34 and may as a result reflect a 
skewed characterization of PET within the general Medicare NSCLC population.  The most 
recent year of diagnosis examined in this study was 2005, which is the most recent SEER cohort 
available for which two full years of survival follow-up were available to determine 2-year 
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survival.  Lastly, collection of cancer T, N, and M information used to extract cancer stage 
changed in 1998 and again in 2004.25  Prior to 1998, information used to stage cancers was 
obtained using all available information in the two months following diagnosis.  Beginning in 
1998 onward, this timeframe was extended to four months or first surgery.  This likely resulted 
in a slight increase in advanced stage disease between 1997 and 1998.  In 2004, data collection 
within SEER changed from the extend of disease (EOD) collection system to the collaborative 
staging system (CSS).  It is unclear how this should have affected staging.  Of note, we did 
observe a slight decrease in advanced stage disease and increase in early stage disease between 
2003 and 2004, which we attribute to this change.  Regardless, no changes in the staging system 
were made between 1998 and 2003, when we observed the largest changes in PET utilization and 
stage migration.   
 
Conclusions 
In this study we show that overall two-year survival of NSCLC Medicare patients has 
remained relatively constant following the widespread adoption of PET.  Previous reports 
demonstrating an association of PET with large increases with NSCLC patient survival during 
this period are likely explained by a combination of stage migration and preferential 
administration of PET to patients with less advanced disease.  Emerging screening technologies 
and treatments must be rigorously evaluated to prevent physicians, policy makers, insurers, and 
patients from making misinformed decisions about their health care as a result of unappreciated 
selection bias and/or stage migration.  The ability of PET to affect patient management, health 
care utilization, and costs remain important areas of ongoing research that may change as new 
treatments become available in the future. 
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Table 6.1 –Baseline Patient Characteristics by Pre-PET (1993-1994), Initial PET (1998-
1999), and Post-PET Cohorts (2004-2005) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Chi-squared test.  Abbreviations: HS, High School  
Characteristic 
Year of Diagnosis 
P-Value* 
 
Pre-PET 
(1993-1994) 
N = 8,837 
Initial PET 
(1998-1999) 
N = 8,017 
Post-PET 
(2004-2005) 
N = 10,436 
Age > 80, No. (%) 1287 (14.6) 1460 (18.2) 2342 (22.4) <0.0001 
Male, No. (%) 5111 (57.8) 4416 (55.1) 5312 (50.9) <0.0001 
Black, No. (%) 672 (7.6) 670 (8.4) 862 (8.3) <0.0001 
Comorbid conditions, No. (%)    <0.0001 
     0 5404 (61.2) 4514 (56.3) 5186 (49.7)  
     1 2283 (25.8) 2185 (27.3) 3071 (29.4)  
     2+ 1150 (13) 1318 (16.4) 2179 (20.9)  
Census tract characteristics 
(2000): 
(Highest Quartile)    
 
     Did not complete high school --- 1687 (25.8) 2135 (23) c 
     Percent below poverty  line --- 1704 (26.1) 2156 (23.3) <0.0001 
     Percent black --- 1608 (24.6) 2211 (23.8) 0.25 
Married (%) 5024 (56.9) 4533 (56.5) 5496 (52.7) <0.0001 
Metropolitan (%) 7748 (87.7) 6819 (85.1) 8977 (86) <0.0001 
Any Therapy (%) 7626 (86.3) 6791 (84.7) 8755 (83.9) <0.0001 
Region    <0.0001 
     West 3894 (44.1) 3464 (43.2) 4749 (45.5)  
     Midwest 2920 (33) 2847 (35.5) 3376 (32.4)  
     Northeast 1417 (16) 1156 (14.4) 1626 (15.6)  
     South 606 (6.9) 550 (6.9) 685 (6.6)  
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Table 6.2 – Baseline Patient Characteristics by Receipt of PET, 1996-2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Chi-squared test.  Abbreviations: HS, High School  
Characteristic Receipt of PET 
P-Value* 
 
No PET 
(N=27,196) 
PET 
(N=11,163) 
Age > 80, No. (%) 5278 (19.4) 1956 (17.5) <0.0001 
Male, No. (%) 14612 (53.7) 5730 (51.3) <0.0001 
Black, No. (%) 2434 (9) 662 (5.9) <0.0001 
Comorbidities, No. (%)   <0.0001 
     0 14917 (54.9) 5758 (51.6)  
     1 7505 (27.6) 3263 (29.2)  
     2+ 4774 (17.6) 2142 (19.2)  
Census tract characteristics 
(2000): 
(Highest Quartile)   
 
     Did not complete HS 7248 (26.7) 2218 (19.9) <0.0001 
     % below poverty  line 7183 (26.4) 2212 (19.8) <0.0001 
     Percent black 7026 (25.8) 2362 (21.2) <0.0001 
Married (%) 14609 (53.7) 6223 (55.8) <0.0001 
Metropolitan (%) 23070 (84.8) 9707 (87) <0.0001 
Any Therapy (%) 22455 (82.6) 10059 (90.1) <0.0001 
Region   <0.0001 
     West 11986 (44.1) 5276 (47.3)  
     Midwest 9708 (35.7) 3232 (29)  
     Northeast 3554 (13.1) 2000 (17.9)  
     South 1948 (7.2) 655 (5.9)  
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Table 6.3 –PET utilization, Survival, and Stage by Pre-PET (1993-1994), Initial PET (1998-
1999), and Post-PET Cohorts (2004-2005) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Chi squared test was used to test for an association between categorical variables and year of diagnosis.   
† P-Value for the difference between initial-PET and post-PET survival is not significant (P = 0.01)  
Abbreviations; PET, Positron Emission Tomography; AJCC, American Joint Committee on Cancer 
 
 
 
 
  
Characteristic 
Year of Diagnosis 
P-Value* 
 
Pre-PET 
(1993-1994) 
N = 8,837 
Initial PET 
(1998-1999) 
N = 8,017 
Post-PET 
(2004-2005) 
N = 10,436 
Any PET scans, No. (%) 0 (0) 380 (4.7) 6303 (60.4) <0.0001 
Any PET Facility, No. (%)  0 (0) 954 (11.9) 7476 (71.6) <0.0001 
Any PET Physician, No. (%)  0 (0) 1263 (15.8) 10238 (98.1) <0.0001 
Miles to PET ≤ 40, No. (%)  0 (0) 4942 (61.6) 9708 (93) <0.0001 
Alive at 2 years, No. (%) 2809 (31.8) 2703 (33.7) 3709 (35.5)  <0.0001† 
Stage (AJCC 3rd Edition)    <0.0001 
     I 1933 (21.9) 1848 (23.1) 2651 (25.4)  
     II 385 (4.4) 260 (3.2) 438 (4.2)  
     IIIA 742 (8.4) 757 (9.4) 1244 (11.9)  
     IIIB 1466 (16.6) 1462 (18.2) 1655 (15.9)  
     IV 2017 (22.8) 2030 (25.3) 3404 (32.6)  
     Unstaged 2294 (26.0) 1660 (20.7) 1044 (10.0)  
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Table 6.4: PET utilization, Survival, and Stage by Receipt of PET, 1996-2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Chi-squared test.  Abbreviations: HS, High School; PET, Positron Emission Tomography; AJCC, American Joint 
Committee on Cancer 
  
Characteristic Receipt of PET 
P-Value* 
 
No PET 
(N=27,196) 
PET 
(N=11,163) 
Any PET scans, No. (%) 0 (0) 11163 (100) <0.0001 
Any PET Facility, No. (%)  6420 (23.6) 8796 (78.8) <0.0001 
Any PET Physician, No. (%)  11025 (40.5) 11154 (99.9) <0.0001 
Miles to PET ≤ 40, No. (%)  15970 (58.7) 10258 (91.9) <0.0001 
Alive at 2 years, No. (%) 7906 (29.1) 5078 (45.5) <0.0001 
Stage (AJCC 3rd Edition)   <0.0001 
     I 5478 (20.1) 3400 (30.5)  
     II 828 (3) 543 (4.9)  
     IIIA 2400 (8.8) 1491 (13.4)  
     IIIB 5073 (18.7) 1796 (16.1)  
     IV 8447 (31.1) 2651 (23.8)  
     Unstaged 4965 (18.3) 1282 (11.5)  
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Table 6.5: Multivariable Logistic Regression of the Likelihood of Stage IV disease and 2-
Year Survival as a Function of PET (N = 38,359). 
Characteristic Model 1 Model 2 Model 3 
 
Stage IV disease as a 
function of PET 
OR (95% CI) 
2-Yr Survival as  a 
function of PET 
OR (95% CI) 
2-Yr Survival as  a 
function of PET, 
controlling for stage 
OR (95% CI) 
Any PET 0.44 (0.39-0.49)* 2.58 (2.37-2.82)* 1.4 (1.28-1.53)* 
Any PET Facility 1.13 (1.05-1.22) 1.01 (0.94-1.07) 1.08 (1-1.16) 
Any PET Physician 1.18 (1.06-1.32) 0.87 (0.75-1.01) 0.91 (0.81-1.03) 
PET > 40 miles away 0.95 (0.88-1.02) 0.98 (0.92-1.04) 0.98 (0.91-1.05) 
Year of Diagnosis    
     1996 0.88 (0.82-0.95) 0.97 (0.9-1.05) 0.89 (0.8-0.98) 
     1997 0.88 (0.77-0.99) 1.02 (0.9-1.15) 0.94 (0.84-1.05) 
     1998 (Reference) --- --- --- 
     1999 1.01 (0.89-1.14) 1.05 (0.94-1.17) 1.05 (0.95-1.16) 
     2000 0.99 (0.86-1.14) 1.07 (0.91-1.26) 1.07 (0.91-1.24) 
     2001 1.18 (0.97-1.44) 0.85 (0.75-0.96) 0.92 (0.83-1.01) 
     2002 1.33 (1.13-1.56)* 0.76 (0.66-0.88)* 0.83 (0.74-0.94) 
     2003 1.48 (1.31-1.68)* 0.73 (0.62-0.86)* 0.87 (0.75-1.01) 
     2004 1.66 (1.42-1.95)* 0.74 (0.62-0.89) 0.87 (0.74-1.02) 
     2005 1.88 (1.6-2.22)* 0.7 (0.6-0.82)* 0.82 (0.72-0.93) 
Stage (AJCC 3rd Ed)    
II --- --- 0.52 (0.47-0.58)* 
IIIA --- --- 0.19 (0.17-0.21)* 
IIIB --- --- 0.08 (0.08-0.09)* 
IV --- --- 0.04 (0.03-0.04)* 
Unstaged --- --- 0.21 (0.19-0.23)* 
II                x PET --- --- 1.08 (0.96-1.22) 
IIIA            x PET --- --- 1.26 (1.07-1.48) 
IIIB            x PET --- --- 1.9 (1.62-2.23)* 
IV              x PET --- --- 2.1 (1.7-2.61)* 
Unstaged x PET --- --- 1.32 (1.11-1.57) 
Age >80 0.78 (0.72-0.83)* 0.64 (0.62-0.66)* 0.58 (0.55-0.61)* 
Black 1.14 (1.01-1.28) 0.85 (0.8-0.91)* 0.97 (0.9-1.03) 
Comorbidities     
    One 0.76 (0.72-0.8)* 0.98 (0.92-1.04) 0.82 (0.75-0.9)* 
     Multiple 0.68 (0.66-0.71)* 0.79 (0.73-0.85)* 0.61 (0.56-0.66)* 
Male 1.07 (0.93-1.23) 0.57 (0.55-0.61)* 0.57 (0.54-0.59)* 
Married (%) 0.99 (0.9-1.09) 1.26 (1.17-1.35)* 1.29 (1.18-1.41)* 
Metropolitan (%) 0.98 (0.89-1.08) 1.09 (0.93-1.27) 1.1 (0.91-1.32) 
Region    
     Midwest 0.89 (0.82-0.96) 1.04 (0.96-1.14) 0.96 (0.9-1.03) 
     Northeast  0.95 (0.88-1.03) 1.08 (1.03-1.14) 1.04 (0.99-1.09) 
     South 0.87 (0.76-1) 0.83 (0.75-0.93)* 0.77 (0.69-0.84)* 
*P < 0.001, Census tract variables were omitted due to space constraints. 
Abbreviations: PET, Positron Emission Tomography; AJCC, American Joint Committee on Cancer 
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Table 6.6: Univariate Comparison of Patients by Receipt of PET Before and After 
Matching by PET Propensity for Stage and Survival Analysis, 1996-2005. 
 
* P < 0.001, Chi-squared test.  Abbreviations: HS, High School
Characteristic Propensity Matched for Stage 
Analysis 
 (Matched for Survival) 
Propensity Matched for Survival 
Analysis 
 (Matched for Stage) 
No PET 
(N=7,222) 
PET  
(N=7,222) 
No PET 
(N=1,462) 
PET  
(N=1,462) 
Any PET scans, No. (%) 0 (0)* 7222 (100)* 0 (0)* 1462 (100)* 
Alive at 2 years, No. (%) 2257 (31.3) 2304 (31.9) --- --- 
Stage (AJCC 3rd Edition)     
     I --- --- 1462 (100) 1462 (100) 
     II --- ---      <11 (<1.0)      <11 (<1.0) 
     IIIA --- ---      <11 (<1.0)      <11 (<1.0) 
     IIIB --- ---      <11 (<1.0)      <11 (<1.0) 
     IV --- ---      <11 (<1.0)      <11 (<1.0) 
     Unstaged --- ---      <11 (<1.0)      <11 (<1.0) 
Any PET Physician, No. (%)  7211 (99.8) 7213 (99.9) 1462 (100.0) 1462 (100.0) 
Miles to PET ≤ 40, No. (%)  6569 (91.0) 6566 (90.9) 1317  (90.1) 1317  (90.1) 
Age > 80, No. (%) 1413 (19.6) 1399 (19.4) 284   (19.4) 290   (19.8) 
Male, No. (%) 3745 (51.9) 3792 (52.5) 722   (49.4) 735   (50.3) 
Black, No. (%) 6692 (92.7) 6710 (92.9) 100     (6.8) 91      (6.2) 
Comorbidities, No. (%)     
     0 3772 (52.2) 3792 (52.5) 682 (46.6) 707 (48.4) 
     1 2051 (28.4) 2037 (28.2) 456 (31.2) 459 (31.4) 
     2+ 1399 (19.4) 1393 (19.3) 324 (22.2) 296 (20.2) 
Census tract characteristics (2000): 
(Highest Quartile)     
     Did not complete HS 1630 (22.6) 1596 (22.1) 332  (22.7) 338  (23.1) 
     % below poverty  line 1604 (22.2) 1583 (21.9) 327  (22.4) 341  (23.3) 
     Percent black 1655 (22.9) 1635 (22.6) 339  (23.2) 341  (23.3) 
Married (%) 3892 (53.9) 3925 (54.3) 810  (55.4) 795  (54.4) 
Metropolitan (%) 6246 (86.5) 6259 (86.7) 1280 (87.6) 1279 (87.5) 
Any Therapy (%) 5975 (82.7) 6420 (88.9) 1348 (92.2) 1389 (95.0) 
Region     
     West 3285 (45.5) 3284 (45.5) 640 (43.8) 658 (45.0) 
     Midwest 2429 (33.6) 2408 (33.3) 527 (36.0) 517 (35.4) 
     Northeast 1082 (15.0) 1097 (15.2) 204 (14.0) 212 (14.5) 
     South 426     (5.9) 433     (6.0) 91    (6.2) 75    (5.1) 
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Figure 6.1: Conceptual Schematic of Stage Migration as a Result of PET. 
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Figure 6.2: CONSORT diagram 
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Figure 6.3: Stage Distribution by Alternative Staging Systems among NSCLC Medicare 
Patients from 1993 to 2005. 
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Figure 6.4: Stage Distribution and 2-Year Survival by Selected NSCLC Medicare Patient 
Subgroups from 1993 to 2005. 
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Figure 6.5: Distribution of PET Propensity Before and After Matching, 1996-2005. 
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CHAPTER 7: THE ASSOCIATION OF PET WITH TRENDS IN THE TREATMENT 
AND HEALTH CARE UTILIZATION OF THE MEDICARE NON-SMALL CELL 
LUNG CANCER POPULATION BETWEEEN 1998 AND 2005 
 
 
  
124 
 
Abstract 
 
Context: 
The use of positron emission tomography (PET) spread rapidly among Medicare non-small cell 
lung cancer (NSCLC) beneficiaries following its approval in 1998.  Small randomized trials 
suggest that PET has the potential to save costs by reducing rates of futile thoracotomy. The use 
of PET in such trials, however, may differ systematically from how this technology has been 
used in clinical practice within the Medicare NSCLC population.  How PET affects treatment 
decisions and overall health care costs of NSCLC patients is an important question that has not 
been studied previously within the Medicare NSCLC patient population. 
 
Objective: 
To examine the association of PET with changes in treatment and overall healthcare costs among 
Medicare NSCLC beneficiaries. 
 
Design, Setting, and Patients: 
Using Surveillance Epidemiology and End Results (SEER)-Medicare data, we conducted a 
retrospective cohort study of NSCLC Medicare beneficiaries diagnosed with NSCLC between 
1993 and 2005. 
 
Main Outcome Measures: 
Receipt of surgical resection, inpatient costs, and overall health care costs. 
 
Results: 
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A total of 58,575 cases of Medicare NSCLC met study criteria between 1993 and 2005.  From 
1998 to 2005, the proportion of NSCLC cases receiving a PET scan increased from 5% to 60%.  
During this same period, the overall proportion of patients undergoing surgical resection 
decreased by 3.1 percentage points and radiation therapy by 6.0 percentage points, whereas 
chemotherapy increased 10.8 percentage points (all P < 0.0001).  Overall average patient costs 
increased by $10,200 between 1998 and 2005.  After controlling for changing patient 
demographics, lung resection rates and inpatient expenditures decreased steadily from 1998 to 
2003, resulting in an 11% decrease in inpatient expenditures following the adoption of PET.  
Non-inpatient costs increased during the same period, largely driven by increased use of 
chemotherapy in advanced stage disease. 
 
Conclusion: 
The widespread adoption of PET between 1998 and 2005 for evaluation of early stage 
disease was accompanied by stage migration, reduced rates of lung resection, and decreased 
inpatient health care expenditures by 2005 after controlling for patient demographics. Over the 
same period, the proportion of patients undergoing chemotherapy and patients with multiple 
comorbidities increased, resulting in an overall increase in Medicare NSCLC patient costs.  The 
increased use of PET in the Medicare NSCLC patient population and how it affects patient 
management and health care utilization remains an important area of ongoing research and 
evolving health policy. 
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7.1 Introduction 
 
Positron emission tomography (PET) is an advanced imaging modality used in the 
clinical diagnosis, staging, and restaging of non-small cell lung cancer (NSCLC).  Three out of 
the four small randomized controlled trials (RCTs) of PET use in the initial evaluation of 
NSCLC1-4 have suggested that PET results in upstaging of occult metastatic NSCLC from early 
(I-IIIA) to late stage disease,5 providing the potential to avoid futile resection of incurable, occult 
metastatic disease2.  In privately-insured patient populations, PET has been associated with 
upstaging of NSCLC, 5 suggesting the potential of PET to allow patients to avoid futile 
thoracotomy and associated inpatient hospitalization in clinical practice outside RCTs. 
We previously found evidence of PET-induced stage-migration among Medicare NSCLC 
patients. 6  Given the presumption that more appropriate clinical staging reduces futile local anti-
neoplastic therapies, it remains an open question whether the introduction of PET within the 
Medicare NSCLC population was associated with decreased rates of futile local therapy and 
avoidable inpatient costs.  In this study, we examine the treatment, health care utilization, and 
overall health care costs of PET use in Medicare beneficiaries with NSCLC.  We test the 
hypotheses that the adoption of PET within the Medicare NSCLC population between 1998 and 
2005 was associated with 1) a reduction in the use of surgical resection and 2) that this reduction 
in locally definitive treatment resulted in inpatient cost-savings and/or 3) a shift towards 
systemic chemotherapy.  
 
7.2 Methods 
Data Source 
127 
 
Data are from the Surveillance Epidemiology and End Results (SEER)-Medicare linked 
data.  SEER-Medicare is a collaborative effort between the National Cancer Institute (NCI) and 
Centers for Medicare and Medicaid Services (CMS) that links routinely-collected population-
based data from cancer registries across the country to Medicare administrative data and health 
care claims.7  The SEER data include demographic and incident cancer characteristics including 
grade, and stage for approximately 25% of the U.S. cancer population. Medicare provides health 
insurance for 97% of Americans aged 65 and older, and these data reflect health care services 
used and co-morbid health conditions.  SEER-Medicare data have been used previously to 
examine factors that affect cancer care quality including sociodemographics, physician and 
hospital characteristics, surgery, chemotherapy, radiation, comorbidities, complications, 
screening, relapse, and costs8-18.  This study was approved by the Office of Human Research 
Ethics at the University of North Carolina, Chapel Hill.    
 
Study Population 
 
All analyses were conducted using SEER-Medicare data from the 12 SEER registries that 
were active from 1993 onward. Within these registries, we included all patients who had a 
diagnosis of cancer of the lung and bronchus with microscopically confirmed NSCLC histology 
between 1993 and 2005, were > 66 years at diagnosis, and had Medicare Part A & B coverage 
without participating in an Health Maintenance Organization (HMO) or Medicare Part C for the 
year prior to and following their diagnosis or until death.  We excluded patients who were 
diagnosed at autopsy or death or who had another diagnosis of malignancy in the year prior to 
their NSCLC diagnosis.  We excluded patients who did not survive at least 2 months after 
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diagnosis to exclude clinically morbid patients for whom we expected PET use would be less 
likely.  To help ensure full acquisition of claims for cancer-related claims, patients were required 
to have a primary diagnosis of lung cancer on an inpatient, outpatient, or carrier-based Medicare 
claim (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-
CM] diagnosis of lung cancer [162.2-162.9, 231.2]). 
 
Study Variables 
 
 To determine patient treatment and health care costs, we used claims data on receipt of 
surgery, chemotherapy, radiation, and total Medicare payments from 2 months prior to 12 
months following the month of NSCLC diagnosis in SEER.  Receipt of each modality was 
ascertained using previously defined sets of HCPCS (Health Care Procedural Coding System) 
and ICD-9-CM codes (Table 7.Supplemental).19,20  Receipt of surgery was defined using claims 
for lung resection from inpatient, outpatient, or carrier claims files.19 Receipt of chemotherapy 
was defined using claims from outpatient, carrier, and durable medical equipment (DME) claims 
files.20  Receipt of radiation therapy was ascertained using outpatient and carrier claims.20 
Total patient costs were examined in the period 2 months prior to and 12 months 
following diagnosis in order to ensure that we captured all initial workup and treatment costs.  
Total Medicare payments were obtained within each claim file by summing line item payments 
(home health, hospice, outpatient files), total claim payment amounts (carrier and DME), or total 
reimbursement plus total daily per diem charges (inpatient) and adjusting all payments to 2008 
dollars using the health care component of Consumer Price Indices (CPI).  
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Receipt of PET was detected using outpatient and carrier claims in the period 2 months 
prior to, and 4 months following SEER diagnosis to coincide with the 4-month follow-up period 
used by SEER to provide cancer stage from 1998 onward21.  SEER-based patient zip codes and 
Medicare carrier claim zip codes were used to determine the straight-line distance between 
patients and the closest PET providing physician at the time of diagnosis.   
All remaining variables were obtained from the SEER Patient Entitlement and Diagnosis 
Summary File (PEDSF).  Cancer stage was ascertained from SEER data and extrapolated to the 
American Joint Committee on Cancer (AJCC) 3rd edition staging system to provide a common 
staging system throughout the study period. 6  Survival at two years was obtained from the 
SEER-based date of death.  Demographic variables included age, sex, race, ethnicity, marital 
status, and local census tract characteristics (metropolitan urban or rural status, percent not-
finishing high school, percent below the poverty line, and percent black).  Histology of NSCLC 
was classified as adenocarcinoma, large cell carcinoma, squamous cell, or NSCLC “otherwise 
undifferentiated” using the ICD-O-3 (International Classification of Disease in Oncology, 3rd 
Edition) code on SEER diagnosis. The 12 SEER registries included in the study were grouped 
according to their census regions: Northeast (Connecticut), Midwest (Detroit, Iowa), South 
(Atlanta, Rural Georgia), and West (San Francisco, Hawaii, New Mexico, Seattle, Utah, San 
Jose, Los Angeles). 
 
Statistical Analysis 
 
To study changes in treatment and costs over time, we defined three distinct NSCLC 
cohorts based on year of diagnosis that represented the pre-PET (1993-1994), initial-PET (1998-
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1999), and post-PET (2004-2005) phases of PET adoption.  We used comparisons between these 
three cohorts to assess changes in treatment patterns and costs before and after PET had become 
commonly used in Medicare patients.  Data from the 1993-1997 years were used to detect any 
ongoing trends in treatment practice prior to the introduction of PET and to help to assess 
changes in treatment that occurred before PET.  Direct comparison of 1998-1999 and 2004-2005 
were made when assessing changes in practice that accompanied PET adoption and could be 
potentially attributed to increased PET use.   
 
Cohort Comparisons 
Treatment and cost patterns can both be heavily influenced by demographic shifts 22 and 
by selection bias. 23  Previous, we have observed that PET experienced rapid adoption between 
1998 and 2005. 23  To capture changes in the study population over this time period, we 
examined demographics and patient characteristics between pre-PET, initial-PET, and post-PET 
cohorts composed of patients with no, little, and substantial PET use, respectively, as well as 
between patients who did and did not receive PET within the post-PET cohort (2004-2005).  In 
these single variable analyses, chi-squared tests were used to compare categorical variables and 
Kruskal-Wallis non-parametric tests used to compare costs.    
 
Assessment of Treatment Patterns 
Multivariable logistic regression models were used to examine the use of 1) surgical 
resection, 2) radiation therapy, and 3) chemotherapy between 1996 and 2005 to capture changes 
in treatment patterns during the adoption of PET into Medicare NSCLC practice.  Regression 
models were alternatively examined by limiting analysis to patients with early stage disease.  We 
131 
 
hypothesized that a smaller proportion of NSCLC beneficiaries would receive surgery or 
radiation in the years following increased PET use in 1998.  Trends in stage distribution and 
resection, radiation, and chemotherapy rates were plotted by year of diagnosis from 1993 
through 2005 to examine temporally correlated shifts in PET use, stage migration, and treatment 
patterns both before and after the widespread adoption of PET among the overall Medicare 
NSCLC population. 
 
Assessment of Health Care Costs 
Multivariable ordinary least squares (OLS) regression models were similarly used to 
examine total Medicare payments within the 1) inpatient 2) non-inpatient claims, and 3) total 
claims files between 1996 and 2005.  Medicare payments were modeled as logged costs to adjust 
for left-skewed cost data and to avoid non-normally distributed error terms.  Relative percent 
differences in costs were calculated per Kennedy (1981). 24,25  Costs were alternatively modeled 
as costs per month survival to calculate a monthly spending rate as an alternative measure of 
cost.  Regression analyses were run both with (not shown) and without receipt of surgery, 
radiation, and chemotherapy in order to analyze the impact that treatment had on observed 
changes in costs over time in the years after PET adoption into use.  We hypothesized that 
following the introduction of PET in 1998 that inpatient costs would decrease secondary to 
decreased rates of lung resection, and that non-inpatient costs would either remain the same or 
increase due to increased use of chemotherapy.  Inpatient, non-inpatient, and overall costs were 
plotted over the study period. 
All regression models controlled for disease stage and patient demographics including 
age, race, sex, marital status, residence in a metropolitan area, region, and census tract-based 
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levels of local education, income, and demographic composition.  In order for all observations to 
use sociodemographic variables from the 2000 census, 1996 was the earliest year included in 
regression analyses.  Errors were clustered by SEER registry for all regressions 7.  Additional 
sensitivity analyses included the inclusion of SEER registry as a control, the removal of PET and 
stage interaction terms from the model to allow interpretation of PET and stage alone, and the 
restriction of the study cohort to 1998-2003 to limit analysis to a period during which changes in 
staging system occured.  All results were considered significant at P < 0.001 unless otherwise 
stated in order to adjust for the considerable number of statistical tests conducted.  All analyses 
were conducted using SAS version 9.2. 
 
7.3 Results  
 
Study Population 
 
 We identified 204,664 Medicare beneficiaries diagnosed with cancer of the lung and 
bronchus in the included SEER registries between 1993 and 2005.  From these beneficiaries we 
identified 207,291 cases of incident lung cancer.  We sequentially excluded patients (Figure 7.1) 
who were diagnosed at death or autopsy, were younger than 66 years of age, did not have 
microscopically-confirmed NSCLC histology, had another malignancy in the year before or after 
their diagnosis, participated in an HMO or did not have part A and B coverage for the year 
before and after their diagnosis, did not survive a minimum of 2 months from their diagnosis, did 
not have an prior malignancy outside of SEER, and had a Medicare claims-based ICD-9 
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diagnosis of lung cancer within two months prior to and four months following SEER diagnosis.  
The final cohort consisted of 58,575 NSCLC cases. 
 
Comparison of Pre-PET, Initial PET, and Post-PET Cohorts 
 
NSCLC cases differed by cohort 2005 (Table 7.1).  In later years, NSCLC Medicare 
patients were composed of a larger percentage of patients older than 80, female patients, patients 
with comorbidities, and non-married patients (P<0.0001). Within the 2004-2005 cohort, patients 
who received PET were less likely to be older than age 80 (20% vs. 27%), black (7% vs. 11%), 
come from a census tract with less education, more poverty, or more blacks (20-22% vs. 27-28% 
for each), be unmarried (49% vs. 55%), or come from the Midwest (30% vs. 36%; all P <0.001; 
Table 7.2). 
As reported previously, there was a 12-fold increase in the use of PET was observed 
between the initial and post-PET patient cohorts (Table 7.3, 5% vs. 62%, P<0.0001).  The 
proportion of patients who resided within 40 miles of a PET providing facility increased between 
1998 and 2005 due to an increase in the number of zip codes providing PET scans (62% vs. 
93%).  The proportion of patients alive two years after diagnosis increased from 32% in 1993 to 
36% in 2005 (P<0.0001).  Overall, the proportion of patients who underwent some form of 
treatment for their cancer was unchanged. However, there was there was a marked decrease in 
the proportion of NSCLC cancers that went unstaged (26% vs. 10%) and a concomitant increase 
in cases staged as advanced disease (40% vs. 49%).  PET scans were preferentially received by 
patients with early stage disease (Table 7.4, 51% vs. 27%).  Health care utilization was markedly 
increased among patients who underwent one or more PET scans.   
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Changes in Treatment Patterns 
Between 1993 and 2005, a decreased proportion of patients underwent any resection 
(Table 7.3, 33% vs. 28%, P<0.0001) or radiation (56% vs. 46%, P<.0.0001).  In contrast, the 
proportion of patients receiving chemotherapy more than doubled from 19% to 46% (P<0.0001).  
Total costs per patient increased from $49,384 to $56,045 between 1998 and 2005 (P<0.0001).  
Increasing costs were entirely driven by non-inpatient costs.  The average non-inpatient cost per 
patient increased by approximately $7,300 between 1998 and 2005 ($20,809 vs. $28,145, 
P<0.0001).  Inpatient costs did not exhibit a significant change in costs over the study period, but 
instead exhibited a trend towards decreased costs of approximately $700 between 1998 and 2005 
(P = 0.02).   
Among patients diagnosed in the post-PET period, patients receiving PET were more 
likely to undergo surgical resection (Table 7.4, 37% vs. 16%), chemotherapy (50% vs. 40%), 
and incur greater non-inpatient ($30,387 vs. $24,726) and overall health care costs ($58,115 vs. 
$52,890).  No significant differences between patients receiving vs. not receiving PET were 
observed regarding utilization of radiation therapy or inpatient costs.  
Between 1993 and 2005, advanced stage disease increased in frequency among the 
overall Medicare NSCLC population (Figure 7.2).  The proportion of patients with advanced 
stage disease was stable at roughly 40% prior to the introduction of PET in 1998, after which it 
increased to nearly 50% by 2005.  For these patients with advanced disease, surgical resection 
was used in less than ten percent over the study period (not shown).  The frequency of early 
stage disease remained relatively stable over the study period, but experienced a slight increase 
in 2004 and 2005.  The proportion of overall patients undergoing surgical resection began 
decreasing in 1998, but had been relatively constant in the years prior to that time.  The 
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proportion of patients receiving radiation decreased through 1995, stabilized, and then began 
decreasing again in 2002.  The proportion of patients receiving chemotherapy increased steadily 
from 1993 to 2004. 
After controlling for shifting patient demographics and using 1998 as a baseline, several 
changes in treatment were observed (Table 7.5).  The likelihood of a patient to undergo surgical 
resection steadily decreased from 2001 to 2005.  The likelihood of radiation decreased over the 
study period, while chemotherapy use increased.  Surgical resection was more likely among 
patients who underwent PET, had localized disease, or were married (Table 7.5).  Surgery was 
less likely in elderly, uneducated, male patients with advanced stage disease or multiple 
comorbidities.  Both radiation and chemotherapy were more likely in patients with advanced 
disease, and were also less likely in patients over 80 (all P <0.001). 
Repeating these analyses stratifying by early vs. late stage disease (not shown) produced 
similar results. 
 
Changes in Health Care Costs 
 Total inpatient and overall average costs per patient increased between 1993 and 2005.  
Total inpatient costs increased from 1993 to 1997, and then decreased beginning in 1998 (Figure 
7.2).  After controlling for shifting patient demographics and using 1998 as a baseline, several 
changes in healthcare costs were observed (Table 7.6).  Average inpatient costs per patient 
decreased by an average of 12% by 2005 compared to 1998, after controlling for patient 
demographics.  When surgical treatment was controlled for, inpatient costs did not experience 
any change over time (not shown), suggesting that changes in surgery drove decreases in 
inpatient expenditures.  Patients located further away from PET facilities, patients older than 80, 
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and patients in the South had decreased inpatient expenditures compared with their counterparts 
in the West.  Increased inpatient expenditures were associated with black race, localized disease, 
comorbidities, and lower education attainment (all P < 0.001).  Non-inpatient costs increased 
from 2002 onward and were elevated in patients with comorbidities or who were married.  Non-
inpatient costs were also elevated in patients receiving PET or with advanced disease in models 
excluding PET x stage interaction terms (not shown).  Total costs per patient did not change 
significantly between 1998 and 2005 after controlling for patient demographics.    
Analyses of costs were repeated using cost per month of survival (Table 7.7).  Results 
were overall similar, except that PET was associated with reduced inpatient costs per month.  
This is likely an effect of selection bias, whereby patients who received PET were more to live 
longer and have lower costs per month since costs were spread out over a longer period.  
Similarly, advanced stage disease was associated with per month increased spending across 
inpatient, non-inpatient, and total health care expenditures per month, likely as a result of shorter 
survival times.  The analysis may be limited with regardless to examining costs per unit time 
since only one year of claims are examined for health care expenditures in this study. 
 Inpatient, non-inpatient, and overall costs did not change over time after controlling for 
patient receipt of surgery, radiation, or chemotherapy.  Receipt of surgery was associated with an 
88% increase in inpatient expenditures and only a 6% increase in non-inpatient costs, whereas 
receipt of chemotherapy was associated with a 97% increase in non-inpatient costs and no 
change in inpatient expenditures.  Radiation therapy was associated with an 12% increase in 
inpatient and 26% increase in outpatient patient expenditures.  For overall costs, use of surgery 
(48%), radiation (20%), or chemotherapy (34%) each resulted in increased total health care 
expenditures (all P < 0.0001). 
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Sensitivity Analysis 
 
To examine whether cost analyses were sensitive to the time window, we performed 
separate sensitivity analysis using a 2-year, rather than a 1-year, cost window.  Inpatient, non-
inpatient, and overall costs summed over two years were approximately 15-25% greater than 
costs summed over one year.  Both univariate and multivariable analyses using 2-year vs. 1-year 
costs yielded qualitatively similar results.  Additional sensitivity analyses including SEER 
region, excluding interaction effects, and limited to 1998-2003 all yielded qualitatively similar 
findings as the main analysis. 
 
7.4 Discussion 
 
 After controlling for shifting demographics, we found that patients were less likely to 
receive surgery and have lower inpatient costs in the years following the adoption of PET in the 
Medicare NSCLC population.   During the same time period total and non-inpatient costs 
increased.  Because of bidirectional associations between PET and stage, demonstrating a direct 
association of PET with reduced thoracotomies is difficult using a non-experimental approach.  
Nonetheless, this study provides evidence that PET-induced stage migration may have reduced 
rates of futile thoracotomy resulting in subsequent inpatient health care savings.  However, 
during the same period, the use of chemotherapy and non-inpatient expenditures increased 
rapidly, offsetting potential savings in inpatient expenditures. Estimates from 2003-2005 suggest 
a relatively stable reduction of 11% in inpatient expenditures, which in 2005 would have 
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amounted to roughly $2,800 savings per patient.  Accounting for the average cost of a PET scan 
during the same period ($1,400) suggests that the introduction of PET into the Medicare NSCLC 
may have saved roughly $1,400 per diagnosis in inpatient costs.  During the same time period, 
these potential inpatient cost savings were offset by increased non-inpatient costs of 15%-22%, 
more than enough to counteract any inpatient cost savings.  This increased non-inpatient cost 
appears to have occurred largely as a result of increased chemotherapy use, which began to 
include the use of dual vs. single agent chemotherapy per the American Society of Clinical 
Oncologist (ASCO) 2003 guidelines. 26   
 One large private California insurer5 and three out of four small randomized controlled 
trials (RCTs)1-4 have suggested that PET may result in upstaging of occult metastatic NSCLC 
from early to late stage disease,5 with most studies finding a reduction in futile thoracotomies of 
one half, similar to the odds ratios we estimated in our study.  Assuming a similar effect size in 
our study and a historic rate of early stage disease of roughly 60% would predict a decrease in 
overall surgical resection of approximately 4%, comparable to 3.4% reduction we observed 
between the 1998-1999 and 2004-2005 cohorts.  To date, no randomized trial of PET staging has 
demonstrated any trend towards decreased mortality.1-4 
 Despite stable or decreasing inpatient costs, overall health care costs increased by an 
average of $10,300 per patient between 1993-1994 and 2004-2005.  We previously reported an 
average increase in overall imaging costs of $1,500 per patient between 1999 and 2004 27, which 
would leave an unexplained increase in overall costs of $8,800.  Increased costs between 1993 
and 2005 coincided with a substantial increase in the proportion of patients undergoing 
chemotherapy and the proportion of patients with multiple comorbidities, both of which were 
associated with substantial increases in total health care costs.  Randomized trials of PET use in 
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NSCLC have been accompanied by cost-effectiveness analyses attempting to capture PET-
associated savings from reduced rates of futile thoracotomies. 1  PET can be used to avoid these 
futile thoracotomies, which might otherwise occur when a patient presents with occult metastatic 
disease undergoes local, definitive treatment for an incurable disease.  Our results suggest that 
although the introduction of PET may have reduced the number of futile thoracotomies, it may 
have also inadvertently led to the increased use of chemotherapy and observed increase in overall 
Medicare spending.  Although we did not analyze the cost of chemotherapy directly in our study, 
the ASCO-recommended use of doublet chemotherapy in 2003 would certainly increase material 
costs of chemotherapy compared with a single agent.  This shift in care from thoracotomy to 
chemotherapy has not previously been appreciated within small randomized trials and represents 
an important consideration when evaluating the overall effect of PET use on health care 
expenditures.  Continuing evaluation of the effect of PET on overall cancer patient evaluation, 
management, and outcomes will likely be aided in the future by the continued implementation of 
national, prospective databases of PET use such the National Oncologic PET Registry 
(NOPR).28-30  
There are many questions that arise in response to our study findings that may warrant 
further research.  The increased use of PET and its role in clinical decision making and its use, 
timing, and value in conjunction with other diagnostic and evaluative tests is not fully 
understood.  How patient performance status affects the likelihood of receiving PET might help 
provide a more accurate model of how performance status affects imaging use and how these 
factors might impact attempts to legislate changes in health care reform.  A PET-induced shift in 
care from thoracotomy to chemotherapy has not previously been appreciated within small 
randomized trials and represents an important consideration when evaluating the overall effect of 
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PET use on health care expenditures.  Future studies examining how PET directly augments or 
alters the use of chemotherapy or alternative treatments could provide valuable insight into cost-
drivers of the rapidly increasing chemotherapy-rich landscape of treatment.  The emergence of 
molecularly-targeted therapies occurred largely after the time frame analyzed by this study, and 
will almost certainly alter how PET use changes both the approach to treatment and costs of 
NSCLC in the future. 
 
Limitations 
 
 This study has several limitations as a retrospective, claims-based analysis. Only PET 
scans paid for by Medicare could be detected in our analysis.  In order to minimize the 
proportion of missed claims, all analyses were limited to Medicare beneficiaries with both Part A 
and B coverage and no HMO participation or Part C coverage for the 12 months prior to and 
following their diagnosis.  Patients within the SEER registry are overall more likely to be non-, 
live in non-poverty areas, and live in urban areas. 7 Medicare claims include IV chemotherapy 
and oral equivalents, but do not include chemotherapy or supportive medications filled as 
outpatient prescription drugs and were not captured in this study.  Oral chemotherapy can pose a 
substantial cost to patients and outside insurers, and our analysis likely underestimates the 
overall costs to cancer patients.  Two examples of oral chemotherapy agents used in the 
treatment of lung cancer include etoposide and tarceva, which were not observed in this study 
but are often administered in the palliative setting.26,31  Because of a largely palliative role of 
these agents, their use may be specifically increased by PET-induced stage migration.  Future 
studies to examine more specifically how PET affects patient management and chemotherapy 
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selection provide a value avenue of future research.  The most recent year of diagnosis examined 
in this study was 2005, which is the most recent SEER cohort available for which two full years 
of survival follow-up were available to determine 2-yr survival. Our analysis of distance between 
patient residence and PET providing facilities was based on distances between zip code centroids 
as a surrogate for travel time 32. 
 
Conclusions 
 
 We found that surgical resection and corresponding inpatient costs decreased in the 
NSCLC Medicare patient population following the widespread adoption of PET.  This study and 
previous work2,5 supports a role for PET in the upstaging of early stage NSCLC patients and 
corresponding reduction in futile attempts at local control of occult metastatic disease.  Inpatient 
savings associated with the adoption of PET may have been offset by increased rates of non-
inpatient chemotherapy used to preferentially treat advanced stage disease.  The ability of PET to 
affect patient management, health care utilization, and costs remain important areas of ongoing 
research that may change as new treatments become available in the future. 
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Table 7.1 – Case Demographics by PET Diffusion Cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PET: positron emission tomography 
  
Characteristic 
Year of Diagnosis 
P-Value 
Pre-PET 
(1993-1994) 
N = 8,837 
Initial PET 
(1998-1999) 
N = 8,017 
Post-PET  
(2004-2005) 
N = 10,436 
Age > 80, No. (%) 1287 (14.6) 1460 (18.2) 2342 (22.4) <.0001 
Male, No. (%) 5111 (57.8) 4416 (55.1) 5312 (50.9) <.0001 
Black, No. (%) 672 (7.6) 670 (8.4) 862 (8.3) 0.14 
Comorbid conditions, No. (%)    <.0001 
     0 5404 (61.2) 4514 (56.3) 5186 (49.7)  
     1 2283 (25.8) 2185 (27.3) 3071 (29.4)  
     2+ 1150 (13) 1318 (16.4) 2179 (20.9)  
2000 Census Tract Demographics: 
     (Highest Quartile) 
    
     Did not complete high school --- 1687 (25.8) 2135 (23) 0.0002 
     Percent below poverty  line --- 1704 (26.1) 2156 (23.3) <.0001 
     Percent black --- 1608 (24.6) 2211 (23.8) 0.25 
Married (%) 5024 (56.9) 4533 (56.5) 5496 (52.7) <.0001 
Metropolitan (%) 7748 (87.7) 6819 (85.1) 8977 (86) <.0001 
Region    <.0001 
     West 3894 (44.1) 3464 (43.2) 4749 (45.5)  
     Midwest 2920 (33) 2847 (35.5) 3376 (32.4)  
     Northeast 1417 (16) 1156 (14.4) 1626 (15.6)  
     South 606 (6.9) 550 (6.9) 685 (6.6)  
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Table 7.2 – Case Characteristics by PET use within 2004-2005 Cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PET: positron emission tomography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Characteristic 
NO PET  
(N = 4,133 ) 
PET  
(N = 6,303) P-Value 
Age > 80, No. (%) 1101 (26.6) 1241 (19.7) <.0001 
Male, No. (%) 2127 (51.5) 3185 (50.5) 0.35 
Black, No. (%) 452 (10.9) 410 (6.5) <.0001 
Comorbid conditions, No. (%)   0.19 
     0 2044 (49.5) 3142 (49.9)  
     1 1191 (28.8) 1880 (29.8)  
     2+ 898 (21.7) 1281 (20.3)  
2000 Census Tract Demographics: 
(Highest Quartile) 
   
     Did not complete high school 1014 (27.5) 1121 (20.1) <.0001 
     Percent below poverty  line 1029 (27.9) 1127 (20.2) <.0001 
     Percent black 990 (26.8) 1221 (21.9) <.0001 
Married (%) 2026 (49) 3470 (55.1) <.0001 
Metropolitan (%) 3531 (85.4) 5446 (86.4) 0.16 
Region   <.0001 
     West 1876 (45.4) 2873 (45.6)  
     Midwest 1503 (36.4) 1873 (29.7)  
     Northeast 493 (11.9) 1133 (18)  
     South 261 (6.3) 424 (6.7)  
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Table 7.3 – Univariate Outcomes, Treatment, and Costs by PET Diffusion Cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*PET costs are a subset of non-inpatient costs.  PET: positron emission tomography 
 
  
Characteristic 
Year of Diagnosis 
P-Value 
Pre-PET 
(1993-1994) 
N = 8,837 
Initial PET 
(1998-1999) 
N = 8,017 
Post-PET  
(2004-2005) 
N = 10,436 
Any PET scans, No. (%) 0 (0) 380 (4.7) 6303 (60.4) <.0001 
Distance to PET < 40 miles, No. (%) 0 (0) 4942 (61.6) 9708 (93) <.0001 
Stage, No. (%)    <.0001 
     Localized Disease (I-IIIA) 3060 (34.6) 2865 (35.7) 4333 (41.5)  
     Advanced Stage Disease (IIIB-IV) 3483 (39.4) 3492 (43.6) 5059 (48.5)  
     Unstaged 2294 (26) 1660 (20.7) 1044 (10)  
 Overall 2-yr Survival, No. (%) 2809 (31.8) 2703 (33.7) 3709 (35.5) <.0001 
Treatment     
     Any Resection, No. (%) 2923 (33.1) 2518 (31.4) 2956 (28.3) <.0001 
     Any Radiation, No. (%) 4954 (56.1) 4126 (51.5) 4744 (45.5) <.0001 
     Any Chemotherapy, No. (%) 1670 (18.9) 2819 (35.2) 4805 (46) <.0001 
     No Treatment, No. (%) 1449 (16.4) 1271 (15.9) 1855 (17.8) 0.0013 
Costs (Mean, 2008 dollars)      
     Inpatient $27,410 $28,575 $27,900 .02 
     Non-inpatient $18,324 $20,809 $28,145 <.0001 
          PET * $0 $39 $842 <.0001 
     Total $45,734 $49,384 $56,045 <.0001 
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Table 7.4 – Univariate Outcomes, Treatment, and Costs by Receipt of PET  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*PET costs are a subset of non-inpatient costs.  PET: positron emission tomography 
  
 
Characteristic 
NO PET  
(N = 4,133 ) 
PET  
(N = 6,303) P-Value 
Distance to PET < 40 miles, No. (%) 3817 (92.4) 5891 (93.5) 0.03 
Stage, No. (%)   <.0001 
     Localized Disease (I-IIIA) 1100 (26.6) 3233 (51.3)  
     Advanced Stage Disease (IIIB-IV) 2500 (60.5) 2559 (40.6)  
     Unstaged 533 (12.9) 511 (8.1)  
 Overall 2-yr Survival, No. (%) 911 (22) 2798 (44.4) <.0001 
Treatment    
     Any Resection, No. (%) 658 (15.9) 2298 (36.5) <.0001 
     Any Radiation, No. (%) 1819 (44) 2925 (46.4) 0.02 
     Any Chemotherapy, No. (%) 1626 (39.3) 3179 (50.4) <.0001 
     No Treatment, No. (%) 1140 (27.6) 715 (11.3) <.0001 
Costs (Average, 2008 dollars)     
     Inpatient $28,164 $27,728 0.04 
     Non-inpatient $24,726 $30,387 <.0001 
          PET * $0 $1,394 <.0001 
     Total $52,890 $58,115 <.0001 
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Table 7.5 – Regression Analysis of Receiving Any Resection, Radiation, or Chemotherapy 
between 1996 and 2005 (N=38,359) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*P<0.001; Abbreviations: OR, Odds Ratio; PET, positron emission tomography; QRTL, quartile, CI, confidence 
interval 
Characteristic 
Any Resection 
OR (95% CI) 
Any Radiation 
OR (95% CI) 
Any Chemo 
OR (95% CI) 
Year of Diagnosis    
     1996 1.01 (0.88-1.16) 1.09 (1-1.19) 0.67 (0.61-0.74)* 
     1997 1.03 (0.94-1.13) 1.05 (0.92-1.19) 0.83 (0.75-0.92)* 
     1998 (Reference) --- --- --- 
     1999 1.07 (0.95-1.21) 0.96 (0.88-1.04) 1.14 (1.01-1.28) 
     2000 0.95 (0.86-1.05) 0.98 (0.9-1.06) 1.23 (1.11-1.36)* 
     2001 0.77 (0.68-0.87)* 0.92 (0.81-1.04) 1.18 (1.03-1.35) 
     2002 0.67 (0.6-0.75)* 0.76 (0.67-0.86)* 1.21 (1.03-1.41) 
     2003 0.6 (0.55-0.65)* 0.69 (0.62-0.78)* 1.3 (1.16-1.46)* 
     2004 0.5 (0.46-0.55)* 0.65 (0.57-0.76)* 1.55 (1.32-1.81)* 
     2005 0.49 (0.46-0.53)* 0.61 (0.52-0.71)* 1.42 (1.21-1.66)* 
Any PET 1.79 (1.49-2.14)* 1.56 (1.36-1.79)* 1.55 (1.42-1.69)* 
Localized Disease 6.49 (5.27-8)* 0.64 (0.58-0.71)* 0.45 (0.39-0.52)* 
Advanced Stage 0.27 (0.22-0.34)* 1.61 (1.44-1.79)* 1.5 (1.37-1.65)* 
Localized  x PET 0.95 (0.82-1.11) 0.98 (0.87-1.12) 1.04 (0.88-1.23) 
Advanced x PET 1.77 (1.53-2.04)* 0.94 (0.81-1.1) 1.14 (0.99-1.32) 
PET > 40 miles away 0.95 (0.86-1.06) 1.05 (0.95-1.16) 1 (0.87-1.16) 
Age >80 0.47 (0.43-0.51)* 0.84 (0.8-0.89)* 0.36 (0.34-0.38)* 
Black 0.7 (0.63-0.78)* 1.13 (1.02-1.24) 1 (0.9-1.12) 
Comorbidities     
    One 0.91 (0.84-1) 0.97 (0.94-1.01) 0.89 (0.86-0.93)* 
     Multiple 0.74 (0.68-0.81)* 0.96 (0.92-1) 0.65 (0.6-0.72)* 
Census tract:% 
Education < 12 years 
   
     2nd QRTL 0.8 (0.72-0.9)* 1.07 (1.02-1.12) 1.02 (0.99-1.05) 
     3rd QRTL 0.76 (0.63-0.9) 1.05 (0.98-1.13) 1 (0.91-1.1) 
     4th QRTL 0.71 (0.6-0.86)* 1.08 (0.99-1.18) 1 (0.87-1.15) 
Census tract:% Below 
Poverty Line 
   
     2nd QRTL 1.04 (0.95-1.14) 0.95 (0.89-1.02) 0.93 (0.89-0.98) 
     3rd QRTL 1.04 (0.93-1.16) 0.91 (0.85-0.98) 0.86 (0.79-0.92)* 
     4th QRTL  0.99 (0.86-1.14) 0.95 (0.87-1.03) 0.79 (0.66-0.95) 
Census tract:% Black    
     2nd QRTL 1.04 (0.98-1.1) 1.01 (0.95-1.08) 1.02 (0.96-1.08) 
     3rd QRTL 1 (0.9-1.13) 1.02 (0.95-1.09) 1.05 (0.97-1.13) 
     4th QRTL 1.12 (1.03-1.22) 0.97 (0.89-1.06) 0.94 (0.84-1.04) 
Male 0.74 (0.7-0.78)* 1.2 (1.14-1.26)* 1.2 (1.13-1.28)* 
Married (%) 1.33 (1.27-1.4)* 1.05 (1.01-1.09) 1.36 (1.29-1.42)* 
Metropolitan (%) 1.05 (0.91-1.2) 0.96 (0.86-1.07) 1.02 (0.83-1.25) 
Region    
     Midwest 1 (0.81-1.24) 1.22 (1.14-1.31)* 1.1 (0.87-1.39) 
     Northeast  1.13 (0.9-1.41) 1.07 (1-1.15) 1.12 (0.98-1.29) 
     South 0.83 (0.65-1.05) 1.17 (1.05-1.3) 1.51 (1.3-1.77)* 
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Table 7.6 – Regression Analysis of Inpatient, Non-Inpatient, and Total Costs between 1996 
and 2005 (N=38,359) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*P<0.001; Abbreviations: PET, positron emission tomography; QRTL, quartile, CI, confidence interval.   
† Relative Δ % Cost = Relative Percent Change in Costs  = Exp (β – ½ σβ
2
) – 1 (per Kennedy 1981).   
Characteristic 
Inpatient 
Relative Δ % Cost  
(95% CI)† 
Non-Inpatient 
Relative  Δ  % Cost 
(95% CI)† 
Total 
Relative  Δ % Cost 
(95% CI)† 
Year of Diagnosis    
     1996 -1.5 (-9, 6.7) -3.6 (-6.9, -0.1) -2.0 (-7.5, 3.8) 
     1997 -4.3 (-10.7, 2.5) -2.6 (-6.3, 1.2) -3.3 (-8.6, 2.3) 
     1998 (Reference) --- --- --- 
     1999 -3.8 (-6.3, -1.2) 0.6 (-3, 4.5) -1.8 (-4, 0.5) 
     2000 -9.7 (-13.3, -5.8)* 1.0 (-2.7, 4.9) -5.2 (-9.2, -1.1) 
     2001 -9.1 (-13.9, -4)* 6.6 (2, 11.3) -2.5 (-7.3, 2.6) 
     2002 -6.0 (-11.3, -0.4) 9.1 (4.7, 13.7)* 0.0 (-4.2, 4.5) 
     2003 -10.7 (-15.7, -5.3)* 18.2 (11.4, 25.5)* 1 (-4.3, 6.7) 
     2004 -11.2 (-18.8, -3) 22 (16.6, 27.6)* 2.4 (-4.2, 9.5) 
     2005 -11.9 (-16.3, -7.3)* 14.6 (8.4, 21.1)* -1.1 (-6.2, 4.2) 
Any PET -3.5 (-12.5, 6.6) 24.9 (18.8, 31.2)* 11.2 (5, 17.7)* 
Localized Disease 29.8 (25.3, 34.3)* -14.7 (-17.7, -11.6)* 9.4 (7.2, 11.7)* 
Advanced Stage 6.7 (-1.6, 15.7) 4.5 (2.1, 7)* 5.4 (1.2, 9.7) 
Localized  x PET 6.6 (0.5, 13) -2.3 (-6.5, 2) -1.4 (-4.9, 2.3) 
Advanced x PET -0.5 (-8.5, 8.2) 3.9 (-0.6, 8.5) 1.9 (-4, 8.3) 
PET > 40 miles away -15.2 (-22.3, -7.4)* -3.0 (-7.8, 2.1) -9.8 (-16.1, -2.9) 
Age >80 -14.6 (-17.5, -11.6)* -19.6 (-20.4, -18.8)* -16.6 (-18.7, -14.5)* 
Black 19.4 (11.2, 28.2)* 4.1 (-0.6, 9.1) 12.9 (6.9, 19.2)* 
Comorbidities     
    One 11.1 (8, 14.4)* 4.9 (2.3, 7.6)* 8.4 (6.1, 10.8)* 
     Multiple 34.7 (28.5, 41.2)* 10.3 (5.1, 15.7)* 24.2 (18, 30.8)* 
Census tract:% 
Education < 12 years 
   
     2nd QRTL 0.7 (-3.4, 4.9) 0.1 (-3.6, 4) 0.7 (-2.9, 4.4) 
     3rd QRTL 5.1 (-0.4, 10.9) -0.1 (-6.2, 6.4) 2.7 (-2.8, 8.4) 
     4th QRTL 16.1 (7.6, 25.4)* 2.7 (-4.3, 10.2) 10.0 (3.2, 17.3) 
Census tract:% Below 
Poverty Line 
   
     2nd QRTL -2.3 (-4.6, 0.1) -2.9 (-5.8, 0) -2.6 (-4.9, -0.2) 
     3rd QRTL -4.1 (-10.8, 3.1) -5 (-10.2, 0.4) -4.8 (-10.6, 1.4) 
     4th QRTL  0.5 (-11.4, 14) -6.5 (-16.1, 4.1) -2.3 (-13.4, 10.1) 
Census tract:% Black    
     2nd QRTL 2.6 (-1, 6.4) 0.3 (-2.6, 3.2) 1.6 (-0.7, 4.1) 
     3rd QRTL 6.8 (2, 11.8) 3.1 (-1.3, 7.6) 5.2 (2.1, 8.5) 
     4th QRTL 5.7 (-1.3, 13.2) 2 (-4, 8.3) 4.3 (-1.8, 10.8) 
Male 4.1 (1.5, 6.7) -0.2 (-2.1, 1.7) 2.1 (0, 4.3) 
Married (%) -5.2 (-8.4, -1.9) 7.3 (5.6, 9.1)* 0.2 (-2.5, 3) 
Metropolitan (%) 24.1 (9, 41.4) 11 (1.5, 21.4) 17.1 (6.6, 28.7)* 
Region    
     Midwest -15.3 (-31.1, 4.2) 1.2 (-11.9, 16.3) -7.4 (-21.8, 9.7) 
     Northeast  -4.4 (-18.6, 12.2) 4.1 (-0.4, 8.8) -0.4 (-10.6, 10.9) 
     South -27.8 (-39.2, -14.3)* 2.0 (-2.8, 7) -15.1 (-24.4, -4.6) 
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Table 7.7 – Regression Analysis of Monthly Inpatient, Non-Inpatient, and Total Costs 
between 1996 and 2005 (N=38,359) in the first 12 months following diagnosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*P<0.001; Abbreviations: PET, positron emission tomography; QRTL, quartile, CI, confidence interval.   
† Relative Δ % Cost = Relative Percent Change in Costs  = Exp (β – ½ σβ
2
) – 1 (per Kennedy 1981).   
Characteristic 
Inpatient 
Relative Δ % Cost  
(95% CI)† 
Non-Inpatient 
Relative Δ % Cost  
(95% CI)† 
Total 
Relative Δ % Cost  
(95% CI)† 
Year of Diagnosis    
     1996 -2.1 (-7.9, 4) -3.9 (-6.7, -1) -2.7 (-6.6, 1.4) 
     1997 -3.1 (-7.7, 1.7) -2.7 (-5.3, 0) -2.8 (-6.2, 0.7) 
     1998 (Reference) --- --- --- 
     1999 -4.7 (-10.7, 1.7) -1.1 (-4.3, 2.2) -3.1 (-7, 0.9) 
     2000 -9.3 (-12.4, -6)* -0.5 (-3.3, 2.4) -5.8 (-8.7, -2.8)* 
     2001 -4.7 (-8.9, -0.3) 6.6 (3.3, 10)* -0.3 (-3.9, 3.4) 
     2002 0.1 (-6.4, 7.1) 10.1 (6.7, 13.7)* 3.7 (0, 7.5) 
     2003 -5.3 (-9.5, -0.8) 18.4 (12.3, 24.9)* 3.8 (-0.2, 7.9) 
     2004 -5.5 (-11.5, 0.8) 23 (18.2, 27.9)* 5.6 (0.9, 10.5) 
     2005 -2.8 (-7.2, 1.9) 17.5 (12.6, 22.7)* 4.9 (1.3, 8.6) 
Any PET -20.6 (-29, -11.1)* 10.8 (6.9, 14.9)* -5.6 (-11.1, 0.3) 
Localized Disease 14.4 (9.4, 19.6)* -21.3 (-24, -18.5)* -0.9 (-2.9, 1.1) 
Advanced Stage 30.4 (20.7, 40.9)* 21.1 (18.4, 23.8)* 26.1 (20.6, 31.8)* 
Localized  x PET 16.6 (6.7, 27.5)* 2.5 (-1.3, 6.5) 6.1 (0.9, 11.6) 
Advanced x PET -3.7 (-11.7, 5) -0.9 (-4.8, 3.1) -3.0 (-8.3, 2.6) 
PET > 40 miles away -18.3 (-25.9, -9.8)* -4.0 (-8.7, 0.9) -12.1 (-18.8, -4.9) 
Age >80 -9.1 (-12.6, -5.4)* -14.3 (-15.6, -13.1)* -11.2 (-13.8, -8.4)* 
Black 20.2 (13.3, 27.6)* 1.6 (-2.7, 6.2) 12.7 (7.3, 18.3)* 
Comorbidities     
    One 13.6 (8.4, 19)* 5.3 (3.1, 7.6)* 10.0 (6.4, 13.8)* 
     Multiple 41.9 (35.2, 48.9)* 14.7 (9.8, 19.8)* 30.7 (24.5, 37.3)* 
Census tract:% 
Education < 12 years 
   
     2nd QRTL 1.7 (-1.7, 5.2) 0.1 (-2.8, 3.1) 1.3 (-1.7, 4.3) 
     3rd QRTL 7.9 (2.2, 13.9) 0.5 (-4.8, 6.1) 4.6 (-0.5, 10) 
     4th QRTL 22.1 (12.1, 32.9)* 4 (-2, 10.4) 14 (6.9, 21.6)* 
Census tract:% Below 
Poverty Line 
   
     2nd QRTL -3.4 (-6.2, -0.5) -3.6 (-6.2, -1) -3.6 (-5.9, -1.1) 
     3rd QRTL -6.5 (-13.6, 1.2) -5.7 (-11, -0.1) -6.4 (-12.3, 0) 
     4th QRTL  -0.3 (-13.8, 15.4) -7.4 (-16.5, 2.7) -3.1 (-14.7, 10.2) 
Census tract:% Black    
     2nd QRTL 2.9 (-1.8, 7.8) 0.6 (-2.1, 3.4) 1.9 (-1, 4.9) 
     3rd QRTL 9.3 (3.8, 15.1)* 3.7 (-0.4, 7.9) 6.9 (3.5, 10.5)* 
     4th QRTL 6.6 (-2.8, 16.9) 2.9 (-3.3, 9.4) 5.4 (-1.8, 13.2) 
Male 8 (5.5, 10.7)* 3.7 (1.6, 5.8)* 6.3 (3.8, 8.8)* 
Married (%) -8.5 (-11.2, -5.7)* 4.3 (2.5, 6.1)* -3.3 (-5.8, -0.7) 
Metropolitan (%) 25.9 (9.1, 45.4) 11.4 (2.7, 20.9) 18.5 (7.4, 30.6)* 
Region    
     Midwest -17.1 (-32.9, 2.3) 1 (-11.1, 14.8) -9.1 (-23.4, 7.9) 
     Northeast  -8.9 (-23.1, 7.9) 1.6 (-3.3, 6.8) -4.3 (-15.2, 7.9) 
     South -29.5 (-40.9, -15.9)* 2.4 (-2.7, 7.8) -16.8 (-26.6, -5.7) 
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Table 7.Supplemental – HCPCS and ICD-9-CM codes used to detect surgical resection, 
chemotherapy, and radiotherapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCPCS: Healthcare Common Procedure Coding System 
ICD-9 CM: International Classification of Diseases – 9th edition – Clinical Modification 
DME: Durable Medical Equipment  
 
 
 
  
Treatment Modality Claims Files Codes 
Surgery  
(Lung Resection) 
Inpatient 
Outpatient 
Carrier  
HCPCS    
31766, 32440, 32442, 32445, 32480, 32484, 32485, 32486, 
32488, 32500, 32520, 32522, 32525, 32657, 32663 
 
ICD-9-CM  
32.29, 32.3-32.99 
 
Chemotherapy Outpatient 
Carrier 
DME 
HCPCS 
95549, 96400, 96404, 96406, 96410, 96412, 96414, 96420, 
96422, 96423, 96425, 96440, 96445, 96450, 96542, 96545, 
C9017, J0182, J8510, J8530, J8560, J8610, J899, J9000, J9001, 
J9010, J9045, J9060, J9062, J9070, J9080, J9090-J9097, J9170, 
J9180-J9182, J9190, J9201, J9206, J9208, J9230, J9250, J9260, 
J9265, J9280, J9290, J9291, J9350, J9360, J9370, J9375, 
J9380, J9390, J9999, Q0083, Q0084, Q0085, Q0125, Q0127-
Q0129, S0178, S0182, S9329, S9330, S9331 
Radiation Therapy Outpatient 
Carrier 
HCPCS 
31643, 77300, 77301, 77305, 77310, 77315, 77321, 77326, 
77327, 77328, 77331-77334, 77336, 77370, 77380, 77381, 
77399, 77401-77404, 77406-77409, 77411-77414, 77416-
77420, 77425, 77427, 77430-77432, 77470, 77499, 77520, 
77522, 77523, 77525, 77750, 77761-77763, 77781-77784, 
77799, C1716-C1720, C1790-C1806, C2616, G0126, G0173   
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Figure 7.1: CONSORT diagram. 
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Figure 7.2: Stage Distribution, Treatment, and Costs of the overall NSCLC Medicare 
Patient Population from 1993 to 2005. 
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CHAPTER 8: DISCUSSION 
 
 
Overview 
Positron Emission Tomography (PET) is an advanced imaging modality that began to be 
used to differentiate malignant and benign solitary pulmonary nodules in 19921 and was initially 
approved for this use by Medicare in 19982.  Since then, PET utilization has increased in clinical 
practice among both Medicare and privately-insured NSCLC patients3,4, with Medicare lung 
cancer beneficiaries receiving an average of one PET scan per patient by 20063.  Overall 
incidence of lung cancer among Americans older than age 65 is an order of magnitude higher 
than it is for younger individuals5, making NSCLC outcomes among the elderly an important 
topic of ongoing research.  Remarkably little is known about how PET affects Medicare NSCLC 
patient treatment, outcomes, and health care costs.  In this dissertation I explored how the rapid 
expansion of PET use within Medicare patients affected the access, quality, and care of NSCLC 
patients. 
 
8.1 Study 1: Demographic Variation in the use of PET in Medicare NSCLC 
 
 
Previous work suggests that the rapid expansion of PET may have occurred non-
uniformly throughout the NSCLC patient population following the national coverage decision by 
Medicare in 1998. 6,7  Such discrepancies in delivery of technology could have had considerable 
implications with regards to quality, access, and care, and are particularly concerning from the 
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perspective of a public insurer that must balance health care needs and expenditures on a 
nationwide scale.   
This study found that PET utilization among NSCLC patients increased following its 
approval by Medicare in 1998, reaching a utilization rate of 50% or more by 2005 regardless of 
race, age, region, or local census characteristics.  Despite widespread adoption of PET overall, 
patients who were older, black, or from less educated or more impoverished census tracts had 
lower utilization of PET that persisted through 2005, with an absolute decrease in PET utilization 
of approximately ten percentage points within each group.  Expansion of PET occurred 
preferentially within the Northeast following Medicare expansion of PET indications for the 
diagnosis, staging, and restaging of NSCLC in 2001.  Contrary to our hypothesis that unequal 
utilization of PET would decrease with increasing PET availability, we found that differences in 
PET utilization rates persisted among sociodemographic and regional subgroups through 2005.  
Specifically, PET use was higher for non-blacks, patients under the age of 80, and patients living 
in the Northeast.  Whether persistently disparate PET use represented underutilization or 
overutilization is unclear. 
On July 1 2001, PET was approved for the diagnosis, initial staging, and restaging of 
NSCLC.  This national coverage determination should in theory have equally affected the 
adoption of PET use in NSCLC nationwide.  However, between 2001 and 2002, the Northeast 
(Connecticut) registry increased its use of PET significantly faster than all other registries.  It has 
been previously shown that the introduction of new technology often occurs heterogeneously 
during the early phases of growth7 8 9.  Our results suggest that introduction of national coverage 
policies may also introduce potential sources of increased heterogeneous use of existing 
technology.  A potential policy implication of this would be to increase efforts to promote equal 
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dissemination of services among Medicare patients following expansion of any Medical service, 
not just new or emerging technology. 
Possible explanations for disparate use of PET include differences in the availability of 
technology, cost, physician preference, and patient preference.  Disparities in race, gender, and 
age have been observed with regards to cancer health care access, treatment, and survival 10-28, 
particularly with regards to receiving new or higher-technology services 11.  Our analysis 
suggests that reduced access to PET as a result of distance from PET facilities had largely 
disappeared by 2005.  Whether this disappeared as a result of social networking, changes in 
general knowledge, or aggressive marketing is not known.  Understanding how the effect of 
distance has been mitigated in the receipt of NSCLC PET could provide insight into how we 
might be able to neutralize unequal utilization of other limited health care resources. 
 
8.2 Study 2: PET-induced stage migration and selection bias among Medicare NSCLC 
patients 
 
The use of PET and PET/CT was covered by Medicare because of its ability to more 
sensitive and specific staging and evaluation of NSCLC compared with CT alone29.  PET use 
was rapidly adopted within the Medicare NSCLC population following its approval by CMS.   
Early observational studies had reported an association between PET and superior NSCLC 
patient outcomes in Medicare beneficiaries4 and one large privately insured California 
population30.  However, such findings could have been biased if PET was selectively 
administered to populations with greater access to health care.  Specifically, if observational data 
suggest that early detection via PET could improve survival, it is possible that this benefit could 
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be an artifact of upstaging, rather than a true improvement in survival. This concern prompted 
our second study, which investigated 1) if PET improved outcomes and 2) if not, why had a 
survival benefit been observed by previous epidemiologic studies.   
We found that despite widespread adoption of PET, overall survival among the Medicare 
NSCLC population increased less than 4% between 1993 and 2005.  Using regression analyses, 
we found that previous optimistic assessments of the survival benefit of PET may be attributed in 
part to selection bias. That is, PET use was associated with decreased likelihood of stage IV 
metastatic disease, suggesting that receipt of PET is more common among patients with less 
advanced disease.  Because PET is a more sensitive modality for detecting extent of disease, we 
expected its use to be associated with more advanced disease.  We found that PET was 
preferentially administered to patients with early stage disease.  This is likely due to the 
appropriate use of PET in evaluating primarily localized disease for evidence of occult 
metastases, avoiding of PET use in frank metastatic disease, preferential use of PET in patients 
with improved health care access, or a combination of all three.  The 2003 American Society of 
Clinical Oncologists (ASCO) guidelines recommend that PET be reserved for patients in whom 
metastatic disease was not evident, instead using it to rule out occult metastatic disease prior to 
invasive lung surgery.31  Our findings may explain results from a previous report which 
concluded that PET use conferred a roughly two fold increase in survival4.  Had gains in survival 
of this magnitude been caused by PET, overall improvement in NSCLC survival should have 
increased by 30% following uptake of PET by over half of the Medicare NSCLC population. 
In addition to selection bias, we also found that the proportion of patients staged as 
having incurable disease increased from 40% to 50% between 1998 and 2005.  In addition, we 
found that stage-specific survival improved dramatically among patients with advanced disease, 
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with the likelihood of being alive two-years after a diagnosis of incurable disease increasing 
from 10% to 16% between 1998 and 2005.  These findings provided evidence of PET-induced 
stage migration between 1998 and 2005 that resulted in stage-specific improved survival in the 
without similar changes in overall survival.32,33  The clinical value of PET may evolve with 
emerging molecularly-targeted therapies, which were not in use during the time frame analyzed 
by this study.  The artificial improvement in stage-specific survival is important, since trials of 
new therapies often rely on historical controls to evaluate the effect on patient survival.  If 
historical patient cohorts are used in this manner without consideration of PET use and stage 
migration, new treatments could falsely claim a survival benefit in advanced stage disease.   
 
8.3 Study 3: The Effect of PET on patient treatment and health care costs 
 
Another potential benefit of PET is the avoidance of futile thoracotomy, which occurs 
when a patient with metastatic disease undergoes local, definitive treatment for an incurable 
disease.  One small randomized trial34 has suggested that the use of PET may result in 
appropriate upstaging, reduce futile thoracotomy, and save costs, although it is unknown whether 
or not this can be extrapolated to the general Medicare NSCLC population.  In privately-insured 
patient populations, PET has been associated with upstaging of NSCLC 33 that would also 
suggest a potential towards avoiding futile thoracotomy and associated inpatient hospitalization.  
In our second study, we found evidence of PET-induced stage-migration among Medicare 
NSCLC patients.  Prior to this study, however, the potential of PET to reduce futile local control 
and decrease inpatient costs had not been examined within the Medicare NSCLC population.   
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After controlling for shifting demographics, we found that Medicare NSCLC rates of 
surgery decreased between 1998 and 2005, supporting the possibility that PET-induced stage 
migration reduced rates of futile thoracotomy and could potentially have resulted in subsequent 
inpatient health care savings.  Estimates from 2003-2005 suggest a reduction of 11% in inpatient 
expenditures, which in 2005 would have amounted to $2,800 in inpatient savings per patient.  
After accounting for the average cost of a PET scan during the same period ($1,400) suggests 
that the introduction of PET into the Medicare NSCLC may have saved roughly $1,400 per 
diagnosis. 
Previous studies support a similar concept.  A randomized trial of PET use in 337 early 
stage NSCLC patients found that PET-CT correctly upstaged an additional 7% of patients and 
reduced futile thoracotomy and overall costs compared with conventional CT-based staging 34.  
Assuming a similar effect size in our study and a historic rate of early stage disease of roughly 
60% would predict a decrease in overall surgical resection of approximately 4%, comparable to 
3.4% reduction we observed between the 1998-1999 and 2004-2005 cohorts.   
An unexpected finding, however, was that during the same period, the use of 
chemotherapy and non-inpatient expenditures increased rapidly, offsetting potential savings in 
inpatient expenditures.  Despite stable or decreasing inpatient costs, overall health care costs 
increased by an average of $10,200 per patient between 1993-1994 and 2004-2005.  We 
previously reported an average increase in overall imaging costs of $1,500 per patient between 
1999 and 2004 3, which would leave an unexplained increase in overall costs of $8,500.  
Increased costs between 1993 and 2005 coincided with a substantial increase in the proportion of 
patients undergoing chemotherapy and the proportion of patients with multiple comorbidities, 
both of which were associated with substantial increases in total health care costs.  One 
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interpretation of these findings are that PET reduces health care costs by reducing rates of futile 
thoracotomy, but increases costs by now referring these patients for systemic chemotherapy 
reserved for incurable disease.  Our results suggest that changing patient demographics and the 
increase use of chemotherapy are in part responsible for the observed actual increase in Medicare 
spending.   
 
8.4 Limitations 
This study has several limitations as a retrospective, claims-based analysis. First, only 
PET scans paid for by Medicare could be detected in our analysis.  However, it is likely that 
relatively few PET scans for our sample of Medicare beneficiaries would be paid by third party 
insurers or out of pocket.  Second, it is unknown how reliable Medicare claims data are for 
determining receipt of PET. However, studies examining the accuracy of Medicare claims for 
assessing alternative imaging modalities such as mammography have had observed concordance 
rates of 94% 35.  Third, patients within the SEER registry are overall more likely to be non-white, 
live in non-poverty areas, and live in urban areas36, which may limit the ability to generalize our 
findings. Fourth, we did not incorporate patient stage, treatment decisions, survival, or other 
factors that could themselves altered by receipt of PET.  Fifth, our analysis of distance between 
patient residence and PET providing facilities was based on distances between zip code centroids 
as a surrogate for travel time 37.   Finally, SEER-Medicare data are released with a several year 
lag, limiting the ability of the analysis to extend beyond 2005 at the time of the study.   
Collection of cancer T, N, and M information used to extract cancer stage changed in 
1998 and again in 2004.38  Prior to 1998, information used to stage cancers was obtained using 
all available information in the two months following diagnosis.  Beginning in 1998 onward, this 
timeframe was extended to four months or first surgery.  This likely resulted in a slight increase 
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in advanced stage disease between 1997 and 1998.  In 2004, data collection within SEER 
changed from the extend of disease (EOD) collection system to the collaborative staging system 
(CSS).  It is unclear how this should have affected staging.  These complicated changes in 
staging were fortunately accompanied by an opportunistic window between 1998 and 2003, 
during which no known artifacts in staging occurred, but the largest changes in PET utilization 
and stage migration were observed.  
On a more general level, studies 2 and 3 were both extremely limited by the bidirectional, 
causal link between receipt of PET and disease stage.  The selective administration of PET to 
patients with early stage disease made direct inference of the effect of PET on NSCLC stage, 
survival, costs, and treatment challenging.  The inability to draw reliable inference from 
conventional epidemiology methodologies in this setting provided a significant challenge to my 
research and its conclusions.  In the end, simple plots of overall survival, stage distribution, 
treatment, and costs provided significant support for our theories.   
There are several potential factors other than the introduction of PET that may have 
affected patient outcomes between 1998 and 2005.  In 2003, ASCO recommendations were 
expanded to include the use of dual vs. single chemotherapy agents in the treatment of NSCLC.  
Recently, a randomized trial of early palliative care found a survival benefit comparable to 
chemotherapy. 39  The incorporation of new chemotherapy, molecularly targeted drugs, palliative 
care, or alternative interventions that could have affected survival over the study period make it 
difficult to interpret temporal changes over time.   
 
8.5 Future Research 
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 Many questions remain regarding the use of advanced imaging modalities in 
oncology and a large number of potential research directions stem from the current work.  
Potential avenues of research range from further imaging studies in NSCLC, examination of 
advanced imaging modalities in other cancer sites such as prostate cancer or lymphoma, 
methodologic work to model how imaging enters clinical decision making and outcomes, cost-
effectiveness research of advanced imaging use in cancer, or any of the above in combination 
with newly emerging treatment options.  All of these potential projects may be additionally 
assisted by availability of Medicare Part D prescription drug data, which recently became 
available beginning with patient data from 2006 onward.  Two examples of oral chemotherapy 
agents used in the treatment of lung cancer include etoposide and tarceva, which were not 
observed in this study but are often administered in the palliative setting.31,40  Because of a 
largely palliative role of these agents, their use may be specifically increased by PET-induced 
stage migration.  Future studies to examine more specifically how PET affects patient 
management and chemotherapy selection could make a significant impact on how we allot health 
care dollars in these settings.  Modeling these complex interactions between imaging and cancer 
management may be useful to develop effective cost-conserving policies in an era of rapidly 
increasing health care costs. Recently, a randomized trial of early palliative care found a survival 
benefit comparable to chemotherapy, 39 highlighting the potential for other factors besides 
chemotherapy to have affected patient survival and could be investigated. 
Continuing evaluation of the effect of PET on overall cancer patient evaluation, 
management, and outcomes will likely be aided in the future by the continued implementation of 
national, prospective databases of PET use such the National Oncologic PET Registry 
(NOPR).41-43  However, because the use of PET in NSCLC has long been approved by Medicare, 
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it is unlikely that the NOPR registry will provide coverage with evidence development (CED) for 
a significant portion of NSCLC PET scans.   
 
8.6 Conclusion 
 Fully understanding the utilization of PET and how it affects staging, management, 
outcomes, and health care spending in lung cancer patients has considerable implications for 
establishing future imaging guidelines.  Prior to the studies performed in this dissertation, 
previous analyses have suggested an association between PET and improved NSCLC patient 
survival 4, 4,33,44.  Our finding suggest that these studies may not have fully adjusted for PET 
selection bias and PET-induced stage-migration, both of which may exaggerate the beneficial 
effect of PET on patient survival.  Because there is unlikely to be a large randomized controlled 
trial to definitively assess the overall effect of PET on patient outcomes, researchers must 
carefully characterize and control for PET selection bias and stage-migration when performing 
non-experimental evaluations of PET.  When we did so, we concluded that PET does not confer 
a survival benefit in NSCLC.  However, we provide evidence that PET may be able to reduce 
futile thoractomies and potentially save health care dollars.  This research marks the first effort to 
fully assess both the direct and indirect costs and benefits of PET use in the Medicare NSCLC 
population and helps to inform future Medicare policy decisions regarding the use of PET. 
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